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Abstract 
 Vascular targeted carriers (VTCs) increase the specificity of drug delivery while also 
protecting drugs from degradation in the bloodstream, and therefore, have the potential to 
revolutionize many clinical treatments of common diseases. It has previously been shown that 
rigid microparticles (MPs) are significantly more efficient than rigid nanoparticles (NPs) at 
adhering to target vasculature from bulk blood flow; yet, despite this increased efficiency, MP 
VTCs have not been successfully developed for therapeutic applications, and are routinely 
passed over in favor of NP systems, which better evade capillary occlusion and promote tissue 
transport. Here, we investigate different physical properties of VTCs, including the interplay 
between particle modulus, size, and targeting ligand regime, to enhance the translational 
potential of MP VTC therapeutics and to optimize the overall design of VTCs for a range of 
clinical applications. 
We systematically varied the physiochemical properties of particle modulus via 
poly(ethylene glycol) crosslinking density, targeting ligand (varied density, composition), and 
size (50 nm polystyrene to 2 µm hydrogels) and evaluated the impact of each property on 
targeted adhesion. VTC designs were evaluated in vitro using parallel plate flow chamber assays 
with inflamed human umbilical vein endothelial cells enabling controlled hemodynamic shear 
with primary human blood. VTC designs were evaluated in vivo using real time imaging of acute 
mouse mesentery inflammation, and full biodistribution studies following acute lung injury. The 
methods developed and employed here represent accurately simulated physiological conditions 
to encourage translatability of trends into that expected in the body.  
We confirmed that MPs were significantly better in targeted adhesion than NPs for all 
experimental conditions, with anywhere from 50% to 5,450% increase versus NPs, depending on 
the hemodynamic conditions. We found that both VTC modulus and targeting ligand regime 
could be tailored in vitro and in vivo to optimize adhesion given known hemodynamics. More 
deformable particles performed better at low wall shear rate (WSR), while more rigid particles 
 xvii 
adhered better at high WSRs. At high WSR, an increased ligand surface density improved the 
adhesion of deformable particles 27-fold, but not sufficiently to match the adhesion of rigid 
counterparts. While local shear rate dictated the optimal particle modulus, the local cellular 
protein expression dictated the adhesion kinetics required for optimized rigid NP and hydrogel 
MP adhesion. We found that a 25%-75% mix of ligand, skewed to the receptor which is lesser 
expressed, was consistently the most efficient at providing NP VTC adhesion, producing up to 9-
fold more adhesion.  
We found that the addition of targeting ligand to MPs did not significantly decrease the 
circulation in vivo. Targeted, deformable MPs showed maximal retention at the target site over 
time versus rigid particles of any size. Finally, we showed that hydrogel MPs can greatly 
increase the transport of 50 nm NPs to the vascular wall, up to 5,450% versus free 50 nm NPs. 
This work explores and explains trends that depend on both the physiological conditions and 
particle properties in vitro and in vivo. Overall, we emphasize the importance of particle size, 
modulus, targeting ligand regime, and the local targeted tissue environment in engineering 
maximally efficient VTCs. We present work from VTC formulation which concludes with 
applications in multiple in vivo models, to provide a big picture view of how multiple particle 
properties cooperate to affect targeted adhesion. 
 1 
: Introduction Chapter 1
 
1.1 Publication Information  
 The following text is in part from the publication: Fish, Margaret B., Alex J. Thompson, 
Catherine A. Fromen, and Omolola Eniola-Adefeso. “Emergence and Utility of Nonspherical 
Particles in Biomedicine.” Industrial & Engineering Chemistry Research. 2015. 54 (16): 4043-
4059. 
 
1.2 Background and Significance  
The design of new drug delivery systems has garnered significant attention in recent 
decades with the goal to greatly improve the treatment and diagnosis of major diseases including 
cancer and atherosclerosis.
1,2
 Systemic administration of small molecule pharmaceutics results in 
undirected distribution of the therapeutic throughout the body. This leads to unnecessary delivery 
to healthy cells, resulting in potentially severe side effects that trigger dose-limiting toxicity.
3
 
Paul Ehrlich coined the term “magic bullet” over a century ago, with the vision that a drug could 
be designed to preferentially target disease, thereby introducing the idea of drug delivery 
selectivity.
4,5
 To overcome the non-specific delivery of free therapeutics, particulate drug 
delivery systems ranging in size from a few nanometers to a few micrometers have been 
designed to specifically accumulate in the diseased tissue of interest, simultaneously increasing 
the local concentration and efficacy of the drug and decreasing systemic side effects.
6
  
 The change in size scale from a small molecule therapeutic to a particle creates both new 
opportunities, along with new challenges, for improving drug efficiency and specificity. The 
 2 
loading of drug cargo into or onto particle carriers
7
 improves upon freely soluble systems by 
protecting the cargo from degradation in the blood (enzymatic and hydrolytic) while providing 
controlled, sustained release. Unlike small molecule drugs, particle systems larger than 3 nm are 
unable to pass through the tight junctions of healthy endothelial cells (ECs) to the surrounding 
tissue, with some dependence on vasculature type.
8,9
 Particles are restricted to the circulatory 
system, subsequently increasing exposure to the vasculature and ECs. Capitalizing on this 
increased exposure, vascular targeted carriers (VTCs) have been proposed with surface ligands 
to actively target diseased ECs. Covalently attached ligands can complex with specific cellular 
membrane receptors to produce firm adhesion and can be designed with high specificity to ECs 
with various disease pathophysiology.
6,10
 Therefore, the gold standard in this field is to engineer 
VTCs which simultaneously increase local therapeutic payload through specific EC-targeting 
while decreasing systemic exposure and related toxicity.
11,12
 Realization of such a system will  
greatly improve the therapeutic outcome of a wide variety of treatments, impacting diseases 
ranging from cancer, autoimmune disorders, cardiovascular disease, and more. This work has the 
true potential to unlock treatments by molecules previously unavailable, due to systemic toxicity, 
for a broad range of ailing patients. 
In the design of targeted drug carriers, it is imperative to engineer for the entire biological 
journey, from injection to intended site of delivery, to achieve maximal targeting efficacy. While 
the golden standard of VTCs sounds miraculous, there have been significant hurdles limiting 
translation into the clinic,
13,14
 requiring the understanding of complex biological systems to 
progress towards successful vascular-targeting. VTCs must successfully evade immune capture, 
distribute to the targeted organ, localize to the endothelial layer of a blood vessel in dynamic 
blood flow, be taken up by cells of interest, and release drugs on an appropriate time scale for the 
 3 
disease model. Given this complex series of barriers, further understanding of targeted particle 
delivery systems is required before they become commonplace in the clinic. Control of physical 
particle properties to alter particle behavior at different stages of this biological journey holds 
great promise for improving the efficacy of targeted particulate carriers.
15–17
 While many studies 
have approached the concept of optimizing physical VTCs properties, often the studies are 
conducted in over-simplified systems, when maximally physiological experiments are needed to 
truly imitate the biological barriers to VTC adhesion. Here, we aim to provide a holistic view 
engineered VTC properties, with the hypothesis that VTC physical parameters, including the 
size, modulus, targeting regime, and more, interplay with each other to collectively determine the 
final success of VTC systems in vivo. Furthermore, we hypothesize that these particle properties 
interplay with physiological considerations, such as local hemodynamics and endothelial cell 
expression patterns, to result in optimized VTC properties, tailored for each different 
experimental condition.  
 
1.3 Important Physiological Considerations for Vascular Targeting 
By loading drugs into or onto particulate carriers, the resulting change in size scale from 
small molecule to particle has revealed new biological hurdles that are highly specific to certain 
particle sizes.
18
 Injected particles face physical barriers throughout the body, including filtration 
by the spleen, liver, and kidney, which restrict passage of particles of varying sizes and 
deformabilities. Particle carriers are the ideal size to interact with the reticuloendothelial system 
(RES), an active network of phagocytic cells, such as monocytes and macrophages, which are 
responsible for clearing foreign objects rapidly from the blood stream. Macrophages of RES 
organs, especially in the spleen and liver, are known to clear a large number of particle carriers 
 4 
from the blood stream.
19,20
 Furthermore, recent work in our lab has demonstrated that circulating 
neutrophils, phagocytic blood cells, are also capable of actively sequestering and clearing 
particles from blood stream.
21
 This cellular clearance has an obvious impact on the number of 
particles that have the chance to interact with the tissue of interest. Overall, it is imperative to 
understand each biological barrier individually affects our VTC efficacy in order to design 
particles to avoid as many clearance mechanisms as possible. 
 
RES clearance and organ biodistribution 
 As VTCs travel through the blood stream, they encounter an enormous number of 
barriers, which must be accounted for in the particle design to ensure eventual targeted delivery. 
The kidney’s glomerular filtration relies on the convection and mostly the diffusion of small 
compounds through the fenestrated capillary endothelium and across the subsequent podocyte 
filtration slits. The kidney freely filters hydrophilic particles and compounds with radii less than 
6 nm, meaning drug delivery particle systems are typically too large for kidney filtration.
22
 
Overall, kidney clearance can be diminished or eliminated if at least one axis of the particle is 
larger than 6 nm, irrespective of the specific shape. This is in stark contrast to hydrophilic small 
molecule drugs, which are often limited by renal clearance and toxicity, as the drug freely filters 
through the fenestrated capillary endothelium.
23
 Lipophilic small molecule drugs often bind to 
serum proteins, such as albumin, which can decrease their accumulation in the kidney until 
broken into more hydrophilic portions by endogenous enzymes.
24,25
 
 Circulating particles will rapidly encounter clearance mechanisms in the complex 
vasculature of the spleen. The human splenic artery branches and narrows through cords of 
billroth, which serve as an immunoactive filter with a pore size ~500 nm.
26
 Anything caught in 
 5 
the spleen is readily phagocytosed by resident macrophages.
27
 Researchers widely accept spleen 
filtration as a mechanism to clear damaged red blood cells (RBCs) and other objects above the 
pore size cut-off. Whereas free drug simply passes through the spleen, the spleen pore size 
requires that particles larger than 200 nm deform to pass through the filtration system or risk 
immune clearance.
28
 Larger, spherical VTCs have always shown significant accumulation in the 
spleen and researchers have proposed deformability as a way to mitigate this accumulation.
29
 
 The liver is a large organ of the digestive system but also plays a significant role in RES 
responses. In the context of the RES, the liver is comprised of hepatocytes and liver-specific 
macrophages called Kupffer cells, which both metabolize foreign or toxic substances. In the 
liver, blood flow splits into discontinuous sinusoids lined with fenestrated endothelium with gaps 
up to 150 nm. Hepatocytes form a layer behind the endothelium and phagocytic Kupffer cells, 
which project into blood flow to collect foreign entities in blood.
30
 Kupffer cells account for 80-
90% of fixed macrophages in the entire body; they use foreign surface protein patterns to 
identify non-endogenous entities, rendering the liver a highly immunoactive organ.
31
 To avoid 
this well-known mechanism of liver clearance, much research has aimed at alleviating the 
absorption of plasma proteins onto particle surfaces.
18,19
 Overall, the size of particles entrapped 
into the liver is controlled by both the size of capillary fenestrations and the phagocytic 
capabilities of resident Kupffer cells.  
These interactions the innate defenses of the human body will dictate the overall fate, or 
biodistribution, of a VTC in an animal. Particles will continue to pass through the various 
filtration systems and RES mechanisms and ultimately distribute to different tissues in the body. 
One challenge with the implementation of injectable micro/nanocarriers is in understanding and, 
more importantly, controlling the fate of the carrier system. Typically, particulate drug carriers 
 6 
large enough to avoid kidney clearance accumulate in the organs of the RES, with the majority 
of the dose removed from circulation in minutes to hours. Biodistribution can be skewed to the 
targeted organ by modifying the particle surfaces with various ligands.
32,33
 Changes in particle 
material type (lipid-based, polymeric, metallic)
34
, size (nanometer to micrometer scale)
35
, drug 
loading method (encapsulated, ionic interaction, or covalently linked)
36
, and surface chemistry 
(use of targeting ligands, surface coatings, and charge) have been explored to alleviate RES 
particle clearance.
37
 Additionally, researchers have extensively shown that deformable VTCs 
remained in circulation longer, shifting the overall time horizon and biodistribution versus rigid 
equivalents.
38,39
 Indeed, physical and chemical properties of particulate drug carriers dictate the 
overall biodistribution; this information is key to engineering systems which avoid the RES 
sufficiently to deliver a clinically viable drug delivery system.
11
 
 
Particle margination 
If particles are able to elude the clearance mechanisms of the RES, they must then 
navigate the vasculature, interact with the correct tissue and cell type, and release the payload for 
maximal therapeutic effect. Thus, VTCs must navigate the dynamic environment of the blood 
stream to reach the target tissue. The ability of an injected carrier to “marginate”, or localize 
from human blood flow to adhere the periphery of the vessel, is key to ensuring properly specific 
EC distribution. In blood flow, a RBC core develops for two key reasons: 1. due to 
heterogeneous collisions between highly deformable RBCs and more rigid leukocytes, and 2. due 
to wall-induced lift preferentially experienced by more deformable entities in flow.
40,41
 Similar to 
leukocytes and platelets, VTC with functionality designed to interact with the endothelium needs 
to also exit the RBC core of bulk blood flow and marginate under physiological conditions.  
 7 
It is well known that RBCs play a role in the margination of leukocytes and platelets; 
thus, it is important to determine how RBCs influence particle margination. It is imperative to 
conduct these studies in whole blood flow, so that true margination can be experienced by the 
VTCs, unlike in buffer flow. Researchers have shown that for rigid and deformable particles, the 
ability to marginate in the presence of blood components is highly dependent on size.
10,42–46
 In 
general, particles with diameters 2-5 micrometer, markedly about the same size as a platelet, 
preferentially displace to the RBC cell-free layer (RBC-FL) in the presence of RBCs, while 
smaller 100-500 nm particles do not experience this enhanced localization.
42–46
 This difference in 
margination directly results in significantly better adhesion of 2 µm particles versus 500 nm 
particles. While size is well-established as a particle property that significantly influences 
hemodynamic behavior, the importance of other physical properties, such as deformability, are 
less understood both experimentally and computationally.  
 
Opsonization and protein coronae 
 Once particles are at the vascular wall, the integrity and steric availability of the targeting 
ligands is key for adhesive functionality. Adsorption of plasma proteins onto the surface of 
particles initiates the inevitable biological clearance of VTCs by phagocytes. This rapid, 
unavoidable effect of intravenously delivered particles begins within seconds,
47
 and directly 
defines the biological signature of the VTC, with significant implications for immune clearance 
rate. This protein corona is a function of many variables, including particle size, shape, 
hydrophobicity, material, exposure time, and more,
48
 and it produces opsonization, or the 
adsorption of “opsonins”, typically immunoglobulins and complement, which initiate 
phagocytosis and clearance of VTCs from the blood. Phagocytes in the RES then rapidly clear 
 8 
VTCs from the blood stream, diminishing their clinical utility.
18,19,49,50
 For this reason, the 
plasma protein corona is very well studied on many different particle types, mostly with the end 
goal of lessening or eliminating adsorption all together. 
 Poly(ethylene glycol) (PEG) is a hydrophilic monomer that has been reviewed and used 
extensively as a surface coating or ligand to mitigate plasma protein adsorption and opsonization 
effect and the immune recognition described above.
51
 The efficiency of PEG as a coating is 
highly dependent on the particle surface concentration; low concentrations (mushroom regime) 
do not exhibit efficient repulsion of plasma proteins whereas high concentrations (brush regime) 
allow for the most effective immune evasion. This transition from mushroom to brush is 
determined by the PEG molecular weight and the spacing between monomers.
52–54
 In general, 
PEGylated particles show longer circulation times in animal models versus non-PEGylated 
particles; particles with brush conformation show better immune evasion than mushroom 
conformation, though any amount of surface grafted PEG greatly improved the pharmacokinetic 
(PK) parameters versus a polymerized surface.
32
 For polymerized PEG-based materials this 
“PEGylation” effect is lessened due to the lack of free, hydrophilic PEG end groups.38,55 Overall, 
PEG was initially proposed as a hydrophilic ligand to decrease immune response, and while 
some clinically viable systems have been developed, the initial excitement for this strategy has 
faded. Therefore, it is of key interest to study and understand how other VTC properties may 
improve targeted adhesion.  
 
1.4 VTC Design Parameters 
The biological barriers innate to the human body, which efficiently protect against 
infection and disease, also prescribe certain restrictions on VTC design, however, there is an 
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immense parameter space of physical properties that can be optimized to maximize the 
accumulation at the targeted site. The efficiency of vascular targeting is determined by the 
amount of the particle dose that specifically accumulates in the diseased region or tissue of the 
body. Therefore, particles with high targeting specificity must be designed to maximally 
accumulate in the region of disease while minimally accumulating elsewhere in the body. 
 
Particle fabrication and composition 
 There are a wide variety of fabrication methods for drug delivery particles, including top-
down methods such as soft lithography, specifically particle replication in non-wetting templates 
(PRINT),
56
 and bottom-up methods including emulsion, self-assembly, spray drying, 
electrospraying, any many more.
57–61
 In addition, some of these methods are amenable to 
multiple of the traditional biomaterials, including a whole host of biocompatible polymers, such 
as poly(lactic-co-glycolic acid), poly(capralactone), PEG, polylactic acid, dextran, chitosan and 
many more.
62
 Additionally, polymer chemists and physicists have engineered “smart” polymers 
which respond to different stimuli such a pH, temperature, magnetic fields, and much more.
63
 
Other than polymers, VTCs can also be composed of inorganic materials, such as iron oxide, or 
lipid, which are frequently seen in clinical trials. Taken together, this massive range of particle 
fabrication techniques, in combination with all of the possible biocompatible materials, affords 
an incredible range of physiochemical properties to be tuned. As such, the fabrication method 
and material are likely the first design parameter to consider. Simply put, this many degrees of 
freedom in design necessitates well-designed studies to identify key VTC properties without 
confounding variables.   
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Particle size  
 Size is the most-studied physical characteristic of particulate drug carriers. Indeed, the 
conception of particulate drug carriers was driven by the idea of tailoring particle size to exploit 
the leaky vasculature of cancerous tissues. Particles were designed with diameters between 20-
100 nm to preferentially leak out of the abnormally fenestrated tumor vasculature while avoiding 
both renal and RES clearance, in a phenomenon labeled the enhanced permeation and retention 
(EPR) effect.
11
 Since the origination of particulate drug delivery, many levels of complexity have 
been imparted into particle design, but particle size often still drives the overall behavior.  
 When detailing the RES clearance mechanisms, it is clear that particle size determines 
many biological interactions in vivo. At the organ level, particles less than 6 nm will be cleared 
by diffusion through the kidneys, rigid particles larger than ~500 nm will become entrapped in 
the spleen, and particles 1-2 µm in size range will be cleared via the liver. At the blood flow 
level, particle size has been shown to control the margination efficiency in bulk blood flow, with 
microparticles performing significantly more efficiently than nanoparticles.
10,46,64,65
 Finally, on 
the cellular level, the radius of curvature has been identified as the key property that controls 
both the amount of protein opsonization and rate of phagocytosis.
18,66–68
 Phagocytes use the 
radius of curvature to extrapolate the overall size of the object; particles with large radii of 
curvature induce frustrated phagocytosis and better avoid uptake,
68–70
 whereas particles with a 
small enough radius of curvature avoid protein opsonization and are not recognized by 
phagocytes.
71
 Overall, controlling or evading these clearance mechanisms increases the 
probability that the particles will accumulate at the site of interest. 
 On the blood flow level, particle size has been shown to control the margination 
efficiency in bulk blood flow.
10,46,64,65
 Particle size also drives critical ligand-receptor 
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interactions necessary for VTCs. Targeted adhesion requires that the adhesive force between the 
particle and endothelium receptors is stronger than the shear removal force of the blood flow. 
Size affects this delicate balance in two competing ways: (1) larger particles experience larger 
shear removal forces that can produce particle detachment and (2) larger particles have more 
ligand-receptor pairs available for adhesion at the cell-particle interface due to the larger radius 
of curvature. 
 Particle size greatly affects the amount of cargo that can be loaded into the particle and 
the resulting release kinetics.
72,73
 The exact effect depends on the physiochemical interactions 
between the drug and particle. Zero-order drug release kinetics have been the golden standard in 
drug delivery for decades; zero-order means that the drug release rate is constant independent of 
the amount remaining in the particles.
74
 If one can achieve sustained release at a constant rate, 
then a therapeutic dosage can be maintained and controlled over much longer periods of time 
compared to free drug administration. First order release slows linearly as the concentration in 
the particle decreases and second order slows exponentially; these release kinetics still deliver an 
improvement over free drug, but are not considered truly sustained release. For spherical 
particles, the smaller the particle, the larger the surface area to the volume ratio, which has direct 
implications on the release kinetics; the more exposed surface area, the faster the particle 
degradation and the more of an overall burst release. Larger particles degrade slower and 
therefore provide more of an extended release profile. The release of drugs loaded physically or 
covalently into a biomaterial matrix depends on many factors, including drug-polymer 
interaction strength, diffusivity out of the particle, surface area to volume ratio, amount of drug 
loaded, and more. Size directly affects the surface area to volume ratio, and thereby greatly 
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changes drug release profiles. 
57
 Overall, particle size directly determines the amount and overall 
release profile out of biocompatible drug carriers. 
 
VTC targeting ligands 
  VTCs achieve tissue specificity with active ligand-receptor targeting, which exploits 
differential expression of certain inflammatory proteins on the membranes of vascular ECs, 
thereby eliminating the need to rely on size for passive accumulation. Marked changes in 
endothelial surface expression occurs in disease;
75–77
 particles are engineered to capitalize on 
these variations, to have high affinity in the diseased vasculature and low affinity elsewhere. For 
example, in generally inflamed vasculature, which is associated with many acute and chronic 
diseases, multiple classes of molecules are upregulated on the endothelium surface. These 
markers include E-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular 
cell adhesion molecule-1 (VCAM-1), which all play a different role in the leukocyte adhesion 
cascade (LAC).
78,79
 The upregulation of inflammatory markers leads to the recruitment, 
adhesion, and transmigration of circulating leukocytes into the tissue space, which progresses the 
inflammatory disease.
80
 While leukocytes typically bind to these receptors, the change in EC 
expression provides a platform for targeting particulate therapeutics to these receptors, and 
subsequently, the site of disease.   
 Targeting ligands come in many sizes and molecular motifs, including small molecules, 
aptamers, affibodies, receptors, and antibodies.
6,81–83
 Researchers have evaluated selectins for 
their natural ligands on WBCs and contributions to the LAC and inflammation.
84
 Some of the 
initial motivation for targeting these particular molecules arose out of observing the innate LAC. 
Most studies of VTCs focus on particle designs with a single ligand-receptor (LR) pair, with 
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emphasis on disease outcome of the delivered drug. Efficacy studies that have probed dual 
ligands are largely qualitative, comparing multi-ligand particles versus their single ligand 
counterparts with minimal control over the total ligand presentation on the particle.
85–89
 Many 
studies have probed the importance of ligand ratios between two LR pairs in static conditions, 
which fail to capture the LR pair dynamics under physiologically relevant flows.
85,90
 Studies 
involving three distinct targeting ligands delivered improvements in targeted adhesion in vivo 
over a single ligand, but not over dual targeting. Often these systems are tested in buffer under 
static conditions in vitro, and then are injected into animal models. Much more robust 
understanding of targeting ligand kinetics in hemodynamic blood flow is required to inform the 
intelligent design of VTCs for targeting. 
 For VTCs, the conjugation of these constructs onto the surface of particles imparts high 
affinity for areas of vasculature with overexpression of the targeted molecules. Ideally, the 
particles will freely circulate until they encounter an area of vasculature for which their targeting 
ligands impart high binding affinity, and then they will bind. However, adding targeting ligands 
changes the protein corona opsonized onto the surface and is thought to decrease the overall 
circulation time.
12,91
 Therefore, there is still open discussion in the field about whether targeting 
ligands are rational in vivo due to their added complexity and resulting decrese in circulation 
time. A few strategies have been employed to try and mitigate this: PEG has been conjugated 
with targeting ligand to decrease immune recognition. Sterically, the targeting ligand must 
extend further than the PEG layer to be available for targeted receptor binding. The targeting 
ligand on the free end of PEG increases the amount of protein opsonization versus free PEG—
researchers confirmed that the targeting moiety itself changes the pattern of proteins on the 
surface, regardless of brush PEG density.
92,93
 In vivo, the amount and length of PEG must be 
 14 
optimized versus the corresponding length and amount of targeting ligand present; otherwise 
there may be sacrifices in both stealth and targeting functionality.
94
 Despite decades of research, 
PEG has not provided a “one size fits all” solution for decreasing the immune recognition of 
VTCs. An additional hurdle with PEG has been uncovered recently; humans have increasing 
amounts of anti-PEG antibodies in their blood stream due to the amount of PEG found in 
consumer products and therapeutics.
95
 Thus, there is not yet a magic bullet solution that increases 
the circulation time of all particle systems. With all of this in mind, one is left wondering what 
the actual effect of targeting ligand addition is on diseased site accumulation, independent of 
circulation time. 
 
Particle modulus 
 As more biocompatible particulate carriers are developed for commercial use, researchers 
have increasingly employed PEG as the bulk material, rather than just a surface coating, because 
of its modularity and broad range of functionalities.
96,97
 Both top-down and bottom-up 
approaches allow for the tuning of PEG-based particle modulus, by either altering the amount of 
covalently cross-linked PEG (%v/v) in the synthesis or by altering the cross-linking density 
within the hydrogel by including monofunctional monomers. Of note, the higher the molecular 
weight of the PEG, the less soluble in water and hydrophilic;
98
 the free end groups are key for 
producing the “PEGylation” effect of resisting protein opsonization, and therefore are not 
imparted on crosslinked PEG particles. Macrophages readily recognize polymerized PEG 
surfaces, which leads to rapid clearance from the blood stream.
32,38
 Therefore, despite 
researchers’ best efforts, many of these crosslinked PEG particles are afflicted with the same 
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issues as particles composed of other polymers, including rapid clearance and lack of 
accumulation into the targeted tissue. 
Recently, much of the development in PEG-based particles has focused on exploring the 
particle modulus as a key parameter to shift the overall biodistribution and circulation profiles. 
Indeed, the entire field of bio-mimetic particle carriers uses mimicry of many biological features, 
including the highly deformable nature of most endogenous biological entities.
38,99–102
 
Researchers have explored particles of varying modulus to determine how the RES system 
responds and the resulting biodistribution. In general, more deformable particles are known to 
circulate longer by avoiding recognition, filtration by or interaction with the immune system, and 
by better squeezing through natural immune filters such as the spleen.
38,39,103
 Additionally, it has 
been well-established that phagocytic immune cells, such as macrophages, phagocytose rigid 
particles significantly more rapidly than deformable particles of the same composition.
38,39,104–106
 
Therefore, by understanding the mechano-responsiveness of phagocytic immune cells, particles 
can be engineered to better avoid immune clearance. Overall, particle modulus is emerging as a 
key VTC physical property, with researchers interested in circulation time, biodistribution, cell 
uptake, and margination processes. 
1.5 Opportunities in Vascular Targeting 
Despite the idea of vascular targeting has existed for decades, few systems have made it 
through clinical trials; those particle systems that are approved are mainly non-targeted 
liposomes or PLGA NPs.
14,107,108
 The concept of vascular targeting has the potential to 
revolutionize the treatment of a broad range of diseases; the main requirement being that the 
endothelium has a different surface protein marker pattern than healthy endothelium. In 
particular, diseases such as cancer and cardiovascular disease, which cause a massive number of 
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deaths per year and are marked by chronic inflammation, are amenable to advances in particulate 
drug delivery.  Researchers have spent a massive amount of time and energy investigating 
different particulate, and more recently, VTC systems. Recurring from throughout the 
introduction, VTCs need to be evaluated in increasingly physiological systems. As a prime 
example, many VTCs are studied in the absence of shear flow and without key blood 
components, such as RBCs and phagocytic leukocytes. While this work provides basic insight 
into VTC behavior, in order to contribute the most translatable work possible, relevant 
physiological components should be included in studied. For instance, VTC uptake by cells in 
static buffer cannot accurately represent the dynamic environment of blood, which must be 
navigated to accomplish any cellular uptake in vivo. VTCs in static buffer do not have to evade 
immune clearance or compete with leukocytes for binding sites on the inflamed endothelium. 
Indeed, most research lacks the key complexity delivered by the involvement of blood. We 
hypothesize that through fine control of particle modulus, better-characterized ligand kinetics, 
and experiments designed to facilitate conclusions about the collective influence of multiple 
VTC properties, we have the potential to deliver significant advances in the field of VTCs based 
on physiologically relevant scenarios.  
 
1.6 Organization of the Dissertation  
The work presented in this dissertation is focused on the engineering of the physical 
properties of PEG-based particles, including size, modulus, and targeting ligand regime, for 
optimal targeting performance and adhesion, evaluated extensively both in vitro and in vivo. We 
hypothesize these parameters of the physiochemistry of the particles can dramatically increase 
the VTC efficiency to produce large impacts in the clinic.  
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 Chapter 1 lays out the background and motivation for the experimental work presented in 
this dissertation, including a general overview of VTCs and the key design parameters to lever in 
engineering new systems.  
 Chapter 2 is a description of the materials and methods utilized to obtain the experimental 
data for the rest of the dissertation.  
 Chapter 3 is an experimental exploration of the importance of PEG-based particle 
modulus and size for both in vitro and in vivo targeted adhesion and drug delivery. We detail the 
margination, responses to physiological blood forces, and adhesion to inflamed endothelium 
using both a flow chamber and intravital microscopy in murine mesentery venules.  
 As we only focused a single ligand receptor system and a single site density in chapter 3, 
chapter 4 provides experimental analysis of the interplay of two different targeting ligands, their 
site densities, and particle modulus on hydrogel MPs to prescribe the final targeted adhesion to 
inflamed endothelial cells in vitro. 
 In an effort to improve the targeted adhesion of rigid NPs, chapter 5 employs two 
different targeting ligands on 500 nm PS particles to explain how dual targeted particles with 
ligands of different kinetics work together to produce maximal binding both in vitro and in vivo 
in a model of mesentery inflammation. This chapter is a collaborative project with Dr. Catherine 
Fromen; I have only included the work to which I contributed significantly. 
 Considering the extensive investigation into targeting ligand regime in chapters 4 and 5, 
chapter 6 provides a detailed in vivo perspective on how adding targeting ligand to PEG particles 
affect both their circulation time, biodistribution, and accumulation at the site of inflammation. 
 Chapter 7 combines much of the previous accrued knowledge to highlight how PEG-
based particles can be used as Trojan Horse carriers for much smaller NPs to the vascular wall. 
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This experimental work provides clear head to head comparisons of how free NPs and packaged 
NPs accumulate at the site of inflammation both in vitro and in vivo. 
 Chapter 8 provides the overarching conclusions of this dissertation and the future 
directions and outlook for both this work and the general particulate drug delivery field.  
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: Materials and Methods Chapter 2
 
2.1 Introduction 
This chapter details the materials and methods utilized to complete the experimental 
research described in the following five chapters of data. Details about the materials and 
protocols are given to allow for reproduction of results described. A range of VTCs are prepared 
and the ability to adhere to inflamed endothelium under a variety of hemodynamic and 
inflammatory conditions are investigated, both in vitro using a parallel plate flow chamber 
(PPFC) assay and in vivo using murine models of inflammation with a variety of tools to 
evaluate adhesion in real time and over longer time scales. The materials (and source) are listed 
within the specific subsection for which that material was utilized. 
 
2.2 Particle Fabrication  
Polystyrene (PS) particles 
Fluoresbrite® YG, Carboxylated polystyrene spheres (50 nm, 500 nm, and 2 μm 
diameter) were purchased commercially from Bangs Laboratories (Fishers, IN).  
 
PEG- hydrogel particle fabrication 
Poly(ethylene glycol) diacrylate (PEGDA, Sigma Aldrich, St. Louis, MO), 2-
carboxyethyl acrylate (CEA, Sigma Aldrich, St. Louis, MO), acryloxyethyl thiocarbamoyl 
Rhodamine B (Rhodamine, Polysciences, Warrington, PA), and lithium phenyl-2,4,6-
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trimethylbenzoylphosphinate photoinitiator (PI) were combined into methanol at predetermined 
concentrations to produce a range of crosslinking densities and a range of hydrogel material 
properties. The PI was synthesized in house as previously published by others.
109,110
 The 
methanol-PEG solution was emulsified into silicone oil via probe sonication at 15% intensity. 
The solutions were then exposed to a 365 nm UV light for 2 minutes to initiate polymerization. 
A series of centrifugation and filtration steps were utilized to obtain particles of desired size and 
monodispersity. First, the particles were filtered through 2 µm filter tips to eliminate larger 
particles. Then, the stocks were diluted into 15 mL conical tubes and centrifuged at 1500xg for 5 
minutes; the pellets were kept and the supernatants containing smaller particles were moved to a 
different tube. The pellets were resuspended in 1% PVA and probe sonicated. This process was 
repeated twice more to remove smaller sized particles and establish a 2 µm particle stock. The 
collected supernatants containing smaller particles were centrifuged at 3000xg for 10 minutes 
three times. The pellet was kept and resuspended in 1% PVA each repetition. The final pellet 
was kept as the 500 nm hydrogel particle stock. The particles were covalently modified and 
characterized, as described in more detail later. 
 
Loaded PEG-hydrogel fabrication 
  PEGDA, CEA, Rhodamine, and PI were again combined into methanol at predetermined 
concentrations. Unmodified, carboxylated PS nanoparticles (NPs) (Bangs Laboratories, Fishers, 
IN) were loaded directly into hydrogels matrices in the following way. First, the commercial 
stock of NPs was concentrated via centrifugation and then lyophilized to remove any residual 
liquid. All other components of the hydrogels were added directly to this dried NP powder to 
minimize any possible loss by powder transport. The resulting solution was emulsified and 
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polymerized such that the NPs were physically entrapped into the hydrogel matrix. All particle 
stocks were diluted in 1% PVA, filtered through a 2 µm filter, and washed at least 3 times before 
quantifying the median fluorescent intensity (MFI). The % v/v used in the hydrogel formulation, 
specifically 2.3%, 3.9%, 7.8%, and 15.6% v/v, is reported quantitatively in chapter 7 so that NPs 
of different sizes can be directly compared. To convert the MFI to a number of NPs per hydrogel 
microparticle (MP), a standard curve of NP concentrations was established on a Biotek 
microplate reader (Winooski, VT). After thorough washing to remove any free 50 nm NPs, 
hydrogel MPs were evaluated in a 96 well plate at a fixed concentration of 1E7 hydrogel 
MPs/well. The reading was converted to number of NPs loaded after subtracting out unloaded 
MP background and using a calibration curve of 50 nm NPs.  
 
Particle characterization methods 
Malvern Zetasizer Nano-ZS (Malvern, Westborough, MA) was used to determine the 
size, zeta potential, and polydispersity index (PDI) of all particle stocks. Particle samples were 
diluted in water for all measurements and run in triplicate. Particle morphology was monitored 
by scanning electron microscopy (SEM); samples were sputter-coated with 10 nm of Au (SPI-
Module Carbon/Sputter Coater, West Chester, PA) and imaged dry using a Philips XL30 FEG 
scanning electron microscope (SEM) (Hillsboro, OR). The NP-loaded hydrogels were imaged 
via confocal fluorescent microscopy, to confirm the co-localization of rhodamine in the hydrogel 
matrix backbone and green fluorescence of the 50 nm PS NPs. 
 
2.3 PEG Material Characterization Methods 
Equilibrium swelling ratios(ESRs) 
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 Bulk hydrogels of the same composition as particles were polymerized in 
polytetrafluoroethylene molds (Ted Pella, Redding, CA) and transferred into 5 mL water to 
swell. The water was exchanged twice to rinse out unpolymerized polymer. The hydrogels were 
then placed in water or blood plasma for 24 hours at 37°C. The swollen samples were weighed, 
rinsed of possible residual plasma proteins, lyophilized for 48 hours (Labconco Freezone 2.5, 
Kansas City, MO), and then weighed again dry. The ESR is calculated as shown in equation (1).  
 
𝐸𝑆𝑅 =
𝑆𝑤𝑜𝑙𝑙𝑒𝑛 𝑀𝑎𝑠𝑠
𝐿𝑦𝑜𝑝ℎ𝑖𝑙𝑖𝑧𝑒𝑑 𝑀𝑎𝑠𝑠
; 𝑢𝑛𝑖𝑡𝑙𝑒𝑠𝑠 
[1] 
 
The experimental dried mass was directly compared to the theoretical dried mass to confirm 
complete polymerization of all samples.  
 
In situ rheometry 
In situ polymerization was performed beginning with unpolymerized hydrogel precursor 
solutions, whose compositions are detailed in the respective chapters. These precursor solutions 
were injected into a 500 µm gap between the head and stage of an AR-G2 Rheometer (TA 
Instruments, New Castle, DE). A 20 mm rheometer head was used for in situ polymerization data 
collection. The 365 nm UV light source, built into the stage, was turned on at an intensity of 10 
mW/cm
2
 at time 0 and the resulting changes in G′ and G″ were recorded ~8 times/second. 
 
Swollen rheometry 
Hydrogel coupons were polymerized in polytetrafluoroethylene molds (Ted Pella, 
Redding, CA), allowed to swell in water overnight, and then 8 mm cylinders were punched out 
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for experimental sampling. For all rheometry, the same formulation was used in the bulk molds 
as for the particles of interest, including when loaded with NPs. For all swollen conditions, an 8 
mm rheometer head was used and the % strain was altered on the AR-G2 Rheometer (TA 
Instruments, New Castle, DE) depending on the material properties, from 0.1% for rigid and 
10% for deformable. The rheological sampling parameters were validated via frequency and 
amplitude sweeps, as shown in Figure 2.1, prior to gathering experimental data. To convert from 
shear modulus (G) to Young’s modulus (E) we use equation (2), assuming a Poisson’s ratio, of 
𝜐=0.5, as can be done for elastic materials such as swollen hydrogels.111  
 
𝐸 = 2𝐺(1 + 𝜐); 𝑃𝑎  [2] 
 
The controlled shear stress experiments were conducted on swollen bulk hydrogels at a gap 
height of 3 mm. The rheometer swept a range of predetermined stress inputs at 37°C and 
determined the resulting percent strains, dependent on hydrogel condition.  
 
 
 
Figure 2.1 Validation of rheological sampling parameters.  
(A) Frequency and (B) amplitude sweeps of a hydrogel composed of 40% solids. These sweeps 
ensure hydrogel integrity over sampling ranges used to test bulk materials. Across the frequency 
sweep, different oscillatory frequencies are tested to determine if internal structure of the gel 
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changes with measuring conditions; Figure 2.1A shows that the internal structure of our gels is 
consistent. The amplitude sweep defines the viscoelastic amplitude range for hydrogels; Figure 
2.1B shows little change over a broad range of oscillatory stresses tested.  
 
Calculated hydrogel properties  
The density (kg/m
3
) and pore size (nm) of our hydrogel materials were calculated as 
previously reported.
112
 Density is calculated utilizing equilibrium volume fractions of each 
precursor component. Pore size depends on the bulk density, Young’s modulus, temperature and 
polymer volume fraction. 
 
2.4 Particle Surface Modifications and Ligand Density Quantification 
Targeting for in vitro experiments 
CEA functionality was incorporated throughout the hydrogel particles, resulting in 
terminal carboxylic acid functional groups. NeutrAvidin (Thermo Scientific, Waltham, MA) was 
covalently attached to the carboxylic acid end groups on both PS and hydrogel particles via 
carboiimide chemistry. Particles were washed with 2-(N-morpholino)ethanesulfonic acid buffer 
(Thermo Scientific, Waltham, MA) and incubated with a NeutrAvidin® solution (5 mg/ml) for 
15 minutes at room temperature, after which an equal volume of N-(3-Dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDC, 75 mg/ml, Thermo Scientific, Waltham, MA) was 
added and pH adjusted to 8.0. After incubating for 24 hours, glycine (7.5 mg/ml, Sigma Aldrich, 
St. Louis, MO) was added for 30 minutes to quench the reaction. NeutrAvidin®-conjugated 
particles were then washed with a phosphate-buffered saline (50 mM) and stored at 4°C until 
ligand conjugation.  
Biotinylated ligands were then coupled as described previously.
46
 NeutrAvidin®-
conjugated particles were incubated for 45 minutes with a mixture of multivalent Sialyl Lewis
A
-
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PAA-biotin (sLe
A
, Glycotech, Gaithersburg, MD) and/or biotinylated anti-human CD54 (R&D 
Systems, Minneapolis, MN) at room temperature. Following incubation, particles were washed 
with phosphate-buffered saline containing calcium and magnesium ions and 1% bovine serum 
albumin and were then stored at 4°C until same day use for flow adhesion experiments or ligand 
site characterization.  
 
Targeting for in vivo experiments 
Particles were conjugated with NeutrAvidin, as detailed above. For in vivo experiments, 
biotinylated anti-mouse CD62P (BD Biosciences, San Jose, CA), sLe
A
, and/or biotinylated anti-
mouse CD54 (Biolegend, London, UK) were coupled to NeutrAvidin-coated particles, by again 
rotating at room temperature for 45 minutes and washing. The particles were characterized by 
comparison to a curve of standard beads, and conjugated for final total site densities detailed in 
each relevant chapter. 
 
Quantification of ligand site density 
Particles with targeting moieties were stained to determine the number of ligands per 
surface area of particle. Anti-cutaneous-lymphocyte-associated antigen-APC/fluorescein 
isothiocyanate (FITC) (Miltenyi Biotec, Auburn, CA), anti-rat IgG2b-PE (Thermo Scientific, 
Waltham, MA), anti-rat IgG2b-APC (Biolegend, London, UK), and anti-rat IgG1-APC were 
used to stain sLe
A
, anti-human CD54, anti-mouse CD54, and anti-mouse CD62P, respectively. 
The MFIs of APC, FITC, or PE were compared to both non-stained particles and either APC, 
FITC, or PE calibration bead curves (Bangs Laboratories, Fishers, IN). Particle surface area and 
MFI were used to compute the site density in # sites/µm
2
, as previously described. 
93,113
 For dual 
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targeted particles, stains were selected that did not overlap in fluorescence, to obtain the site 
densities of both ligands concurrently. A representation of the site densities obtained on Attune 
NxT Focusing Flow Cytometer (Life Technologies, Carlsbad, CA) is shown in Figure 2.2. 
 
 
 
Figure 2.2 Representative gating for particle site density calibrations. 
(A) Calibration beads from Bangs Laboratories were run on the flow cytometer at the same 
voltages as the particles tested. The median fluorescence intensity (MFI) of each bead (0-5) was 
recorded for FITC and a calibration curve made with known molecules of soluble fluorochrome 
(MESF) units provided by manufacturer. (B) Particles (2 µm shown) identified by forward (FSC) 
and side (SSC) area, and positive signal in the BL2 Rhodamine/PE channel. MFIs for FITC was 
determined for sLe
A
 using anti-cutaneous lymphocyte associated antigen, anti-CLA-FITC. MFIs 
were converted to units of MESF using the calibration curve from A. 
 
2.5 HUVEC Culture and Characterization 
HUVEC isolation and culture 
Human umbilical vein endothelial cells (HUVECs) used in all assays were isolated from 
healthy umbilical cords (Mott Children’s Hospital, Ann Arbor, MI), which were obtained via an 
approved human tissue transfer protocol. Briefly, the umbilical vein was filled with collagenase 
and incubated for 20 minutes to degrade the extracellular matrix and free the endothelial cells. 
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The collected cells were then plated onto a gelatin-coated T75 flask and washed until reaching 
confluence. Each cell batch was pooled from at least 3 umbilical cords. Isolated HUVEC were 
cultured in gelatin-coated T75 flasks at 37C and 5% CO2 until passage 5, after which they were 
discarded. For experiments involving flow, HUVECs were seeded onto glass coverslips coated 
with gelatin (cross linked with glutaraldehyde) at 37°C and 5% CO2 with standard media until 
confluent density was reached.
114,115
 
 
HUVEC surface characterization 
6 well plates were coated with gelatin (cross linked with glutaraldehyde) and seeded with 
HUVEC at a confluent density. The cells were activated with 10 ng/mL tumor necrosis factor-α 
(TNF-α, Fitzgerald, Acton, MA) or 1 ng/mL interleukin-1β (IL-1β, Fitzgerald, Acton, MA) for 
varying time points. Following activation, the cells were trypsinized, divided into multiple 
samples, and stained with antibodies to CD54, CD62E, and CD62P as well as an isotype control 
IgG1 (R&D Systems, Minneapolis, MN) at 4°C. All subsequent steps were performed at 4°C. 
After 20 minutes of staining, samples were washed twice in phosphate buffered saline with 0.5% 
bovine serum albumin. Flow cytometry data was collected on an Attune NxT Focusing Flow 
Cytometer (Life Technologies, Carlsbad, CA) and analyzed using FlowJo software (Ashland, 
OR). Data for activated cells are presented as compared to unactivated cells. All data have the 
appropriate isotype controls subtracted from the MFI. The data is represented either as a fold 
increase over unactivated cells or as a quantitative site density. 
 
 28 
2.6 THP-1 Culture and Uptake  
THP-1 monocytes (ATCC, Manassas, VA) were seeded at 1x10
5 
cells/well in 96 well 
plates and incubated with particles at varied times. Cells were incubated with equivalent masses 
of fluorescent particles, corresponding to 2 x 10
6
 particles/well for 2 µm hydrogels or 1.28 x 10
8 
particles/well 500 nm hydrogels in a total well volume of 200 µL. Cells were washed 3 times 
with phosphate buffered saline with 2% fetal bovine serum) and assessed for particle uptake via 
flow cytometry. All studies were performed using Roswell Park Memorial Institute media 
(Thermo Scientific, Waltham, MA) with heat inactivated 10% fetal bovine serum. 
 
2.7 Blood Collection and Preparations 
Phlebotomy was performed according to Institutional Review Board-of UM Medical 
School (IRB-MED) approved protocols and in line with the World Medical Association 
Declaration of Helsinki. Written, informed consent was obtained from all donors prior to 
venipuncture. Anticoagulated, whole blood was obtained from healthy donors directly into acid 
citrate dextrose (ACD), at a ratio of 1.4 mL ACD/10 mL whole blood. White blood cell (WBC) 
depleted, red blood cells + plasma (RBC+plasma) medium was obtained by adding 6% dextran 
(1.4 mL per 10 mL whole blood) to anticoagulated blood in an inverted syringe to sediment red 
blood cells (RBCs) from WBCs and plasma. The RBC fraction was separated from the leukocyte 
rich plasma fraction and phosphate buffered saline was added to the RBCs. All was centrifuged 
at 2250xg for 20 minutes, 3 times. Each time the WBC pellet was discarded from the leukocyte 
rich plasma, and the buffy coat containing leukocytes over the RBC pellet was discarded. 
Finally, isolated plasma and RBCs were recombined at 40% v/v RBCs and designated 
“RBCs+plasma”. Reconstituted blood was put through the same processing as RBC+plasma, 
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except the WBCs were added back in a physiological concentration, to determine if the 
processing itself produced any changes in experimental outcomes. 
 
2.8 Parallel Plate Flow Chamber (PPFC) Assay 
Flow distribution studies  
A 100 µm Ibidi chamber (Fitchburg, WI) was used to perfuse blood containing 1x10
7
 
particles/mL. An Olympus FV 1200 Confocal Microscope (Shinjuku, Tokyo, Japan) was used to 
detect the number of fluorescent particles at each designated height. Particles without rhodamine 
were conjugated with NeutrAvidin, as described above, and then were stained with R-
Phycoerythrin, Biotin XX conjugate (Biotin-PE, Thermo Scientific, Waltham, MA). The MFI of 
each particle type was matched, so to achieve uniform particle brightness. The bottom of the 
chamber was set by first visualizing adherent 500 nm PS particles. Images were taking using 
confocal microscopy with a 543 nm laser at 80% power, with the photo-multiplier tube (PMT) 
voltage set at 700V, 1X gain, and 0% offset. The microscope was run in a round-trip 0.488 
ms/line using a 2x digital zoom and a 20x water immersive objective. Particles were processed 
and counted for a total of 250 images using FIJI software by setting a constant threshold and the 
"Analyze Particle" function. Laser, PMT, and threshold settings were optimized for blank 
samples (no particles) to contain less than 1% count of particle positive trials. The shutter speed 
was set to allow for visualization of individual particles in flow. Results presented are the 
number of detected particles, not simply the MFI. 
  
Adhesion assay 
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HUVECs were cultured on glass coverslips as described in more detail above.
114
 The 
coverslips were held by vacuum to the PPFC (Glycotech, Inc., Gaithersburg, MD). Blood from 
human donors was drawn with the anticoagulant ACD and stored at 37 °C until use. ACD 
chelates calcium and inhibits particle internalization for the assay duration.
116
 HUVECs seeded 
onto gelatin-coated coverslips were activated under static conditions with either TNF-α or IL-1β, 
for either 4 or 24 hours, at 37°C and 5% CO2, to induce E-selectin and ICAM-1 expression.
46
 
Targeted particles, with more details in each chapter and figure about the ligand and site density, 
at a fixed concentration, were mixed with either whole blood, RBC+plasma, or reconstituted 
blood and then perfused through the PPFC in a laminar flow profile for 5 minutes. Non targeted 
particles were avidin conjugated, with no biotinylated ligand. The volumetric flow rate through 
the channel (Q) was controlled via a syringe pump (Harvard Apparatus, Holliston, MA), which 
dictates the wall shear rate (WSR) (𝛾𝑊), as shown in equation (3), 
 
where h is the channel height (0.0127 cm), w the channel width (0.25 cm), and Q the volumetric 
flow rate (mL/second). The h of 127 µm and γw of 200 s
-1
 were chosen to mimic the flow profile 
within a vein/venule of similar dimensions to those studied later via intravital microscopy 
(IVM).
117,118
 The WSR was increased to 500 s
-1
 and 1000 s
-1
  mimic other types of vessels such 
as larger arteries.
119
 After 5 mins of blood media perfusion, 10 images of different areas were 
captured, and firmly adhered particles were counted and scaled by the monolayer surface area, 
producing results in number bound/mm
2
. 
 For rate of attachment experiments, images were collected every 30 seconds in the same 
location, including 5 minutes of blood and particle flow, representing an attachment region, and 
𝛾𝑊 =
6𝑄
ℎ2𝑤
; 𝑠−1 
[3] 
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5 minutes of buffer only flow, representing a detachment region. Adhesion data was captured 
using a Photometric CoolSNAP EZ digital camera sensor, and adherent particles were quantified 
using Metamorph
®
. All experiments are quantified as number of bound particles/mm
2 
HUVEC. 
 The translation of hydrogel MP binding to NPs delivered in chapter 7 was done using a 
scaling factor, which was the average number of NPs loaded per 2 µm hydrogel MP. The 
numbers were as follows: 15% PEG low loading: 3 NPs/hydrogel MP, 15% PEG high loading: 
25 NPs/hydrogel MP, and 50% PEG high loading: 16 NPs/hydrogel MP. In this way, we 
converted the binding of hydrogels to the delivery of NPs. 
 
2.9 Intravital Microscopy  
Animal studies were conducted in accordance with National Institutes of Health 
guidelines for the care and use of laboratory animals and approved by the Institutional Animal 
Care and Use Committee (IACUC) of University of Michigan. C57BL/6 mice were obtained 
from Jackson Laboratories (Bar Harbor, ME) between 3 and 6 weeks of age. All animals were 
maintained in pathogen-free facilities at the University of Michigan. 
Visualization of mesentery vessels was performed to discern particle binding and/or 
rolling.
120–122
 Briefly, female mice (3-4 weeks) were anesthetized and a tail vein catheter placed 
for delivery of particles. A midline incision in the abdominal cavity allowed for exteriorization 
of the mouse intestines, and therefore, the mesentery connective tissue. Mice were placed on a 
custom-made microscope heated stage at 37°C and the mesentery was positioned on a glass 
cover slip. Imaged vessels were chosen based on size, with the diameter of veins ranging from 
100 - 200 µm. Following vessel selection, local injury was induced by topical application of 
TNF-α (10 µL of 200 µg/mL in phosphate buffered saline). Particles were injected 3 minutes 
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following topical TNF-α application via IV catheter and continuously imaged for another 5 
minutes via both brightfield and fluorescent imaging. Particles were dosed by an equivalent mass 
of ~10 mg/kg, unless otherwise specified, corresponding to 4.34 x 10
7
 2 µm particles and 2.78 x 
10
9 
500 nm particles for each mouse of about 20 g, in a 200 µL injection volume. Targeted 
particle adhesion in mesenteric veins was visualized under a 25x oil objective using an inverted 
fluorescence microscope (Zeiss Axio Observer Z1 Marianas Microscope). After 5 minutes, the 
data were quantified by number of individually bound particles for N=4 mice and represented as 
number bound or converted to ng particles /mm
2
 vessel based on the calculated mass of one 
particle. At least 10 different imaging locations were found per mouse, using Slidebook 6 
software (3i, Denver, CO). Analysis of particle number bound was performed using Slidebook 6 
and ImageJ using blinded file names. Particles found in adjacent vessels but within the frame 
were excluded from the analysis. 
 In studies with information about rolling velocities, real time videos were captured in 
addition to still frame images. For each mouse, at least 5 distinct video locations were utilized. 
Particle rolling velocities were obtained using particle tracking software, and all paths were 
manually confirmed until at least 50 particles were tracked per experimental condition. Vessels 
were again measured using Slidebook 6. Particles found in adjacent vessels but within the frame 
were excluded from the analysis. Particles were considered adherent when they appeared in the 
same location for ten consecutive frames of the particle tracking. Particles were considered 
rolling when their tracked paths moved less than 50 µm between frames. Firmly adhered 
particles did not contribute to the rolling velocity data. 
 
Long time mesentery experiments  
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Intravital microscopy was conducted as described above,
106,122
 but modified to extend the 
time window of imaging. Briefly, mice were anesthetized by intraperitoneal injection of a 
mixture of ketamine and xylazine and opened surgically via a midline incision. A tail vein 
catheter was placed and the intestines were manipulated gently to position the mesentery on the 
custom, heated microscope stage. A vein was visualized and topical TNF-α was dropped in the 
area of interest. After 3 minutes, 30 mg/kg particles were injected via tail vein catheter. Firm 
particle adhesion was quantified every 5 minutes by taking 5 pictures in the same physical 
locations. In order to maintain the anesthesia of the mice, every 20 minutes 50 µL of the 
ketamine and xylazine mixture were dropped topically onto the exposed abdominal cavity. The 
data was compiled to obtain time courses of mesentery particle adhesion to an hour post particle 
injection, with N=3 mice for each particle type. 
 
2.10 Acute Lung Injury (ALI) Model 
Near-infrared (NIR) dye was loaded into the PEG hydrogels used for ALI studies to 
facilitate whole organ scans, in place of the rhodamine utilized for previous assays. Female 
C57BL/6 mice (Jackson, Bar Harbor, ME) were anesthetized using isoflurane and 20 µg of 
lipopolysaccharide (LPS) LPS at 0.4 mg/mL in phosphate buffered saline was delivered to the 
lungs via an orotracheal instillation to produce local inflammation, as described previously.
123–125
 
One hour after instillation, particles were injected through the tail vein. Mice received 2 µm MP 
or 500 nm NP in 200 µL injection volume in phosphate buffered saline (~30mg/kg). Depending 
on the time point, mice were euthanized a certain number of hours after particle injection. Blood 
was collected via cardiac puncture in heparin coated tubes. After the blood draw, for those mice 
that were perfused prior to organ harvesting, the right atrium was cut, and cold phosphate 
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buffered saline was injected into the left ventricle, thus perfusing the vasculature.   Organs, 
including the lungs, liver, kidneys, spleen, and heart, were harvested and stored in phosphate 
buffered saline on ice until scanned. Each data point represents N=4 mice per condition and time 
point. 
 Whole organ scans were performed on an Odyssey CLx Infrared Imaging System (LI-
COR, Lincoln, NE) using the 700 nm channel at 169 µm resolution. Total fluorescence for each 
organ was determined by drawing a region of interest (ROI) using Image Studio Software from 
LI-COR. Untreated samples were used to determine the background fluorescence for each organ, 
which was subtracted from the fluorescence obtained for each organ ROI.  
 To account for variability in particle brightness, standard curves of each particle type 
were generated using the Odyssey LI-COR Imaging System. Total fluorescence values of each 
organ were converted to the number of particles per organ using these standard curves. For each 
mouse, this value was then scaled by each organ to achieve mass of particles per mass of organ. 
Total recovered fluorescence was determined as the sum from each organ. The corresponding 
fluorescent percentage was determined as a portion of this total. 
 
2.11 Circulation Time of Particles  
Circulation time curves of both targeted and untargeted particles, again loaded with NIR 
dye, were established via a tail nick procedure. ALI was induced into mice by LPS instillation 
into the lungs; both LPS and non-LPS mice were sampled for circulation time measurements. 
Particles were prepped and dosed by equivalent mass (~30 mg/kg) by injection through a tail 
vein catheter. At each time point post tail vein injection (5 minutes, 30 minutes, 1 hour, 3 hours, 
and 24 hours) 10 µL of blood was collected and diluted 10X into phosphate buffered saline. The 
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blood samples were deposited into black-sided 96 well plates and scanned on the Odyssey CLx 
Infrared Imaging System. The signal intensity was converted to particle concentration by a 
standard curve of each particle type. These values were converted to mass circulating by 
multiplying by the mass of a single particle. PK analysis of the circulation time data was 
completed in PKSolver (Microsoft Excel). Both one and two compartment models were tested 
for all conditions; two compartment models were more accurate for all conditions. 
 
2.12 Finite Element Analysis (FEA) 
Spherical 2 µm particle meshes were generated in SolidWorks CAD Software (Waltham, 
MA) and exported to LISA (Sonnenhof Holdings, Ontario, Canada). Meshes were refined to 
5425 elements and the material properties for each particle type, including Young’s modulus and 
density, were defined with a Poisson’s ratio of 0.5. Surface pressures of 8x10-13 N/ µm2 
(corresponding WSR=200 s
-1
), 4x10
-12
 N/ µm
2
 (corresponding WSR=1,000 s
-1
), 2.5x10
-11
 N/ 
µm
2
, 1x10
-9
 N/ µm
2
, and 1x10
-8
 N/ µm
2 
were applied along the X-direction on the top and bottom 
face of the sphere in opposing directions. The center nodes were fixed with a zero displacement 
in all directions. The Taylor deformability parameter, Δ, was defined as (Dmax-Dmin)/(Dmax+Dmin) 
as detailed previously.
126
 
 
2.13 Data Analysis and Statistics 
For all studies, all data points were included in the analyses and no outliers were 
excluded in calculations of means or statistical significance. Data are plotted with standard error 
bars and analyzed with the statistical test indicated in figure legends. In general, (*) indicates 
p<0.05, (**) indicates p<0.01, (***) indicates p<0.001, and (****) indicates p<0.0001, unless 
 36 
otherwise specified in the figure legend. A lack of asterisks denotes that the difference is not 
significant (n.s). 
Rheometry data represents 3 different bulk hydrogels each, with at least 15 data points 
from each individual hydrogel. ESR experiments were repeated in triplicate for each condition. 
The loading of NPs was measured for 2 different batches of hydrogels fabricated. THP-1 uptake 
studies were performed in duplicate. Characterization of HUVEC expression after activation is 
representative of three independent experiments from different cell isolations, with two technical 
replicates each. All PPFC flow experiment data is an average of 10 pictures from each individual 
experiment, with N≥3 blood donors for each group of data presented. Flow distribution 
experiments were repeated with N=3 blood donors for each perfusion condition. IVM results 
represent at least 4 mice per group, with at least 10 images of particle adhesion quantified from 
each mouse. For particle rolling in intravital microscopy, each group represents at least 4 mice, 
with at least 5 video locations per mouse. For the ALI and circulation time study, each data point 
represents N=4 mice, as with the circulation time data. 
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: Exploring Deformable Particles in Vascular-Targeted Drug Chapter 3
Delivery: Softer is Only Sometimes Better 
 
3.1 Publication Information 
The majority of the work in this chapter is published as: Fish, Margaret B., Catherine A. 
Fromen, Genesis Lopez-Cazares, Alexander W. Golinski, Timothy F. Scott, Reheman Adili, 
Michael Holinstat, and Omolola Eniola-Adefeso. "Exploring deformable particles in vascular-
targeted drug delivery: Softer is only sometimes better." Biomaterials 124 (2017): 169-179. 
 
3.2 Abstract 
 The ability of vascular-targeted drug carriers (VTCs) to localize and bind to a targeted, 
diseased endothelium determines their overall clinical utility. Here, we investigate how particle 
modulus and size determine adhesion of VTCs to the vascular wall under physiological blood 
flow conditions. In general, microparticles (MPs) outperformed nanoparticles (NPs) in all 
experimental conditions tested. Our results indicate that MP modulus enhances particle adhesion 
in a shear-dependent manner. In low shear human blood flow profiles in vitro, low modulus 
particles showed favorable adhesion, while at high shear, rigid particles showed superior 
adhesion. This was confirmed in vivo by studying particle adhesion in venous shear profiles in a 
mouse model of mesenteric inflammation, where MP adhesion was 127% greater (p<0.0001) for 
low modulus particles compared to more rigid ones. Mechanistically, we establish that particle 
collisions with leukocytes drive these trends, rather than differences in particle deformation, 
localization, or detachment. Overall, this work demonstrates the importance of VTC modulus as 
 38 
a design parameter for enhanced VTC interaction with vascular walls, and thus, contributes 
important knowledge for development of successful clinical theranostics with applications for 
many diseases.  
 
3.3 Introduction 
VTCs are particles designed to exploit differential surface protein expression in diseases 
involving the endothelium, for an increase in drug localization and corresponding decrease in 
off-target toxicity. The development and clinical approval of VTC systems could revolutionize 
the treatment of many common but therapeutically challenging diseases, including cancer and 
cardiovascular diseases. Recent consideration of VTC physical properties, including size, shape, 
and surface charge
1,11,37,127,128
 has improved historically low targeted drug delivery efficiency. 
More recently,
15,104,129
 The work presented here integrates these two lines of research to present a 
comprehensive study of the critical role of particle modulus on VTC targeting efficiency.  
As VTCs traverse the vasculature, they must navigate complex blood flow to contact the 
endothelium, otherwise all targeting functionalities are negated. In blood flow, cells segregate 
into a concentrated red blood cell (RBC) core in the center, while white blood cells (WBCs) and 
platelets are excluded to the RBC-free layer (RBC-FL) to interact with endothelial cells (ECs). 
Hydrodynamic, heterogeneous collisions between blood components drive this segregation in 
flow.
40,130–132
 The differences in cellular size and stiffness are often used to explain WBC and 
platelet margination, which, by definition, is the localization to ECs from bulk blood flow. RBCs 
have a Young’s modulus of 26 ± 7 kPa; WBCs are an order of magnitude stiffer than RBCs and 
platelets are 2-5 times more rigid than RBCs.
133–136
 It is vital that VTCs mimic this cellular 
margination process to interact with the designated endothelium and target effectively in vivo. 
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One way to achieve this is to control VTC size. Previous work has shown that optimal VTC size 
depends on the physical blood properties
43,137
; in human blood, 3 µm is the ideal diameter for 
spherical, rigid particles to maximally marginate to ECs as determined in in vitro flow 
assays.
46,113
 Furthermore, rigid NPs demonstrate inefficient margination compared to MPs due to 
decreased localization to the vessel wall, resulting in low adhesion overall to targeted ECs.
46,138
 
Unfortunately, rigid MP VTCs may cause deleterious capillary occlusions and are impractical for 
clinical use. Thus, there is strong motivation to explore a modulus range of both MPs and NPs, 
with interest to circumvent possible capillary occlusions by MPs and to improve the poor 
margination dynamics of rigid NPs. Recent studies with varying modulus particles focus on the 
impact of particle modulus on in vivo circulation time, which does not necessarily translate to 
targeted adhesion.
39
 There is a lack of research directly comparing an entire range of particle 
sizes and physiologically relevant VTC moduli for vascular targeting; there is a critical need for 
well-designed experiments to fill this gap. 
To address this deficiency in the research field, we explore two sizes of four 
poly(ethylene glycol) (PEG)-based VTCs with a range of Young’s moduli, spanning an order 
and a half of magnitude, including one modulus similar to that of WBCs and one to that of 
RBCs. We explore how particle modulus and size collectively dictate VTC efficacy based on a 
range of physiological blood flow conditions, by using particles fabricated with well-controlled 
surface ligand properties. Our data demonstrate that VTCs cannot be designed as “one size fits 
all”, but rather, require the deliberate selection of VTC modulus based on known hemodynamics 
of the disease state. Importantly, this is the first study to report how VTC modulus directly 
affects the final, targeted adhesion of particles both in vitro and in vivo, providing an exciting 
and unique perspective on VTC engineering with potential to influence the future VTC system 
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development. 
 
3.4 Results 
Characterization of PEG-based hydrogel particles 
 We systemically varied fabrication conditions to synthesize hydrogel particles of varying 
modulus, as detailed in Figure 3.1. Reaction conditions for the PEG hydrogels are detailed here; 
we decreased the moduli from A to D by decreasing the hydrogel cross-linking density. The 
synthetic scheme for hydrogel polymerization is shown in Figure 3.1A-B. The in situ 
polymerization of hydrogel conditions B-D is shown in Figure 3.1C. Hydrogel condition A was 
omitted, as it was too rigid for the in situ rheometry. Complete polymerization for each 
condition, determined from the plateaus in the in situ polymerization curves, was achieved 
within several seconds; indeed, the onset of gelation was so rapid that the precise gel point, as 
determined by the crossover of the storage (G′) and loss (G″) moduli,139 could not be ascertained 
(Figure 3.2). We utilized a large excess of photoinitiator to ensure maximal polymerization; any 
unpolymerized monomer was washed out of the swollen hydrogels bulk samples and particles. 
As VTCs are employed in aqueous conditions of media or blood, the most relevant particle 
parameter is the swollen shear modulus, which varied over 1.2 orders of magnitude from 
170,000 ± 40,000 Pa for condition A to 7,700 ± 300 Pa for condition D (Figure 3.1D). By design, 
hydrogel C closely matches WBC moduli while hydrogel D matches that of RBCs. The 
equilibrium swelling ratio (ESR, Figure 3.1E) is the characterization of the swelling properties of 
each bulk material type, is shown in both water and human blood plasma. When comparing 
hydrogel ESR in plasma and water, only hydrogel D showed a significant difference with 
p<0.0001. There were significant differences in ESR when comparing A with B-D. Figure 3.1F 
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details the calculated density, pore size, and young’s modulus of each hydrogel type.112  
 
 
 
Figure 3.1 Hydrogel material properties.  
(A) Designation of chemical moieties for synthetic scheme. (B) Synthetic scheme for lithium 
phenyl-2,4,6-trimethylbenzoylphosphinate photoinitiated polymerization of (poly)ethylene 
glycol diacrylate (PEGDA) and 2-carboxylethyl acrylate (CEA) as described in more detail in 
the SI. (C) In situ rheometry of particle conditions B, C, and D. Condition A too rigid to be 
tested in situ. (D) Swollen shear moduli of particle conditions A-D, statistics displayed represent 
comparison to A. (E) Equilibrium swelling ratios of particle conditions A-D, where (*s) indicate 
significance within hydrogel types to A and (#s) indicate difference between water and plasma. 
(F) Synthesis compositions and calculated bulk material properties of hydrogels.
112
 Statistical 
analyses were performed using one- and two-way ANOVA with Fisher’s Least Significant 
Difference (LSD) test, where (*) indicates p<0.05, (**) indicates p<0.01, and (***) indicates 
p<0.001, (****) indicates p<0.0-01 and (####) indicates p<0.0001. Error bars represent standard 
error. 
 
Type % Solids % MeOH % PEGDA % CEA % PI 
Density 
(kg/m3) 
Pore Size 
(nm)27 
Young’s 
Modulus (Pa) 
A 50 %  50 % 89 10 1 1051 0.376 508,300 
B 40 % 60 % 89 10 1 1039 0.527 307,700 
C 20 % 80 % 87 10 3 1017 1.318 113,000 
D 15 % 85 % 86 10 4 1007 3.539 23,000 
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Figure 3.2 Additional rheological data.  
Representative G’ and G” curves for in situ polymerization. G’ is the storage modulus and relates 
to elastic modulus (closed symbols), while G’’ is the loss modulus, and relates to the viscosity of 
the fluid being polymerized (open symbols).  
 
 Having characterized the bulk materials, hydrogel particles of either 2 µm or 500 nm in 
diameter were fabricated, using the conditions shown in Figure 3.1F. Figure 3.3 is a schematic of 
the hydrogel particle fabrication protocol as further explained in the methods chapter. Resulting 
particles were sized using dynamic light scattering (DLS) and scanning electron microscopy 
(SEM). Figure 3.4A details the resultant zeta potential (ZP) for all particle conditions, ranging 
from -23 mV to -32 mV, attributable to the 2-carboxyethyl acrylate (CEA) incorporated into the 
polymer backbone. Figure 3.4B-C show representative scanning electron microscopy (SEM) 
images of hydrogel particles; the clustering is a function of being dried for imaging. Particles 
within both size groups were found to be spherical and reasonably monodisperse after 
purification. There were no notable differences observed between particle A and D morphology 
as demonstrated in the scanning electron micrographs in Figure 3.4D-E. 
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Figure 3.3 Schematic of hydrogel particle fabrication technique.  
PEG precursor solution dissolved in methanol is emulsified using a probe sonicator. The 
emulsion is exposed to 365 nm light to initiate photopolymerization. Filtering and centrifugation, 
as detailed in materials and methods, completed the synthesis of monodisperse hydrogel 
particles. 
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Figure 3.4 Hydrogel particle properties. 
(A) Diameter, PDI and ZP measurements for fabricated hydrogel particles +/- standard deviation. 
Representative scanning electron microscopy (SEM) image of dried (B) 2 µm and (C) 500 nm 
hydrogel condition A particles, scale bars are 5 µm. Representative scanning electron 
micrographs at 50,000 X magnification of (D) Hydrogel particle type A and (E) D. Scale bars are 
100 nm in length.  
 
 Phagocytic uptake of particles in vitro is a predictive technique of particle clearance rate 
in vivo. In general, cells phagocytose rigid particles more rapidly than more deformable 
counterparts. THP-1 uptake of both 500 nm and 2 µm hydrogels of all particle conditions 
confirmed previously observed trends in the literature,
39,129
 specifically that rigid particles were 
B. A. 
C. 
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more readily phagocytosed, and thus, the rate of particle uptake by THP-1 cells decreased from 
particle A through particle D (Figure 3.5).  
 
 
  
Figure 3.5 Cell uptake of hydrogel particles over time. 
THP-1 cell uptake of particles over time as determined by % particle positive cells via flow 
cytometry. (A) Representative gating of THP-1 uptake. Single cells identified by forward (FSC) 
and side (SSC), and positive signal in the BL2 Rhodamine/PE channel greater than the untreated 
(gray) identified particle positive cells (red). Cellular uptake of 500 nm (B) and 2 µm (C) 
hydrogel particles; error bars represent the standard error. 
 
Modulus dictates hydrogel particle binding under shear in vitro  
 We first evaluated the impact of VTC deformability on adhesion to an inflamed EC 
monolayer from human blood flow in a parallel plate flow chamber (PPFC) to mimic binding in 
a human blood vessel. Human umbilical vein EC (HUVEC) monolayers were prepared and 
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activated with Interleukin-1β (IL-1β). Hydrogel (A-D) and control polystyrene (PS) particles 
were conjugated with ~1,000 sialyl Lewis
A
 (sLe
A
) sites/µm
2
. SLe
A
 is a carbohydrate that has 
high affinity for E-selectin, a molecule that is upregulated on EC monolayers during 
inflammation and is minimally expressed on healthy ECs. Particle adhesion density was 
evaluated at varying wall shear rates (WSRs) that represent a physiological range encountered in 
human vasculature.  
 Particle adhesion of targeted sLe
A
 2 µm rigid PS and varied modulus hydrogel particles 
in human blood flow is shown in Figure 3.6A - C for WSRs of 200, 500, and 1,000 s
-1
, 
respectively, with a particle concentration of 1x10
7
 particles/mL. At 200 s
-1
, 2 µm particle 
adhesion significantly increased with decreasing hydrogel modulus, with particles C and D 
showing a significant increase in adhesion (p=0.037 and 0.029, respectively) relative to the most 
rigid hydrogel particle, A. Adhesion of all hydrogel particles was not significantly different when 
compared to the PS control. At the intermediate WSR of 500 s
-1
, there was no significant trend 
amongst the 2 µm hydrogel particles or PS control. However, at the high WSR of 1,000 s
-1
, the 2 
µm hydrogel adhesion trend flipped relative to the low shear trend; the more rigid hydrogel MPs 
adhered better than low modulus MPs. Hydrogel A showed significant 2.8 and 4.8 fold increases 
over C and D, with p=0.005 and 0.0008, respectively.  
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Figure 3.6 Particle adhesion to inflamed HUVEC monolayer as a function of particle  
modulus. 
Quantified adhesion of 2 µm hydrogel particles at a wall shear rate of (A) 200 s
-1
, (B) 500 s
-1
, 
and (C) 1,000 s
-1
 by modulus after 5 minutes of laminar blood flow over an IL-1β activated 
HUVEC monolayer. N=3-6 human blood donors per particle condition. Statistical analysis of 
adherent density was performed using one-way ANOVA with Fisher’s LSD test between all 
particle adhesion conditions. (*) Represent comparison to PS and (#) represents comparison to 
particle type A. (*) indicates p<0.05, (**) indicates p<0.01, and (***) indicates p<0.001. Error 
bars represent standard error. Representative fluorescent images of 2 µm (D) PS, (E) Hydrogel 
A, and (F) Hydrogel D particles bound to IL-1β activated HUVEC under a WSR of 200 s-1 in 
vitro. Scale bars are 20 µm. 
 
 We then probed the importance of size on the observed trends in our PPFC adhesion 
assays. Particles of the equivalent moduli, but of 500 nm diameter, were evaluated in the same 
manner. Notably, a concentration of 1x10
8
 particles/mL was evaluated in order to observe 
significant particle adhesion, which is an order of magnitude larger than the concentration 
evaluated for 2 µm particles. At all WSRs, the rigid PS control performed significantly better 
than all hydrogel particle types (Figure 3.7). There were no significant differences amongst the 
500 nm hydrogel particles.  
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Figure 3.7 500 nm particle adhesion to inflamed HUVEC monolayer as a function of 
particle modulus. 
Quantified adhesion of hydrogel particles at a wall shear rate of (A) 200 s
-1
, (B) 500 s
-1
, and (C) 
1,000 s
-1
 by modulus after 5 minutes of laminar blood flow over an IL-1β activated HUVEC 
monolayer at 1 × 10
8 
particles/mL. N=3-6 human blood donors per particle condition. Statistical 
analysis of adherent density was performed using one-way ANOVA with Fisher’s LSD test 
between all particle adhesion conditions. (*) Represent comparison to PS where (*) indicates 
p<0.05, (**) indicates p<0.01, and (***) indicates p<0.001. There were no significant 
differences amongst hydrogel particle types A-D within any wall shear rate. Error bars represent 
standard error. 
 
For both particle sizes, increasing the WSR resulted in increased total particle adhesion. 
However, at higher WSR, more particles travel through the PPFC in the fixed 5 minute 
experiment time, thus, adhesion trends were normalized by the total number of particles perfused 
thorough the PPFC, resulting in adhesion efficiency shown in Figure 3.8. From these results, we 
observe that even at a lower particle concentration, 2 µm particles were significantly more 
efficient in PPFC experiments compared to 500 nm particles, as was previously shown with PS.
46
 
For MPs, more rigid particles maintained their adhesion efficiency with increased WSR, while 
adhesion efficiency statistically significantly decreased for the low modulus conditions at higher 
WSRs. Together, these data indicate that targeted vascular wall adhesion of low modulus 
hydrogel MPs is heavily dependent on the imposed local blood flow WSR, which is 
physiologically pertinent, as blood shear varies widely throughout the body.   
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Figure 3.8 Particle adhesion normalized to the number perfused. 
Data from Figure 3.6 and 3.7 normalized between particle concentration and shear rate. Data 
scaled by the number of particles perfused in human whole blood through the PPFC in 5 minutes 
and is represented as the number of particles bound per 10
6
 particles perfused through the PPFC 
in whole blood. Error bars represent the standard error. 
 
Low modulus particles produce superior adhesion in vivo  
 To confirm our in vitro trends, we next visualized actual targeted particle adhesion, in 
real time, to inflamed endothelium in vivo using a model of acute mesentery inflammation. 
Topical TNF-α results in inflammation and corresponding P-selectin expression within minutes 
of stimulation.
140,141
 We explored extreme modulus conditions A and D and both particle 
diameters, 2 µm and 500 nm. All particles types were conjugated with the same surface density 
of anti-CD62P to ensure rapid, firm adhesion to the inflamed endothelium. Fluorescent hydrogel 
particles were dosed by equivalent mass and tracked real-time with fluorescent intravital 
microscopy. An experimental schematic is shown in Figure 3.9A, with representative images of 
2 µm particle binding in mouse mesenteric veins shown in Figure 3.9B. All particles observed 
were firmly adhered to the inflamed mesenteric vein ECs due to the chosen ligand kinetics. 
Figure 3.9C shows the adhesion number of each particle type, scaled by the number of particles 
injected and the surface area of the examined vessels. Minimal adhesion of targeted hydrogels 
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was observed in non-inflamed vasculature, as shown in Video 3.1. Overall, the 2 µm particles 
adhered significantly more than the 500 nm particles, in line with our in vitro adhesion 
efficiencies. Figure 3.10 shows the number of each bound scaled by just the vessel surface area; 
particles were dosed by mass, corresponding to 64.5 times more NPs than MPs, yet NP particle 
adhesion by number was at most only 14 times more than MP adhesion by number. Thus, MPs 
demonstrated superior targeted particle adhesion than NPs for targeted applications in vivo. 
Interestingly, for both particle sizes, hydrogel D significantly outperformed hydrogel A, with 
observed 2.3 fold (p<0.0001) and 7.3 fold increases (p=0.002) for 2 µm and 500 nm, 
respectively. These results correspond to the trend observed in vitro; in the low WSR of the 
mesentery vein, particle D of lower modulus resulted in improved adhesion over stiffer particle 
A. High shear arteries were not evaluated in vivo, as the flow is pulsatile, and hence, not 
comparable to the in vitro laminar studies. Additionally, large high WSR arteries are not 
amenable to real-time intravital imaging, and thus, can only be evaluated posthumously, which 
represents widely varying conditions from those studied in vitro. 
 
 
 
Figure 3.9 Particle adhesion to inflamed mesentery endothelium as a function of modulus 
and size. 
(A) Schematic of mouse surgical technique for intravital imaging, as described in the methods. 
(B) Representative fluorescence images of particle adhesion to inflamed mesentery, images 
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correspond particles A-2µm and D-2µm (top to bottom). Particle fluorescence shown in red, 
overlaid on the bright field image. Scale bar is 50 µm. (C) Quantified adhesion efficiency of 
hydrogel particle conditions A-2µm, D-2µm, A-500nm, and D-500nm, scaled by vessel area, n = 
4 mice per group. Statistical analysis was performed using one-way ANOVA with Fisher’s LSD 
test within particle sizes. (**) indicates p<0.01 and (****) indicates p<0.0001. Error bars 
represent standard error. 
 
 
 
Figure 3.10 Mesentery particle adhesion by number. 
Quantified adherent density by number of hydrogel particle conditions A-2µm, D-2µm, A-
500nm, and D-500nm, n = 4 mice per group. Statistical analysis was performed using one-way 
ANOVA with Fisher’s LSD. (*) Represent comparison to D 500nm and (****) indicates 
p<0.0001. Error bars represent standard error. 
 
Evaluation of hydrogel deformability under physiological shear forces 
We next sought to identify the major interactions driving the observed particle adhesion 
trends. Given that NPs showed low adhesion efficiency both in vitro and in vivo compared to 
MPs, we focused the subsequent evaluation to 2 µm particles. We investigated the bulk 
properties of each hydrogel material (A-D) under controlled rheometry shear inputs to estimate 
changes in hydrogel particle deformation produced by blood flow (Figure 3.11A). The input 
forces translate to the WSRs of our PPFC experiments, where 0.8 Pa and 4.0 Pa correspond to 
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WSR 200 s
-1
 to 1,000 s
-1
, respectively. Figure 3.11A shows deformation responses linearly 
increasing with applied force. This linearity was maintained over a larger range of shear force 
applied by the rheometer (Figure 3.12A). Interestingly, the percent difference in strain between 
materials remained constant; material A deformed between 12-14% of the strain of hydrogel D at 
all applied shears, meaning there is a difference in how these particles will deform in fluid shear 
near the vascular wall. However, at the most physiologically extreme condition the magnitude of 
the % strain was less than 0.2%, indicating minimal deformation. These bulk property results 
were supported by our finite element analysis (FEA). We utilized the Taylor deformability 
parameter (Δ, defined in SI) as a way to quantify to FEA-modeled deformations. Particles A-D 
demonstrate minimal deformation within physiological fluid shear profiles, with FEA results 
showing indiscernible differences in particle shape and height (Figure 3.11B, force diagram in 
Figure 3.12B). Particle deformation results in a slight shrinkage of the particle height, meaning 
particle D will be shorter than particle A.
142,143
 FEA modeling shows that these changes in height 
are small compared to the overall size of the particle, with Δ = 0.002 corresponding to only an 
8.02 nm decrease in particle D height at a WSR of 1,000 s
-1
 (4 Pa). This is in comparison to a 
7.95 nm height decrease in particle A at the same shear rate (Δ=0.001993).  Shear stresses of 
greater than 1,000 Pa would be needed to observe larger differences in deformation between 
particles; the most extreme condition presented in Figure 3.11B at 10 kPa results in a Δ=0.0039 
for particle A and Δ=0.05 for particle D, corresponding to a decrease in height of 12.6 and 116 
nm, respectively. Thus, these particles have the potential to significantly deform in shape due to 
shear forces, but do not exhibit these changes during fluid flow shears in our physiological 
system. To visualize the degree of particle deformation, element displacement of the inset sphere 
has been amplified by 2x. Thus, the continuous hydrogel particles studied here demonstrate 
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surprisingly small changes in their physical dimensions due to fluid induced shears, indicating 
that this phenomenon does not significantly contribute to the shear-based adhesion trends.  
Next, we analyzed particle localization to the vessel wall from human blood flow using 
confocal microscopy to determine if differential particle distribution causes the variation in wall 
adhesion. Figure 3.11C shows the in vitro localization of each 2 µm hydrogel MP type A-D. 
Confocal images were taken at the wall of a PPFC while a mixture of human blood and particles 
were perfused. Figure 3.11C shows no significant differences between the wall localization of 2 
µm hydrogel particles across the four moduli and three WSRs explored. These results indicate 
that differences in moduli did not translate to experimentally detectable changes in particle 
distribution to the wall from blood flow.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 
3.11 
Particles 
+Blood 
Buffer Only 
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Hydrogel particle behavior under shear forces. 
(A) Strain response of bulk hydrogels A-D at controlled, applied shear stress. Arrows represent 
corresponding wall shear rates. (B) Deformability parameter (Δ) determined by FEA for particles 
A-D under a range of shear forces. Inset shows applied shear force directions and representative 
particle deformation of particle D under the largest shear (circled) with an amplification factor of 
2 to visualize deformation. (C) Localization of fluorescent hydrogel particles from human whole 
blood flow to the chamber wall. N = 3 human blood donors per particle condition. Statistical 
analysis was performed using two-way ANOVA with Fisher’s LSD test between groups, 
resulting in non-significant differences at all shear rates. Error bars represent the standard error. 
(D) Representative rate of attachment and detachment to inflamed HUVECs at wall shear rates 
of 1000 s
-1
. The first 300 seconds represent perfusion of whole human blood and hydrogel 
particles, while the remaining time represents perfusion of buffer without particles. 
 
 
 
 
 
 
Figure 3.12 Strain response and FEA particle deformation under controlled shear stress.  
Strain response of bulk hydrogels A-D over an extended range of controlled, applied stress. 
Stress responses remain linear far past physiologically relevant shear stresses. Schematic of 
applied pressure to deformable particle before and after applied forces. Sphere shown is 2 µm 
particle condition D with a Young’s modulus of 23,000 Pa. Applied shear to indicated elements 
was 4x10
-12
 N/µm
2
 (~WSR 1,000 s
-1
) in +/- X direction. Shading represents surface element 
displacement, amplification factor 0. 
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Figure 3.13 Rate of attachment in PPFC assay.  
Representative displays of 2 µm particle rate of attachment and detachment to inflamed 
HUVECs at WSRs of (A) 200 s-1 and (B) 500 s-1. The first 300 seconds represent perfusion of 
whole human blood and hydrogel particles, while the remaining time represents perfusion of 
buffer without any particles. 
 
 Another possible mechanism that could drive trends in PPFC adhesion by modulus is the 
adhesive force of hydrogel particles once present on the EC monolayer. This is indirectly 
represented in our data by the rate of attachment of 2 µm particles (Figure 3.11D). This plot 
displays the adhesion over time, captured every 30 secs, for each particle A-D at 1,000 s
-1
 WSR. 
A mixture of particles and blood were perfused through the PPFC for the first 5 minutes, after 
which, solely buffer was perfused. Figure 3.11D shows that for all 2 µm hydrogel particles A-D, 
there was a linear region of attachment, with only particle A showing detectable detachment in 
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the 10 minutes of buffer only flow. The rates of attachment for the other two WSRs are shown in 
Figure 3.13. The linear rate of attachment indicates dominating adhesion forces. Furthermore, 
this data demonstrates that even at our highest WSR, no significant number of hydrogel particles 
detached once adhered to the inflamed EC monolayer.  
 
Removal of white blood cells eliminates adhesion trends 
Given that discrepancies in particle deformation, localization, and rate of attachment did 
not together account for the observed significant trends in particle adhesion, we hypothesized 
that collisions with WBCs within the RBC-FL may contribute to the experimental phenomena. 
Importantly, WBCs will be present for all clinically relevant applications of VTCs, yet, we 
explored their removal from blood flow to better explain the shear dependence of hydrogel 
adhesion. We repeated PPFC experiments for 2 µm particles as in Figure 3.6, but with WBC 
depleted blood (RBC+plasma). With this blood medium, particle margination remains the same, 
while interactions between cells and particles within the RBC-FL are removed. As shown in 
Figure 3.14A-C, there were no significant differences in adhesion amongst the hydrogel particle 
types at any one WSR. This lack in adhesion trend compared to the whole blood experiments 
indicates that WBCs in the RBC-FL have a clear impact on targeted particle adhesion. To 
determine whether WBCs enhance or reduce particle adhesion, we subtracted RBC+plasma 
particle adhesion from that in whole blood (Figure 3.14D-F). In these plots, positive values 
denote that particle adhesion was greater in whole blood than in RBC+plasma, indicating that 
WBCs enhance particle adhesion; negative values indicate that WBCs reduced particle adhesion. 
WBCs in the RBC-FL had minimal to no impact on PS particle adhesion in low to intermediate 
shear but significantly enhanced PS adhesion at high WSR of 1,000 s
-1
. WBCs in the RBC-FL 
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had either a neutral or enhancing impact on hydrogel particle adhesion. At 200s
-1
 (Figure 3.14D), 
WBCs had limited influence on hydrogels A and B, but enhanced particle adhesion for hydrogel 
particles C and D. At 500 s
-1 
(Figure 3.14E), WBCs enhanced particle adhesion for all hydrogel 
particles in a similar magnitude. A trend becomes pronounced at high shear (1,000 s
-1
; Figure 
3.14F), where collisions with WBCs in the RBC-FL helped rigid particles more than low 
modulus particles. Overall, the impact of WBCs in the RBC-FL was similarly shear dependent as 
adhesion trends in whole blood medium. Therefore, we can conclude that collisions with WBCs 
in the RBC-FL prescribe VTC adhesion trends by modulus.  
To confirm that this effect was due to the presence of WBCs, and not the blood 
processing required to obtain RBCs+plasma, we compared the adhesion of 2 µm particles in 2 
different blood media: whole blood and reconstituted blood. The reconstituted blood is simply 
whole blood processed as it would be to obtain RBCs+plasma, then recombined to have the 
WBCs present. For all particle types at 1000 s
-1
, there was no significant difference between 
whole blood and reconstituted blood as show in Figure 3.15, further confirming that collisions 
with WBCs are producing the particle adhesion trends by modulus. 
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Figure 3.14 Particle adhesion in WBC depleted, RBC+plasma medium to inflamed HUVEC 
monolayer. 
Quantified adhesion of 2 µm hydrogel particles in RBC+plasma at a wall shear rate of (A) 200 s
-
1
, (B) 500 s
-1
, and (C) 1,000 s
-1
 by modulus after 5 minutes of laminar flow over an IL-1β 
activated HUVEC monolayer. N=3-6 human blood donors per particle condition in WBC 
depleted RBC+plasma medium. Particle adhesion in whole blood minus adhesion in 
RBC+plasma is quantified for (D) 200 s
-1
, (E) 500 s
-1
, (F) 1,000 s
-1
 by modulus. Positive values 
signify WBCs enhance particle binding in shear flow. Statistical analysis of adherent density was 
performed using one-way ANOVA with Fisher’s LSD test between all particle adhesion 
conditions. (*) Represent comparison to PS and (#) represents comparison to particle type A. (*) 
indicates p<0.05, (**) indicates p<0.01, and (***) indicates p<0.001. Error bars represent 
standard error. 
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Figure 3.15 Particle adhesion in whole blood and reconstituted blood to inflamed HUVEC 
monolayer.  
Quantified adhesion of 2 µm hydrogel particles in whole blood or reconstituted blood at a wall 
shear rate of 1000 s
-1
. This data ensures that the processing of blood to obtain RBCs+plasma 
does not inherently alter particle behavior in the blood medium. All are non-significant between 
blood types. 
 
3.5 Discussion 
To date, no study has extensively evaluated the mechanism by which particle modulus 
affects vascular targeting and adhesion, especially for particles in the MP size range. As a crucial 
physical property of VTCs, this work suggests the importance of tuning the particle modulus 
based on local hemodynamics and provides exciting insights aimed at improving translation of 
VTC systems from the bench top to bedside. Our findings demonstrate the significance of fluid 
shear in prescribing the ideal modulus for micron-sized particles, shedding light on the 
importance of understanding physical transport mechanisms in the design of a VTC system.  
Previous computational work has predicted that the margination dynamics of particles of varying 
moduli will differ greatly.
135
 While varied moduli particles have been explored for theranostic 
delivery applications in vivo
38,105,144–149
, no study has directly evaluated the experimental 
margination and adhesion propensity of VTCs of varied moduli. Moreover, many previous 
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studies focus on a comparison between two particle moduli and the impact of particle modulus 
on in vivo circulation time, cellular uptake, and tissue biodistribution, which do not necessarily 
translate to targeted adhesion.
39
 There is a critical need to thoroughly evaluate the impact of VTC 
modulus on the relevant biological transport and adhesion processes to maximize the benefits of 
vascular-targeted drug delivery.
128,150,151
  
In this work, a range of particles (A-D) was fabricated using varied amounts of 
crosslinked PEG. PEG is routinely utilized in a wide range of biomedical applications for its 
known resistance to protein fouling, hydrophilicity, biocompatibility, and modularity for 
fabricating scaffolds with a custom range of moduli and functionalities.
96,97
 Of note, covalently 
polymerized PEG particles are known to be highly stable under physiologic conditions.
152
 Many 
studies have utilized PEG or derivatives to develop drug delivery vehicles, ranging in diameter 
from 30 nm
153
 to over 10 µm and with Young’s moduli as low as 200 Pa to as high as 3 
MPa.
38,39,103
 Furthermore, others have demonstrated that measurements of bulk hydrogel 
modulus is representative of the corresponding individual MP moduli, hence, our bulk rheometry 
can be used as a representation of our particle properties.
112
 The bulk materials are well 
characterized in Figure 3.1 showing in situ rheometry, swollen rheometry, ESRs, and calculated 
bulk properties. Shown in Figure 3.1E, hydrogel D was the only material to exhibit differences in 
swelling between blood plasma and water, likely due to both the fact that D is the least cross-
linked material and blood plasma has a higher osmolarity than water, thereby producing less 
swelling.
154
 Our particles have well-characterized surface ligand densities, ensuring that all 
conclusions made here are due to physical properties rather than discrepancies in VTC surface 
ligand presentation. PS was included as an extremely rigid control for the varied moduli 
hydrogel particles, with an Elastic modulus of about 2 GPa, over 4 orders of magnitude more 
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rigid than hydrogel A.
155
 However, we recognize that PS has different material properties than 
PEG, including increased hydrophobicity,
156
 ZP, and more; it is well known that PS particles 
rapidly associate with and are taken up by phagocytes. Furthermore, these extremely rigid 
particles are known to occlude capillaries, particularly in the lung.
157
 Lack of biocompatibility 
and these differences led to our exclusion of PS from in vivo experiments, where this would be 
most pronounced.  
Our in vitro and in vivo adhesion results indicate that hydrogel MP VTCs are better suited 
for vascular adhesion than equivalent NP carriers. This corresponds to previously published 
studies with rigid particles, finding that micron-sized VTCs provide significantly superior vessel 
wall localization and EC adhesion compared to nano-sized. This is explained by superior 
exclusion of micron-sized particles out of the RBC-FL, similar to the reported near wall excess 
of white blood cells,
40,131
 while nano-sized particles are suggested to co-localize with RBCs in 
the center of flow.
10,46
 Previous work has demonstrated that deformable MPs can lead to 
increased circulation time and safe navigation of the vasculature.
38
 Indeed, in vivo we did not 
observe tissue entrapment or capillary occlusion of 2 µm hydrogel particles, as has been shown 
with PS particles in the past.
157
 Thus, our results demonstrate the utility of hydrogel MPs 
specifically for vascular targeting applications, combining improvements in both safety and 
efficiency. Overall, our results indicate that contributions of particle deformability and size, as 
well as the hemodynamics in the target vessel, dictate VTC targeting success. 
For both sizes in vivo, particle D provided significantly elevated adhesion to the inflamed 
mesentery wall, compared to more rigid particle A (Figure 3.9C). Video 3.1 shows minimal 
adhesion of targeted particles to non-inflamed mesenteric vasculature via fluorescent intravital 
microscopy. These results align with a recent comparison of 200 nm targeted particles with 
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moduli of 10 kPa and 3 MPa, which showed improved targeting in vivo of the softer 
formulation.
39
 A prevailing explanation for these trends suggests softer particles exhibit longer 
circulation time, leading to more opportunities to adhere to the target site. Indeed, it has been 
widely shown that lower modulus particles circulate longer in vivo, for their ability to avoid 
filtration and phagocytosis, as confirmed by our THP-1 uptake trends.
7,8,11,42,43
 From our in vivo 
results alone, we cannot rule out this theory, as it is inherently challenging to decouple 
circulation time from particle modulus. However, our in vitro PPFC assay enables isolation of 
other physical factors, and supports the role of other contributing mechanisms at play.  
Our in vitro work exposes an interesting phenomenon that the optimal modulus for 2 µm 
VTC adhesion is heavily dependent on the local shear profile. We utilized WSRs of 200, 500, 
and 1000 s
-1
, which represent a physiological range of blood flow found in human post capillary 
venules and arterioles.
158,159
 Namely, lower modulus PEG particles adhere with a higher 
efficiency compared to more rigid counterparts at low WSRs (200 s
-1
), which was observed both 
in vivo in the inflamed mesentery model (Figure 3.9C) and in vitro in the PPFC assay (Figure 
3.6A, 3.7A). However, at high shear, the softer particles lose this adhesion advantage. 
Interestingly, the lower modulus particles, C and D, behave like adherent WBCs, which also 
adhere less efficiently under high WSR compared to low WSR conditions.
160
 These results are 
anticipated to be highly valuable for the engineering of VTCs; improving targeted adhesion by 
deliberately electing a particle modulus will facilitate the development of more efficient VTC 
systems.  
 We hypothesized that a mix of different phenomena, such as individual particle 
deformation at the wall, localization efficiency, particle adhesion strength, and collisions with 
WBCs may each contribute to collectively determine the VTC efficacy by modulus. Minimal 
 63 
particle deformation under fluid shear flow unifies many of these results. According to our FEA 
simulations, minimal changes in particle deformation and height occurred for the hydrogels in 
flow, on the order of 8 nm or 0.4% of total diameter for particle D at the highest physiological 
WSR. This maximal deformation is small, with differences lacking between particle types. This 
indicates that particle deformation while in flow was not responsible for driving observed 
differences in vascular wall adhesion in vitro. Furthermore, the minimal deformation explains the 
lack of difference in localization amongst all particle types.
135,143
 Deformable particles anti-
marginate towards the centerline of flow, while more rigid particles marginate towards the 
chamber wall.
135,161
 To produce observable differences in margination, particles must be highly 
deformable with capillary number (Ca) on the order of 0.3. Notably, a large Ca denotes a 
deformable particle, while smaller denotes a rigid particle; most computational papers assign 
Ca=0.3-0.5 for the “deformable particle” and Ca<0.2 for rigid particles.135,142 The Ca for particle 
D, presumed as the largest, is 5.2x10
-4
, a full 3 orders of magnitude smaller than the commonly 
studied and simulated range of modulus, indicating that particle deformation drives margination.  
 These results were initially unexpected; we had hypothesized that particles C and D 
would behave like WBCs and highly deformable RBCs, respectively, because of their matched 
bulk moduli. Yet, our particle C did not outperform particle D in all conditions studied. While 
cells are highly deformable, they are typically characterized by surface moduli and internal 
viscosity, rather than a uniform modulus. Conversely, hydrogel particles are considered as a 
continuous polymerized matrix and much better represented with a bulk, elastic modulus. This 
physical difference leads to particles, which, while not rigid, do not deform to the same extent as 
cells in fluid shears alone. However, other aspects of our study, in line with others’ previous 
results, demonstrate that this range of particle modulus still has a considerable impact on cellular 
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interactions and dynamics in flow. Continuous hydrogel particles of this moduli range have 
considerably increased circulation time in vivo,
38,162
 indicating the capacity to deform through 
narrow capillaries, as well as avoid immune clearance. Indeed, in our work, THP-1 phagocytic 
cells showed slower uptake rate of lower modulus particles, despite having proved that their 
shape does not significantly change in fluid flow (Figure 3.5). Furthermore, we observed 
evidence of particle deformation following adhesion at the vascular wall; the most rigid hydrogel 
A was the only particle that experienced noticeable detachment, designating weaker adhesive 
forces versus the other hydrogel particle types. Elongated, bound particles experienced a lower 
removal shear force once wall contact is made, as they were able to minimize their profile 
protruding in the direction orthogonal to blood flow and capitalize on increased adhesive bonds. 
Notably, the ligand-receptor pair chosen for these experiments is considered a catch-bond, which 
prolongs bond lifetime under increased shear force conditions.
163
  
 Interestingly, when WBCs were depleted from the blood medium, there were no clear 
particle adhesion trends as a function of WSR or VTC modulus (Figure 3.14A-C), matching the 
observations of particle localization. Though this result is surprising, it is key to note that WBCs 
will always be clinically present; these experiments simply provide insight into the mechanism 
of hydrogel particle behavior. We determined that the presence of WBCs in the RBC-FL overall 
increased hydrogel MP adhesion, even after the blood processing required to obtain reconstituted 
blood. We hypothesize that these results are a combination of competing effects between the 
frequency of collisions between WBCs and particles, and the force balance of the resulting 
collisions. The frequency of collisions will, in part, be dependent on the RBC-FL thickness, 
which increases with increasing WSR.
164
 A larger RBC-FL means a decrease in number of 
collisions given a constant number of particles and WBCs. Following a collision, the 
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displacement of the colliding cell and particle will be dependent on the moduli, relative size of 
the two bodies, and the momentum involved in the collision. At low shear, the momentum of the 
collisions is not enough to produce differences in final particle adhesion to inflamed ECs 
compared to whole blood experiments. At intermediate WSR, collisions between more rigid 
hydrogels and WBCs result in larger lateral displacements towards the vessel wall, thus evening 
out overall adhesion in whole blood. At 1,000 s
-1
 WSR, the RBC-FL is largest, producing fewer 
collisions between particles and cells. Additionally, both the cells and particles have maximal 
momentum, resulting in larger translational displacements following each collision. As this 
transition to higher shear occurs, the increased displacement becomes a benefit for all hydrogel 
particles, but exceptionally more so for the rigid particles. More rigid particles conserve kinetic 
energy best and have the most elastic collisions. Though we showed that lower moduli particles 
do not significantly deform under fluid shear, they still produce more inelastic collisions due to 
viscous energy dissipation, and therefore, displace less efficiently to the vascular wall for 
targeted particle adhesion. Future analysis, including a computational evaluation of cell-particle 
collisions within the RBC-FL, are needed to verify the details of this mechanism; however, our 
data clearly support the hypothesis that collisions with WBCs can contribute to 2 µm particle 
adhesion as a function of the particle modulus. 
 
3.6 Conclusions 
The presented here is the first demonstration that the impact of VTC modulus depends on 
particle size and WSR. In combination with previous work from others demonstrating that low 
VTC modulus can increase circulation times, navigate capillaries, avoid immune clearance, and 
squeeze through pores, this work presents a comprehensive study of the role that particle 
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modulus and size play on key transport mechanisms required for targeted particle adhesion with 
direct applications in VTC systems. We show that MPs are more efficient than NPs in all in vitro 
and in vivo experimental conditions, regardless of modulus. The presented data show that for our 
particle conditions A-D, there is a small difference in particle deformation under prescribed shear 
forces, no detectable change in particle localization to the vascular wall, and relatively linear rate 
of attachments. Importantly, the presence of collisions with WBCs in the RBC-FL has a dramatic 
role in particle lateral margination, contact with the wall, and subsequent adhesion. Our findings 
indicate that the ideal modulus is highly dependent on local WSR, and that superior particle 
adhesion to inflamed venous ECs in vivo can be achieved with low modulus, hydrogel MP 
VTCs. These VTCs simultaneously overcome margination limitations of NP VTCs and occlusive 
potential of rigid micron-sized VTCs. Hydrogel particles capable of localizing to the 
endothelium have implications for a wide range of applications, including cancer, inflammation, 
and cardiovascular disease. Furthermore, the trends of hydrogel modulus varying with local 
WSR offers potential for customized therapeutics, based on disease and tissue hemodynamics; 
using these findings, VTC modulus can be tuned to target a plaque in a high shear vessel or 
venous disease in a low shear vessel. This unique work stresses the importance of modulus on 
targeted drug delivery, and strikingly demonstrates that one physical property can greatly alter 
VTC success, with possible implications for a wide range of diseases. 
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: Interplay of Ligand Kinetics and Particle Modulus for Chapter 4
Understanding Adhesion Dynamics Under Physiological Flow Conditions 
 
4.1 Publication Information 
This data is not yet published. This chapter has been composed as a manuscript, which 
will be submitted to Langmuir in the coming weeks. The title will be as above, with the author 
list: Fish, Margaret B. and Omolola Eniola‐Adefeso. 
 
4.2 Abstract 
 The ability of vascular-targeted drug carriers (VTCs) to localize, interact with, and bind 
to a targeted, diseased endothelium determines the overall therapeutic functionality of the 
system. Nonetheless, little work has been done that simultaneously combines the study of the 
particle physical properties and surface ligand characteristics. Therefore, in this work, we 
investigate how particle modulus, ligand kinetics, ligand surface density, and hemodynamics 
(blood shear rate) interplay to determine the adhesion of VTCs to the vascular wall under 
physiological blood flow conditions. Specifically, we evaluated the adhesion of sialyl Lewis
A
 
(sLe
A
) and anti-intercellular adhesion molecule-1 (anti-ICAM-1)-coated rigid and deformable 
particles to activated endothelium from whole human blood flow. Of great clinical importance, 
utilizing an optimized ratio of these two targeting ligands equilibrated adhesion for particles of 
all moduli, signifying that particle modulus is no longer the dominating factor in determining 
VTC adhesion. This offers a route to improve the binding of low modulus particles at high shears 
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and that of high modulus particles at low shears. In general, as the wall shear rate and the 
corresponding shear removal forces increase, the site density for both sLe
A
 and anti-ICAM-1 
particles becomes more deterministic in the final adhesion of the particles; the role of anti-
ICAM-1 site density is more significant, likely due to different kinetics between the ligand types. 
The removal of leukocytes highlights how they interact with VTCs in hemodynamic flow to 
produce adhesion trends: for both ligands, lower site density particles are hindered by 
competition with leukocytes at the vascular wall, while higher site density particles are aided by 
the presence of leukocytes. Overall, this is the first work to demonstrate the interplay between 
ligand type, ligand density, and VTC modulus as critical design parameters for enhanced VTC 
adhesion to inflamed vascular walls. This information shows the importance in understanding the 
interplay of multiple VTC characteristics in the engineering of clinical theranostics with 
applications in inflammatory diseases.  
 
4.3 Background 
The concept of particulate drug delivery is to package systemically toxic drugs into 
biocompatible particle carriers capable of preferentially releasing active cargo to a diseased 
target cell population. VTCs are injectable particles designed to harness the differential 
expression of surface proteins on endothelial cells, and are engineered to have a high affinity for 
diseased areas of vasculature and low affinity elsewhere.
11
 Ideally, this allows for both the 
protection of the cargo from degradation and clearance from the bloodstream in vivo, thereby 
lengthening the overall pharmacokinetic release profile from a single dose, while also increasing 
the total local therapeutic payload versus systemic exposure. The concept of VTCs has existed 
for decades, and yet, few systems have proven clinically viable;
165,166
 VTCs, as a particulate 
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system, must deliver a significant benefit versus free drug in a therapeutic outcome to be 
clinically approved. There is still much work needed to fully understand and inform the 
engineering of each targeted system for maximal clinical utility.  
Many critical biological processes need to take place for VTCs to provide tangible 
benefits over traditional free drug administration. Researchers have shown that size, shape, and 
surface charge of VTCs prescribe the blood circulation time and final biodistribution of both 
targeted and non-targeted systems, thereby altering the resulting treatment efficiency.
1,11,37,127
 
However, an additional critical requirement for VTCs is the ability to navigate complex blood 
flow to contact the endothelium; otherwise, targeted ligand-receptor adhesions cannot engage. 
Much work has been done to identify the properties of VTCs that directly affect the ability to 
localize and adhere from human blood flow, which is defined as margination, to produce targeted 
adhesion – this previous work highlights VTC size and shape as the most important parameters. 
Specifically, microparticles (MPs) having a diameter or equivalent spherical diameter, for rods 
and disks, in the 2-5 µm range are shown to marginate significantly better than those 500 nm and 
smaller.
46,113,138
 Unfortunately, rigid MPs of this size may cause deleterious capillary occlusions, 
and thus, may be clinically impractical. This fact, combined with established benefits of 
deformable drug delivery particles, including increased circulation times and decreased immune 
recognition,
38,39
 provides a strong motivation to explore a range of moduli for deformable MPs 
as VTCs. Recent work has shown that the binding of deformable particles is highly shear 
dependent, with more deformable particles adhering better at low blood shears and more rigid 
particles binding significantly better under high wall shears.
106
 However, only one ligand-
receptor system at one constant site density was utilized on the VTCs in this previous work. As 
such, it is conceivable that the previously reported deformable VTC adhesion trends are linked to 
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the specific ligand system explored. This work aims to elucidate how particle modulus and 
ligand kinetics interplay as critical VTC physical properties to prescribe resulting adhesion 
efficacy in physiological human blood flow, for application in the engineering of improved VTC 
systems with a multitude of clinical applications. More specifically, we aim to understand if at 
high shears, deformable VTC adhesion can be increased via ligand kinetics to match that of rigid 
particles. To date, no study has extensively evaluated the mechanism by which particle modulus 
affects vascular targeting and adhesion for different ligand types and kinetics, especially not for 
particles in the micron-size range. While many characteristics of VTCs have been individually 
studied, it is imperative to understand how multiple physical properties interplay to determine the 
final, targeted adhesion of deformable VTCs, to work toward more clinically translatable 
systems. Overall, there is a critical need to thoroughly understand the relevant biological 
transport and adhesion processes of VTCs to maximize the benefits of vascular-targeted drug 
delivery.
128,150,151
  
In this study, we evaluated the coupled importance of ligand-receptor kinetics and 
particle deformability by targeting with sLe
A
 and anti-ICAM-1 antibody, which bind P/E-selectin 
and ICAM-1, respectively, on particles with a wide variation in bulk material modulus. These 
ligand-receptor systems are amongst ones that have been previously explored with rigid drug 
carriers to determine targeted adhesion in vitro.
167,168
 We specifically chose these two ligand-
receptor pairs because they represent different ligand kinetics. The forward (kf) and reverse (kr) 
rate constants of the association between sLe
A
 to E-selectin are approximately 27,000 M
-1
s
-1
 and 
3 s
-1
, respectively.
169
 Those same rate constants for association between anti-ICAM-1 and 
ICAM-1 are known to be 156,000 M
-1
s
-1
 and 1.13 x 10
-4 
s
-1
.
170
 We used polystyrene (PS) and 
poly (ethylene glycol) (PEG)-based hydrogels to represent a range of rigid to deformable VTCs. 
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PS is often a model particle for targeted drug delivery research, used to study different particle 
parameters such as particle size, shape, and ligand kinetics.
46,113,122,171
 Here we used it as a very 
rigid particle type. We found that as the blood wall shear rate (WSR) increases, more sites are 
needed in general to combat the blood shear removal forces. Deformable particles are more 
sensitive to increases in sLe
A
 surface site density whereas rigid particles are more sensitive to 
anti-ICAM-1 site density. White blood cell (WBC) involvement in dynamic blood flow is a 
major driver of particle adhesion, and has varying impacts based on both the wall shear rate and 
ligand kinetics. Overall, our work highlights the importance of understanding the interplay 
between physical properties of VTCs for successful translation into clinical applications. 
 
4.4 Results and Discussion 
Characterization of PEG-based hydrogel materials and particles  
 We varied hydrogel fabrication conditions to obtain particles with a broad range of 
moduli. Poly(ethylene glycol) diacrylate (PEGDA) comprised most the hydrogel, and 2-
carboxylethyl acrylate (CEA) was added for its functional carboxylic acid handle. We fabricated 
and characterized a range of PEG-based particles (15%, 50% and 100% PEG) as previously 
described, with PS as an ultra-rigid control.
106
 Figure 4.1A shows scanning electron micrographs 
of hydrogel particle types (i) 100% PEG, (ii) 50% PEG, and (iii) 15% PEG, which all look 
morphologically similar. We chose PEG because it is approved by the FDA and is routinely 
utilized in biomedical applications for its known biocompatibility, produced by its hydrophilicity 
and resulting resistance to protein adsorption.
96,97
 Additionally, PEG is highly modular and 
allows fine control over material and end group properties; covalently polymerized PEG particles 
are highly stable under physiologic blood conditions.
152
 Swollen modulus is the most 
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physiologically relevant measurement of these PEG-based materials. We fabricated bulk samples 
of each hydrogel type and probed the swollen shear modulus of each on an AR-G2 rheometer at 
37C. The shear moduli of these materials vary widely, as shown in Figure 4.1B. We fabricated 
particles of the same composition using an emulsion method, and Table 4.1 summarizes the 
fabrication conditions of each particle type and the resulting material properties, such as pore 
size.
112
 Polystyrene (PS) is not included in the material characterization portion of this work 
because its material properties are widely known. For reference, the approximate shear modulus 
of bulk PS is 667,000 kPa, which is by far the most rigid particle utilized in this study.
155
 
 
Table 4.1 Hydrogel Formulation and Calculated Material Properties 
 
 
 
Label % MeOH % PEGDA % CEA % PI
Density 
(kg/m3)
Pore Size 
(nm)27
Young’s 
Modulus (Pa)
100% 
PEG
0 89 10 1 1228 0.139 2,526,800
50% 
PEG
50 89 10 1 1051 0.376 508,300
15% 
PEG 
85 86 10 4 1007 3.539 23,000
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Figure 4.1 Hydrogel material and particle properties. 
(A) Representative scanning electron micrographs of 2 µm hydrogel particles with (i) 100%, (ii) 
50%, and (iii) 15% PEG composition respectively. Scale bars are 5 µm in length. (B) Swollen 
shear moduli of all hydrogel particle conditions; the inset better represents the difference 
between 50% and 15% PEG. Statistical analyses were performed using one-way ANOVA with 
Fisher’s LSD test, where (****) indicates p<0.0001 versus 100% PEG for the main figure and 
versus 50% PEG for the inset. Error bars represent standard error. 
 
Characterization of inflammatory markers on human umbilical vein endothelial cells (HUVECs) 
A quantitative understanding of the EC expression of surface receptors is crucial to 
discern the ligand-receptor (LR) adhesion dynamics of VTCs, so we evaluated the leukocyte 
adhesion molecule (LAM) expression by HUVECs upon activation with Interleukin-1 (IL-1). 
We quantified changes in E-selectin and ICAM-1 expression over time with flow cytometry, and 
the calculated site densities are shown in Figure 4.2A. Representative fluorescent staining of 
HUVEC monolayers is shown in Figure 4.2B. Maximal expression of E-selectin and ICAM-1 
occurs at 4 hours and 24 hours, respectively, which is in line with previous reports of these 
molecules on HUVEC.
114,172,173
 Of note, ICAM-1 is expressed approximately at double the 
surface density of E-selectin at these maximal activation times, providing a potential for more 
LR interactions per surface area. We used these time points of activation to evaluate the targeted 
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particle adhesion in a parallel plate flow chamber (PPFC) assay with human blood flow. In vivo, 
it is known that ICAM-1 is expressed at basal levels throughout the vasculature, and especially in 
the lung,
174,175
 while E-selectin is not.
176,177
 This is represented in our data in Figure 4.2A and is 
important to keep in mind the design of VTCs for applications in vivo. 
 
 
Figure 4.2 HUVEC expression profiles in vitro. 
(A) Expression of E-selectin and ICAM-1 by endothelial cells in vitro upon activation with 1 
ng/mL IL-1𝛽, as quantified by flow cytometry. To calculate site density in # molecules/µm2, we 
used D=15 µm for the cells and a calibration curve of standard beads. (B) Representative images 
of endothelial cells after activation and fluorescent staining. Statistical significances not shown.  
 
Interplay of sLe
A
 density, particle modulus, and wall shear rate (WSR) dictates particle adhesion 
 Our previous work investigated the dynamics of sLe
A
 (a carbohydrate ligand to 
selectins)-coated hydrogels at a single site density, which showed some interesting dynamics 
regarding particle modulus. Deformable particles were more efficient at binding at low WSR, 
while rigid particles were significantly better at high WSR. 
106
 In this work, we explore the 
impact of ligand density on each of the four particle types to determine whether the same trends 
hold. We aim to determine if deformable particle binding can be increased to match that of rigid 
particles at high WSR by adding more adhesive forces. Specifically, we utilized our previously 
described PPFC blood flow assay to investigate the intersection of two particle physical 
properties on targeted adhesion, deformability and ligand kinetics. We did this by evaluating the 
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influence of sLe
A
 density in combination with bulk particle modulus on adhesion efficiency 
under physiological blood flow conditions. WSR was dictated by the blood volumetric flow rate, 
as detailed in the experimental section, and the concentration of particles was kept constant at 1 x 
10
7
/mL, so the total number of particles perfused through the chamber in the 5-minute 
experiment time inherently increased with WSR. Thus, we represented the data as adhesion 
efficiencies, which we defined as the number of particles bound per 10
6
 perfused through the 
chamber per mm
2
, so that we can compare adhesion with different WSRs head to head. In Figure 
4.3, and in general, as the particle site density increases the potential adhesive force between the 
particle and HUVEC increases. As the WSR increases, the shear removal force on any bound 
particles increases. It is the balance of these two competing forces that determines the final 
adhesion efficiency of particles in vitro. Others have designated the point where the adhesive 
interaction of the particle is no longer sufficient to maintain binding adhesion with increasing 
WSR as the “critical WSR”.46 We define the “critical WSR” similarly, where the adhesion 
efficiency significantly decreases with increasing WSR, meaning the shear removal forces 
dominate the adhesive forces. 
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Figure 4.3 Particle adhesion efficiency to inflamed HUVEC monolayer as a function of 
particle sLe
A
 site density and modulus. 
Quantified VTC adhesion grouped at 3 wall shear rates (200 s
-1
, 500 s
-1
, and 1,000 s
-1
)
 
by sLe
A
 
site density and particle type: (A) PS, (B) 100% PEG, (C) 50% PEG, and (D) 15% PEG. 
Adhesion quantified after 5 minutes of laminar blood flow over a HUVEC monolayer activated 
with IL-1β for 4 hours. N=3 human blood donors per particle condition. Statistical analysis of 
adherent density was performed using one-way ANOVA with Fisher’s LSD test. (*) indicates 
p<0.01 versus 300 sites/µm
2
 and (
#
) indicates p<0.01 versus 1,000 sites/µm
2
. Error bars represent 
standard error.  
 
Figure 4.3 shows the adhesion efficiency of sLe
A
-coated VTCs as a function of particle 
modulus, sLe
A
 density, and WSR. Importantly, there was minimal non-specific binding of non-
targeted particles after 4 hours of activation, as shown in Figure 4.4A; though the HUVEC were 
activated, particles lacking targeting ligand showed minimal binding after 5 mins of perfusion in 
human blood flow. Therefore, it can be concluded that non-targeted adhesion is minimal in this 
experimental system. Here, in Figure 4.3, we directly compare how adding sLe
A
 site density 
affects overall adhesion at a constant WSR; in other words, we investigated how much more 
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adhesion could be obtained by increasing the adhesive force, with a constant shear removal 
force. This is of key interest for deformable particles at high WSR, as we aim to increase the 
adhesion to that of rigid VTCs with higher site densities.  
 
 
 
Figure 4.4 Non-targeted particle adhesion. 
Quantified non-targeted VTC adhesion at 3 wall shear rates (200 s
-1
, 500 s
-1
, and 1,000 s
-1
) by 
particle type after (A) 4 hours and (B) 24 hours of activation with IL-1𝛽. Adhesion quantified 
after 5 minutes of laminar blood flow over an IL-1β activated HUVEC monolayer. N=3 human 
blood donors per particle condition.  
 
We started with the most rigid PS particles, where increasing the sLe
A
 site density on 
particles did not significantly increase binding at the 200 s
-1
 WSR. At the intermediate WSR of 
500 s
-1
, an increase in site density from 300 to 5,000 sites/µm
2
 delivered the only significant 
increase in binding. We also see that specifically at 1000 s
-1
, this system is reaction-limited, 
rather than transport limited, because the overall adhesion efficiency continues to increase 
through the site densities tested. The data from Figure 4.3 is regrouped and plotted in Figure 4.5 
to highlight different trends. In Figure 4.5, looking across different WSRs within each site 
density on PS, with 300 sLe
A
 sites/µm
2
, the binding efficiency significantly decreased from the 
WSR of 500 s
-1
 to 1000 s
-1
, suggesting a lack of adequate adhesive force at this site density, and 
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designating a critical WSR between 500 s
-1
 to 1000 s
-1 
(Figure 4.3A). With the boost of adhesive 
force delivered by increasing the site density from 300 sLe
A
 sites/µm
2
 to 1,000 and 5,000 sLe
A
 
sites/µm
2
, the PS particles were able to maintain their adhesion efficiency with increasing WSR; 
no critical WSRs were identified for our experimental conditions.  
 
 
 
Figure 4.5 Particle adhesion efficiency to inflamed HUVEC monolayer as a function of 
particle sLe
A
 site density and modulus. 
Quantified VTC adhesion at 3 wall shear rates (200 s
-1
, 500 s
-1
, and 1,000 s
-1
)
 
by sLe
A
 site 
density and particle type: (A) PS, (B) 100% PEG, (C) 50% PEG, and (D) 15% PEG. Adhesion 
quantified after 5 minutes of laminar blood flow over a HUVEC monolayer activated with IL-1β 
for 4 hours. N=3 human blood donors per particle condition. Statistical analysis of adhesion 
efficiency was performed using one-way ANOVA with Fisher’s LSD test. (*) indicates p<0.01 
versus 200 s
-1 
within each site density, while (
#
) indicates p<0.01 versus 500 s
-1
 within each site 
density. Error bars represent standard error. 
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For the 100% PEG particles (Figure 4.3B), each increase in site density at a constant 
WSR produced more binding, except for the increase to 1,000 sLe
A
 sites/µm
2
 at 1000 s
-1
, where 
more adhesive force was needed to combat shear removal forces. Compared to PS, the 100% 
PEG particles bound minimally at sLe
A
 low site densities. In Figure 4.5B, for the 100% PEG 
particles with 300 sLe
A
 sites/µm
2
, the binding efficiency was generally low across all WSRs; 
thus, increasing WSRs did not reduce binding efficiency. At the 1,000 sites/µm
2
, the 100% PEG 
particles binding efficiency decreased with increasing WSR, with a critical WSR between 500 s
-1
 
and 1000 s
-1
 (Figure 4.5B). For 100% PEG particles, 5,000 sLe
A
 sites/µm
2
 was enough adhesive 
force to maintain higher binding efficiency across WSRs 
In Figure 4.3C, increasing the sLe
A 
site density for 50% PEG particles resulted in non-
significant increases in particle adhesion for the 200 and 500 s
-1
 WSRs. At 1000 s
-1
 only the 
increase to 5,000 sLe
A
 sites/µm
2
 resulted in significantly more binding. When considering one 
site density across different WSRs, for the 50% PEG particles in Figure 4.5C, the adhesion 
efficiency only decreased significantly with the 5,000 sites/µm
2
 density for the WSR increase 
from 200 s
-1 
to 500 s
-1
 (Figure 4.5C).  
Finally, in Figure 4.3D, on 15% PEG particles increasing site density to 5,000 sLe
A
 
sites/µm
2
 produced significantly more binding than both 300 and 1,000 sLe
A
 sites/µm
2
. 300 sLe
A
 
sites/µm
2
 delivered minimal targeted binding, and at only 200 s
-1
 was 1,000 sites/µm
2 
enough to 
significantly increase binding. The adhesion efficiency of 15% PEG particles decreased with 
increasing WSR for 1,000 and 5,000 sites/µm
2 
site densities, as shown in Figure 4.5D. Therefore, 
for 15% PEG particles, a critical WSR exists between 200 s
-1
 and 500 s
-1
 for all 1,000 and 5,000 
sites/µm
2 
site densities.  
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In general, the more deformable the particles, the more detrimental increasing the WSR 
were for particle binding efficiency at the same site density, except one key deviation of 100% 
PEG particles with a site density of 1,000 sLe
A
/µm
2
, which were outperformed by the more 
deformable 50% PEG particles. Of note, this deviation does not arise with the anti-ICAM-1 
targeted particles. We speculate that 50% PEG particles outperformed 100% PEG particles for a 
few possible different reasons. We previously concluded that particles are preferentially aided by 
WBCs under high WSR by more inelastic collisions which translate them towards the vascular 
wall; it is possible that such rigid particles with sLe
A
 on the surface may easily bounce away 
from the wall when translated in that direction, due to the further increased inelasticity of these 
particles compared to those in Chapter 3. Alternatively, it is possible that leukocytes more 
rapidly associate with and sweep away the more rigid hydrogel MPs under these hemodynamic 
conditions, and with 1000 sLe
A
/µm
2
, there is simply not enough adhesive force to counteract this 
process. Finally, as this is specific to sLe
A
, it is key to note the catch-slip bond nature of the 
interaction between sLe
A
 and selectin receptors, often produces what is called the shear threshold 
effect, determining when cells bind firmly or roll.
178
 For the 1,000 sLe
A
/µm
2
 at 1000 s
-1
, the 
modulus of 50% PEG particles could offer an optimal interaction between the sLe
A
 and the 
selectin receptors, as compared to the 100% PEG particles, resulting in more firm adhesion. 
Other than for this deviation, lower critical WSRs generally exist for more deformable 
particles. Overall, the more deformable particles, 15% PEG, require higher site densities to 
achieve significant binding at higher WSRs, in line with our previous data with a range of 
hydrogels from 15% PEG to 50% PEG that found that more rigid particles bind better at high 
WSRs (Figure 4.5).
106
 While higher site density allows more 15% PEG particles to bind with 
near the efficiency of rigid, 50% and 100% PEG particles, adding more sLe
A
 was not enough to 
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equilibrate binding across all particle types. With higher sLe
A
 site densities these deformable 
particles are able to lessen the gap in adhesion at high WSR, though rigid particles remain 
significantly better except for the one deviation noted.  
From previous work in Chapter 3, specifically Figure 3.11C, we know that particles of a 
broad range of moduli localize to the vascular wall equivalently;
106
 therefore, the residence times 
of the particles on the vascular wall should be nearly equivalent for a fixed WSR. Thus, the 
trends in adhesion across particle moduli must be due other biophysical forces. We have 
previously shown that dynamic interactions with WBCs drive shear-dependent trends in vitro, 
where more rigid particles are preferentially collided towards the vessel wall.
106
 There are a few 
different physical phenomena that could explain the observed trends. Particles of varying moduli 
have varying abilities to stretch once enough LR pairs are bound on the vessel wall to initiate 
adhesion. In the context of rigid VTC shape, it is widely known that elongated particles interact 
more efficiently with their target site in the presence of shear forces compared to spherical or 
non-elongated particles.
138,168,179,180
 The smaller cross-sectional area normal to flow reduces the 
shear removal force imparted by blood flow that would remove a particle already adhered to the 
endothelial wall. Additionally, the larger, stretched footprint would allow for more LR pair 
interactions total to adhere. We know that particles of these moduli do not significantly deform 
in free blood flow,
106
 but stretching could occur once bound to an inflamed wall. This data 
directly contradicts this argument. Indeed, these phenomena should lead to higher adhesion 
efficiencies for more deformable particles with the same or fewer targeting ligands. Clearly, this 
is not the case for 300 sLe
A
/µm
2
 across WSRs, or all site densities for that matter. Other possible 
phenomena that could produce these trends include the transport of particles to the vessel wall or 
varying rates of detachment of particles once adhesive contact is initiated. According to 
 82 
computational literature, mechanical force imparted by blood shear on a LR bond would be less 
on a deformable particle, as the particle is able to stretch to absorb some of the force.
181
 So if 
anything, rigid particles should detach more quickly, again contrary to our observed trends. 
Finally, it has been shown that leukocytes are able to roll effectively because of their deformable 
nature, whereas more rigid entities do not roll and have the tendency to wash away under flow. 
All of these possible physical explanations are contrary to our observed trends. We hypothesize 
and experimentally explore that this may arise due to the complex involvement of leukocytes, 
which are often overlooked in computational models. To elucidate the governing dynamics at 
play, we continued to explore the kinetics and hemodynamics of the VTC adhesion. 
 
Interplay of anti-ICAM-1 density, particle modulus, and WSR dictates particle adhesion 
 To elucidate the importance of the kinetics on the particle surface, we investigated how 
utilizing anti-ICAM-1, with a significantly slower kinetic off rate than sLe
A
, affects the adhesion 
efficiency of all four particle types. We sought to understand if deformable particles performed 
significantly worse than rigid VTCs with different ligand kinetics. Like the sLe
A
 experiments, PS 
and PEG particles were fitted with anti-ICAM-1 under the same physiological flow and total site 
densities (300, 1,000 and 5,000 sites/µm
2
). We evaluated the adhesion efficiency of particles as 
the adhesive forces were fixed (site density) while the disruptive forces increased (WSR). Figure 
4.6 shows the adhesion efficiency for 2 µm PS particles at a variety of anti-ICAM-1 site densities 
at a fixed WSR. HUVEC monolayers were activated for 24 hours for maximal ICAM-1 
expression. There was minimal non-specific binding of non-targeted particles after 24 hours of 
activation as shown in Figure 4.4B, except for a few points at 200 s
-1
 and one at 500 s
-1
. It is 
known that there are key differences in the cell surface protein expression after 24 hours, versus 
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4 hours, of activation by inflammatory cytokine, as detailed and quantified in Figure 4.2A. 
Therefore, we hypothesize that the higher non-targeted binding after 24 hours of activation is due 
to the higher affinity of our particles to this cell surface protein composition. This non-targeted 
adhesion highlights even further the diminished capacity for low site density of anti-ICAM-1 to 
produce any targeted binding. 
 
 
 
Figure 4.6 Particle adhesion efficiency to inflamed HUVEC monolayer as a function of 
particle anti-ICAM-1 site density and modulus.  
Quantified VTC adhesion at 3 wall shear rates (200 s
-1
, 500 s
-1
, and 1,000 s
-1
)
 
by anti-ICAM-1 
site density and particle type: (A) PS, (B) 100% PEG, (C) 50% PEG, and (D) 15% PEG. 
Adhesion quantified after 5 minutes of laminar blood flow over a HUVEC monolayer activated 
for 24 hours with IL-1β. N=3 human blood donors per particle condition. Statistical analysis of 
adherent density was performed using one-way ANOVA with Fisher’s LSD test. (*) indicates 
p<0.01 versus 300 sites/µm
2
 and (
#
) indicates p<0.01 versus 1,000 sites/µm
2
. Error bars represent 
standard error. 
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The data is plotted and grouped by WSR in Figure 4.6. At 200 s
-1
, PS adhesion increased 
significantly with increasing anti-ICAM-1 site density, which was not the case for the same 
particles with sLe
A
, highlighting a key difference in ligand kinetics. Even at the low WSR of 200 
s
-1
 more than 300 anti-ICAM-1/µm
2
 is required to produce firm adhesion. The gain in adhesion 
efficiency by adding more sites onto PS increased with WSR; at 500 s
-1
, both 1,000 and 5,000 
sites/µm
2 
were statistically higher than 300 anti-ICAM-1/µm
2
. Overall, this demonstrated how as 
the shear removal force imparted by physiological blood flow increased, more adhesive force 
was required to achieve firm VTC binding. The same data as in Figure 4.6 is regrouped and 
plotted in 4.7. In Figure 4.7A, with both 300 anti-ICAM-1 sites/µm
2
 and 1,000 anti-ICAM-1 
sites/µm
2
, as the WSR increases to 1000 s
-1
, the binding significantly decreases, meaning the 
shear removal force dominated the adhesion forces and a critical WSR existed between 500 and 
1000 s
-1
. At the maximum site density of 5,000 anti-ICAM-1 sites/µm
2
, PS adhesion efficiency is 
maintained through 1000 s
-1
; this amount of adhesive force was never overcome by the increase 
in WSR and no critical WSR was identified.  
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Figure 4.7 Particle adhesion efficiency to inflamed HUVEC monolayer as a function of 
particle anti-ICAM-1 site density and modulus. 
Quantified VTC adhesion at 3 wall shear rates (200 s
-1
, 500 s
-1
, and 1,000 s
-1
)
 
by anti-ICAM-1 
site density and particle type: (A) 100% PEG, (B) 50% PEG, and (C) 15% PEG. Adhesion 
quantified after 5 minutes of laminar blood flow over a HUVEC monolayer activated for 24 
hours with IL-1β. N=3 human blood donors per particle condition. Statistical analysis of 
adherent density was performed using one-way ANOVA with Fisher’s LSD test. (*) indicates 
p<0.01 versus 200 s
-1 
within each site density and (
#
) indicates p<0.01 versus 500 s
-1
 within each 
site density. Error bars represent standard error. 
 
For the 100% PEG particles (Figure 4.6B), 5,000 sites/µm
2
 were significantly more 
efficient than both 300 and 1,000 sites/µm
2
 for all WSRs. This suggests that the addition of more 
sites was of a larger benefit to the 100% PEG particles than the PS particles, due to low adhesion 
efficiencies with 300 sites/µm
2
. The 100% PEG particles in Figure 4.7B behaved similarly to the 
rigid PS particles, with a critical WSR identified for both 300 and 1,000 anti-ICAM-1/µm
2
 
between 500 s
-1
 and 1000 s
-1
. The main deviation of 100% PEG from PS is with 5,000 anti-
ICAM-1 sites/µm
2
, we identified a critical WSR between 500 and 1000 s
-1
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The 50% PEG particles in Figure 4.6C exhibited similar statistical trends to 100% PEG 
particles across WSR and anti-ICAM-1 site densities, with the exception being at 1000 s
-1
 for 
50% PEG particles, where the 1,000 sites/µm
2
 density did not produce adhesion that was 
significantly better than 300 sites/µm
2
. For 50% PEG particles in Figure 4.7C, there were no 
statistical changes in adhesion efficiency across WSR for both 300 and 5,000 anti-ICAM-1 
sites/µm
2
; for 300 sites/µm
2
 this was due to low overall binding. For 1,000 anti-ICAM-1 
sites/µm
2
, binding efficiency decreased upon increase of WSR to 1000 s
-1
, designating another 
critical WSR between 500 and 1000 s
-1
. For the 5,000 sites/µm
2
, there was no statistical change 
in binding obtained with increased WSR, due to the overall higher adhesive force between the 
particle and endothelial monolayer counteracting increases in shear removal forces. 
In Figure 4.6D for 15% PEG particles, there were only statistical differences in adhesion 
between 300 and 5,000 anti-ICAM-1 sites/µm
2
 at 200 and 500 s
-1
 and between 1,000 and 5,000 
anti-ICAM-1 sites/µm
2
 at 200 s
-1
. At 1000 s
-1
 this most deformable particles minimally adhered 
across all antibody site densities evaluated. In Figure 4.7D, on 15% PEG particles there was no 
drop in adhesion efficiency with increased WSR with 300 anti-ICAM-1 sites/µm
2
, again due to 
the very low adhesion efficiency at all WSRs. At the two higher anti-ICAM-1 densities of 1,000 
and 5,000 sites/µm
2
, adhesion efficiencies significantly decreased with each increased WSR, 
resulting in extremely low binding efficiencies observed at the 1000 s
-1
, and critical WSRs 
between 200 s
-1
 and 500 s
-1
.  
As expected, more rigid particles adhered better at higher shear, as was observed with 
sLe
A
 conjugated particles in Figure 4.3. Increased anti-ICAM-1 site densities lessened the gap at 
high WSR, but did not fully equalize binding for all particle moduli; rigid particles remained 
superior at high WSRs as they did with sLe
A
.
106
 For all particle types and all WSRs, 300 anti-
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ICAM-1 sites/µm
2
 produced very low adhesion efficiencies, especially in comparison to particles 
targeted with the same ligand surface density, but with sLe
A
. Again, this means that there is not 
sufficient adhesion force established to counteract the shear force of blood flow over the 
endothelial wall. Overall, the interplay of VTC modulus with targeting ligand site density was 
most prominent at the high WSR of 1000 s
-1
, where generally more rigid particles adhered more 
efficiently. The raw adhesion of each particle type, not scaled to adhesion efficiency, can be 
found in Figures 4.8 and 4.9, for sLe
A
 and anti-ICAM-1 particles, respectively.  
 
 
 
Figure 4.8 Raw particle adhesion to inflamed HUVEC monolayer as a function of particle 
sLe
A
 site density and modulus. 
Quantified VTC adhesion at 3 wall shear rates (200 s
-1
, 500 s
-1
, and 1,000 s
-1
)
 
by sLe
A
 site 
density and particle type: (A) PS, (B) 100% PEG, (C) 50% PEG, and (D) 15% PEG. Adhesion 
quantified after 5 minutes of laminar blood flow over a HUVEC monolayer activated with IL-1β 
for 4 hours. N=3 human blood donors per particle condition. Statistical analysis of adherent 
density was performed using one-way ANOVA with Fisher’s LSD test. (*) indicates p<0.01 
versus 300 sites/µm
2
 and (
#
) indicates p<0.01 versus 1,000 sites/µm
2
. Error bars represent 
standard error. 
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Figure 4.9 Raw particle adhesion to inflamed HUVEC monolayer as a function of particle 
anti-ICAM-1 site density and modulus. 
Quantified VTC adhesion at 3 wall shear rates (200 s
-1
, 500 s
-1
, and 1,000 s
-1
)
 
by anti-ICAM-1 
site density and particle type: (A) PS, (B) 100% PEG, (C) 50% PEG, and (D) 15% PEG. 
Adhesion quantified after 5 minutes of laminar blood flow over a HUVEC monolayer activated 
for 24 hours with IL-1β. N=3 human blood donors per particle condition. Statistical analysis of 
adherent density was performed using one-way ANOVA with Fisher’s LSD test. (*) indicates 
p<0.01 versus 300 sites/µm
2
 and (
#
) indicates p<0.01 versus 1,000 sites/µm
2
. Error bars represent 
standard error. 
 
Researchers have investigated increasing site densities on VTCs, but typically with just 
one particle type and one ligand type. For instance, 10 µm latex particles were functionalized 
with increasing amounts of sLe
X
, which produced significantly slower rolling speeds in buffer 
flow over a protein-coated plate.
182,183
 This work had a maximum site density of 90 sites/µm
2
, 
thus rolling velocity was a better metric than firm adhesion. In comparison, our minimum site 
density of 300 sites/µm
2
 produced minimal to no rolling adhesion, therefore we focused on 
binding efficiencies. Researchers have also shown that the rolling of 4.6 µm poly(lactic-co-
glycolic acid) (PLGA) spheres over P-selectin coated plates decreases with increasing sLe
X
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density, indicating increased adhesive forces, again focused on rolling speeds.
184
 In order to 
emphasize clinical utility, final adhesion is the best metric. Our previous work with sLe
A
 on 500 
nm PS spheres in blood flow determined diminishing returns for adding more ligand in vitro;
122
 
our work here corroborates those findings on 2 µm PS and PEG spheres in Figures 4.3 and 4.6. 
Any non-linearity in the graphs represents a diminishing return of adding more targeting ligand- 
the diminishing return is most apparent and present at the lower WSRs (200 s
-1
 and 500 s
-1
). 
Researchers speculate that this is due to the steric crowding of ligands and the inability to initiate 
more adhesive contacts.
185,186
 Others have shown the interplay of size and ligand density, noting 
that 10 µm PS particles are in a transport-limited regime in which adding more sLe
A
 increased 
adhesion, whereas the 5 µm PS particles were in a reaction limited regime as adding more ligand 
did not increase the final binding. Shifting to more complex in vivo models with anti-ICAM-1, it 
has been shown that decreasing particle avidity increases the specificity of the treatment, but not 
the overall accumulation at the site of inflammation.
187
 This is likely due to the baseline 
expression of ICAM-1 in the lungs. Our work, by investigating both ligand kinetics and particle 
modulus, aims to elucidate how these trends change based on the physical properties of the 
particles. 
 
Particle binding kinetics determined by observed attachment rate kACW 
To better explain the adhesion trends, we investigated the kinetics and complex 
hemodynamics of our VTCs. No correlation has been established between molecular LR kinetics 
and those of a whole particle onto a coated plate or cell surface. This is the case because of the 
differences in size as well as the presence of hemodynamic blood flow. To better understand the 
adhesion efficiency data, the observed attachment rate, kACW, was determined by the linear least-
 90 
squares regression of rate of attachment data and plotted in Figure 4.10. We plot this to represent 
how rates of attachment of different particle types change with changes in site density and ligand 
type. We investigated the adhesion kinetics, with sLe
A
 targeted particles to discern how 
increasing the site density of each particle type increases the attachment rate. At 200 and 500 s
-1
, 
the rate of attachment for all particle types begins to saturate, designated by the lack of linearity 
of kACW with increasing site density. This means at these lower WSRs, with smaller shear 
removal forces, there is a diminishing return for adding more sLe
A 
between 1,000 and 5,000 
sites/µm
2
. At the higher WSR of 1000 s
-1
, under larger shear removal forces, increasing site 
densities delivers higher returns than at lower WSRs; in other words, when targeting high shear 
vessels, higher adhesive forces are required to produce firm adhesion. Overall in Figure 4.10, we 
clearly see that PS particles have larger observed rates of attachment, especially at 500 s
-1
 and 
1000 s
-1
. For all particle types, with more sLe
A
/µm
2
, the larger the rate of attachment, as 
expected. With these particle kinetics findings in mind, we decided to explore how changing the 
kinetics of the LR pair would alter the trends in adhesion efficiencies. To date, all our work with 
deformable particles in vitro has been with sLe
A
 as the targeting ligand, which begs the 
investigation of different targeting ligands to see if the binding trends hold.  
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Figure 4.10 Rate of attachment constant by particle sLe
A
 site density. 
The normalized observed attachment rate for particles of varying moduli with varying amounts 
of sLe
A
 (300, 1,000, and 5,000 sites/µm
2
) at varying WSRs of (A) 200 s
-1
, (B) 500 s
-1
, and (C) 
1000 s
-1
. Error bars represent standard error for N=3. 
 
In Figure 4.11 we investigated the adhesion kinetics, with anti-ICAM-1 targeted particles 
to discern how increasing the site density of each particle type increases the attachment rate. 
These were again normalized because more particles were perfused at higher WSRs. Figure 
4.11A shows the trend by modulus and anti-ICAM-1 site density at 200 s
-1
; at the low WSR the 
benefit of adding more sites begins to saturate between 1,000 and 5,000 sites/µm
2
, as designated 
by the lack of linearity. At 500 s
-1
, the rate of attachment is slower at 300 sites/µm
2
 than it was 
for those at the 200 s
-1
, because the higher shear removal force demands more adhesive force. At 
1000 s
-1
 this is even more extreme, where the observed attachment rate saturates less than the 
other WSRs and there are huge benefits to adding more anti-ICAM-1 on the surface of the 
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particles. At this WSR, the rigid particles have a higher observed rate of attachment than 
deformable particles, for all site densities tested. This aligns with our previous publication, that 
rigid particles outperform deformable counterparts in whole blood medium at high WSR.
106
 The 
fact that this holds true with a different ligand-receptor system at a range of site densities, points 
to the transport of deformable particles as the dominant mechanism controlling adhesion. 
 
 
 
Figure 4.11 Rate of attachment constant by particle anti-ICAM-1 site density.  
The normalized observed attachment rate for particles of varying moduli with varying amounts 
of anti-ICAM-1 (300, 1,000, and 5,000 sites/µm
2
) at varying WSRs of (A) 200 s
-1
, (B) 500 s
-1
, 
and (C) 1000 s
-1
. Error bars represent standard error for N=3. 
 
The impact of ligand type on final particle adhesion 
We explored the differences that arose directly from varying ligand receptor kinetics of 
sLe
A
 and anti-ICAM-1. We specifically chose these two ligand-receptor pairs because they 
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represent very different ligand kinetics. The forward (kf) and reverse (kr) rate constants of the 
association between sLe
A
 to E-selectin are approximately 27,000 M
-1
s
-1
 and 3 s
-1
, respectively, 
and for anti-ICAM-1 and ICAM-1 they are known to be 156,000 M
-1
s
-1
 and 1.13 x 10
-4 
s
-1
, 
respectively.
169,170
 The kinetic rate constants for the anti-ICAM-1/ICAM-1 interaction are similar 
to that of the endogenous activated integrin, LFA-1/ICAM-1.
170
 The kf values are in the similar 
in magnitude, while the kr values of the sLe
A
/selectin is 4 orders of magnitude higher. This clear 
difference in reverse reaction rates explain the well-established, distinct roles of these receptors 
and their ligands in the leukocyte adhesion cascade.
188
 Namely, binding to selectins, with large 
reverse rate constants, promotes rolling and slowing of WBCs, while binding to ICAM-1, with a 
smaller reverse constant, promotes firm adhesion.  
While the quantitative kinetic values above describe the adhesive interactions at a 
molecular level, more macroscopic kinetics have been studied in the context of targeted drug 
delivery. Haun and Hammer coined the term “transport-reaction” model as a way to explain the 
kinetics of entire particles associating and dissociating with coated plates, rather than single 
molecular ligand-receptor interactions.
189
 There is a big difference between molecular and 
particulate kinetics, namely, particles have immobilized ligands on the surface, which can be 
sterically hindered and are inherently coupled to the location of other ligands. Additionally, the 
massive difference in size scale and the presence of fluid flow have made it impossible to 
determine a direct correlation between molecular kinetics and particulate binding kinetics.
189
 
While much of this pioneering work determined how particle size and kinetics determine overall 
binding to a receptor-coated plate, translation to the clinic requires development into more 
physiological realms, such as using primary human cells and human blood. Therefore, we 
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compared how particles with all else constant, beside the type of ligand, bound to and inflamed 
endothelium. 
The importance of ligand type is presented in more detail in Figures 4.12A and B. The 
data shown is that of the most extreme moduli particles, PS and 15% PEG. Both Figure 4.12A 
and B are adhesion efficiency of anti-ICAM-1 targeted particles subtracted from sLe
A
 targeted 
particles at the equivalent site density and WSR. For all but one condition, sLe
A 
targeted particles 
outperformed the anti-ICAM-1 targeted counterparts, even though about twice as much ICAM-1 
is expressed on activated HUVECs than E-selectin at corresponding maximal activation times. A 
similar trend has been shown in the past, where significantly more anti-ICAM-1 is required to 
obtain a comparable amount of binding in vitro.
113,122,167
 Of key importance, the interaction 
between sLe
A
 and selectins is considered a catch bond, which strengthens over time under 
increased shear force.
163,190
 Thus, our result of sLe
A
 targeted particle outperforming anti-ICAM-1 
particles at high WSRs aligns with this previously published work and known behavior of catch 
bonds. For rigid particles like PS, across all WSR, the benefit of sLe
A
 targeting decreased with 
increased total surface site density, meaning anti-ICAM-1 was closing the adhesion gap. The 
inverse is true with the most deformable, 15% PEG particles, meaning that the higher the site 
density, the better sLe
A
 targeted particles perform versus their anti-ICAM-1 targeted 
counterparts.  
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Figure 4.12 Difference in adhesion by ligand type. 
(A) Differential particle adhesion efficiency, as defined by subtracting the anti-ICAM-1 adhesion 
efficiency from that of sLe
A
 adhesion efficiency (number bound/10
6
 perfused), shown for the 
two extreme particle types (A) PS and (B) 15% PEG. In general, sLe
A
 adhesion efficiency is 
higher than that of anti-ICAM-1.  
 
The contribution of WBCs to particle binding trends 
Our previous work with sLe
A
 at one site density highlighted collisions with WBCs in the 
cell free-layer as the reason for modulus and WSR dependent binding. This was demonstrated 
when WBCs were removed from the blood flow medium and the sLe
A
 mediated particle binding 
was uniform across all particle moduli. Whereas in the presence of WBCs, deformable particles 
bound best at low WSR and rigid particles bound better than deformable at high WSRs.
106
 We 
expanded on this to determine whether WBCs play a similar role for our particles with varying 
amounts of ligand, with two distinct sets of kinetics. We investigated how removing WBCs from 
hemodynamic blood flow affected binding in vitro. We hypothesized that WBCs would still be a 
major player, as they were in our previous work, even with different ligand kinetics. In Figure 
4.13 we show adhesion efficiencies for the four particle types with either high or low site 
densities anti-ICAM-1, at high and low WSRs, all without WBCs (sLe
A
 shown in Figure 4.14). 
We designate this blood medium RBCs+plasma, as the other main component, WBCs, have been 
removed.  
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Figure 4.13 Anti-ICAM-1 particle adhesion to an inflamed HUVEC monolayer in WBC-
removed, RBC+plasma medium. 
Adhesion efficiency shown for all particle types at both 200 and 1000 s
-1
 WSRs with (A) 300 
anti-ICAM-1/µm
2
 and (B) 5,000 anti-ICAM-1/µm
2
. Change in particle adhesion between whole 
blood (WB, from Fig. 4) and RBC+plasma (RBC+p, from Fig. 7) trials. Adhesion efficiency 
shown for all particle types at both 200 and 1000 s
-1
 WSRs with (C) 300 anti-ICAM-1/µm
2
 and 
(D) 5,000 anti-ICAM-1/µm
2
. All adhesion shown after 5 minutes of laminar RBC+plasma flow 
over a HUVEC monolayer activated with IL-1β for 24 hours. N=3 human blood donors per 
particle condition. Error bars represent standard error. Representative images of adhesion of 
leukocytes to an inflamed HUVEC monolayer at (E) 200 s
-1
 and (F) 1000 s
-1
, after 5 mins of 
laminar whole blood flow. 
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Figure 4.13A shows how particles with 300 anti-ICAM-1/µm
2
 adhere in RBCs+plasma. 
This data follows the trend of our previous work,
106
 in that the binding is equivalent across all 
particle types when WBCs are removed, at both 200 and 1000 s
-1
 WSR. Interestingly here we see 
that removing the WBCs from the blood medium again eliminates the adhesion efficiency trends 
observed earlier (Figures 4.6 & 4.7), except for one condition. The 15% PEG particles with 
5,000 anti-ICAM-1/µm
2
 maintain low binding at 1000 s
-1
. Other than that data point, all binding 
is similar within each of the low and high site densities of anti-ICAM-1, regardless of particle 
modulus. Figures 4.13C and D are the adhesion efficiency in RBCs+plasma subtracted from that 
in whole blood. Therefore, a negative value means binding is more efficient in RBCs+plasma, 
and that WBCs disrupt the binding of the particle to the vascular wall. A positive value means 
binding is higher in whole blood and WBCs aide in the binding of the VTC. For the 300 anti-
ICAM-1/µm
2
 the adhesion efficiency in RBCs+plasma is significantly higher than that in whole 
blood for both 200 s
-1
 and 1000 s
-1
. Because this occurs predominantly at low WSR, this is likely 
not due to collisions in blood flow, but rather due to the adhesive competition between WBCs 
and VTCs at the low WSR. It is well known that WBCs adhere significantly more at lower 
WSRs;
191
 we corroborated this known fact with qualitative images in Figure 4.13E and F, 
showing significantly more WBCs bound in a WSR of 200 s
-1
 versus 1000 s
-1
. We then 
investigated how this trend would translate to higher site density particles. For the particles with 
5,000 anti-ICAM-1/µm
2
, the adhesion efficiency in RBCs+plasma is lower than that in whole 
blood without WBCs present, binding at this site density is statistically similar across all particle 
moduli tested. WBCs hinder binding at low site densities whereas they encourage high site 
density binding. Unlike the lower site density, the particles with higher adhesive force bind less 
in the absence of WBCs, though not statistically. This means, like in our previous work, that with 
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higher site densities, the WBCs help push the particles to the vessel wall;
106
 the larger adhesive 
forces of these particles can bind to the endothelium in the crowded, hemodynamic environment. 
The more rigid particles are aided maximally by WBCs because of their inelasticity; rigid 
particles will displace further after each collision than deformable, elastic particles, increasing 
the probability that contact with the vessel wall occurs. For both site densities, WBCs have a key 
impact on sLe
A
 targeted particles in vitro; for the low site density WBCs competitively disturb 
the area of binding, whereas for the high site density particles, WBCs increase the binding of 
VTCs of varying moduli with anti-ICAM-1
 
by pushing them to the vessel wall. 
In Figure 4.14 we show the same data, but for sLe
A
 particles. A similar trend versus the 
whole blood data exists as does with anti-ICAM-1 targeted VTCs. Figure 4.14A shows how 
particles with 300 sLe
A
/µm
2
 adhere in RBCs+plasma. Interestingly at 200 s
-1
 these adhesion 
efficiencies are significantly higher than those with WBCs, meaning that at low WSR, WBCs 
hinder binding of 300 sLe
A
/µm
2 
particles, except for PS at a low WSR. We again attribute this to 
the inability of particles with lower site density to bind in a crowded, competitive vessel wall 
environment. In Figure 4.14B, the adhesion efficiencies were also equivalent for all particle 
types with 5,000 sLe
A
/µm
2
- without WBCs present, binding at this site density is statistically 
similar across all particle moduli tested. We again attribute this to the increased ability of high 
site density particles to adhere rapidly in a dynamic, collision-filled blood vessel. Overall the 
sLe
A
 binding without WBCs is higher than that with anti-ICAM-1, continuing the trend found in 
the whole blood data. 
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Figure 4.14 SLe
A
 particle adhesion to an inflamed HUVEC monolayer in WBC-removed, 
RBC+plasma medium. 
Adhesion efficiency shown for all particle types at both 200 and 1000 s
-1
 WSRs with (A) 300 
sLe
A
/µm
2
 and (B) 5,000 sLe
A
/µm
2
. Change in particle adhesion between whole blood (WB, from 
Fig. 2) and RBC+plasma (RBC+p, from Fig. 7) trials. Adhesion efficiency shown for all particle 
types at both 200 and 1000 s
-1
 WSRs with (C) 300 sLe
A
/µm
2
 and (D) 5,000 sLe
A
/µm
2
. All 
adhesion shown after 5 minutes of laminar RBC+plasma flow over a HUVEC monolayer 
activated with IL-1β for 4 hours. N=3 human blood donors per particle condition. Error bars 
represent standard error.  
 
The data in Figures 4.13 and 4.14 are key for elucidating and explaining the mechanism 
by which adhesion trends arise in whole blood, but we note that WBCs will always be present in 
physiological conditions. Provided equal transport of particles to the vessel wall as we have 
previously shown,
106
 and only a varying amount of site density, the particles respond differently 
to the removal of WBCs. With low site densities, WBCs hinder the binding of particles with both 
ligands tested, likely by crowding the vessel wall that they must bind too. Higher site density 
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particles can more rapidly adhere firmly, so that they are less affected by this phenomenon. At 
high site densities, the WBCs push or crowd the VTCs to the vessel wall, where the larger 
adhesive force can combat collisions with WBCs. Essentially, once VTCs with higher site 
density contact the vascular wall, they will bind and are not as easily disrupted by collisions or 
shear forces. Whereas the low site density particles are still transported to the vessel wall but 
simply cannot counteract the crowding on the vessel wall. Interestingly in RBCs+plasma, the gap 
in adhesion efficiency between the high and low site densities decreases, as the removal of 
WBCs aids low site density VTCs while hindering high site density VTCs. In light of these 
findings, and recognizing that WBCs are always present in physiological conditions, we next 
investigated if we could increase the binding of all particle types under the same whole blood 
conditions by employing an optimized mix of the two targeting ligands. 
 
Dual targeting standardizes final adhesion across particle moduli 
We utilized a mix of both targeting ligands, with the same total site density of 5,000 
sites/µm
2
, with a ratio known to produce maximal adhesion with 4 hours of activation.
122
 
Increasing the site density of either single ligand, sLe
A
 or anti-ICAM-1, was not enough to 
increase the deformable particle binding at high WSR, so we investigated if optimal dual 
targeting could equilibrate the binding across all moduli. It has been previously shown that 
ICAM-1 facilitated binding is greatly increased with the involvement of selectins; upon particles 
rolling via the selectin LR pair, ICAM-1 facilitated binding engages more completely.
170
 Figure 
4.15A is a schematic of the particle surface composition, which was 25% sLe
A 
and 75% anti-
ICAM-1. The same PPFC flow experiments were conducted with all experimental variables the 
same except the targeting ligand composition. All four particle types with this dual targeting 
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ligand regime adhered equivalently at 200 s
-1
, as shown in Figure 4.15B. At low WSR, the 
optimal mix of targeting ligands produces equivalent binding independent of particle modulus. 
At a high WSR of 1000 s
-1
, the same holds true in Figure 4.15C; dual targeting with the optimal 
mix of ligand based on HUVEC expression equilibrated all binding patterns based on modulus. 
Of note, the binding efficiencies were nearly equivalent from 200 s
-1
 to 1000 s
-1
, meaning that 
this dual targeting regime provides sufficient adhesive force to bind equivalently in the WSRs 
tested. Clearly, the interplay of the two different ligand types produced this trend; sLe
A
 slowed 
the particles rolling along the surface while anti-ICAM-1 facilitated the firm adhesion, negating 
any other possible WBC effects once bound to the endothelium. These results emphasize the 
importance of understanding the targeted particle surface, in that particle modulus no longer 
dictated adhesion trends at any WSR. This work is paramount in understanding how to maximize 
the binding of low modulus particles at high WSRs. While deformable particles are often 
highlighted for ability to circulate for long times in vivo, previous results suggested they may not 
produce efficient adhesion at high WSRs.
106
 This work shows that by designing a dual targeting 
regime that is optimal for the targeted endothelium, particle modulus is no longer the dominating 
factor in determining VTC adhesion. Therefore, if in the development process there is a concern 
about particle adhesion efficiency, especially with deformable particles at high WSRs, it can be 
addressed with dual targeting. 
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Figure 4.15 Particle adhesion efficiency of dual targeted particles to an inflamed HUVEC 
monolayer as a function of particle modulus. 
 (A) Schematic of dual targeted particle with 5,000 sites/µm2 total, 25% of which is sLeA, 75% of 
which is anti-ICAM-1. This composition has been previously determined to produce maximal 
binding for 4 hour activation with IL-1β. Quantified adhesion of hydrogel particles at a WSR of 
(B) 200 s-1 and (C) 1000 s-1 by modulus after 5 minutes of laminar blood flow over a HUVEC 
monolayer activated with IL-1β for 4 hours. N=3 human blood donors per particle condition. 
Error bars represent standard error. All conditions are not significant as determined by using one-
way ANOVA with Fisher’s LSD test. 
 
Previous work evaluating the ligand-dependent binding of VTCs under flow conditions 
are typically targeted to protein-coated plates in buffer flow. Based on our work, WBCs alone 
play an integral role in the binding of targeted VTCs. Therefore, it is key to utilize increasingly 
physiological systems for the future development of VTC systems, while continuing to use 
simplified systems to elucidate the mechanisms at play.  
 
4.5 Conclusions 
The work presented here is the first demonstration that the impact of VTC ligand type 
and surface density depends on both VTC modulus and blood WSR. Previous work from others 
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demonstrated that low VTC modulus can increase circulation time, ability to navigate capillaries, 
and avoidance of immune clearance, making low modulus VTCs attractive for clinical 
applications. This work presents a comprehensive study of the role that particle ligand kinetics, 
ligand density, and VTC modulus play on adhesion mechanisms required for targeted particle 
adhesion in VTC systems. Deformable particles with a single ligand, regardless of site density or 
ligand type, were not able to match the binding of rigid particles in high shear environments. 
Importantly, WSR plays a dramatic role in determining the adhesion efficiency of all VTCs, 
regardless of modulus, ligand type, or ligand surface density. Our findings indicate that rigid 
particles are able to achieve more binding with increases in site density at the same WSR, due to 
the increased adhesion force. The removal of WBCs elucidates their key role in altering VTC 
adhesion from blood flow-with low site densities WBCs disrupt particle binding via competition 
at low WSRs, whereas with high site densities WBCs increased particle binding via productive 
collisions in the red blood cell-free layer. Interestingly, and of huge clinical importance, our 
study shows that by employing the most efficient dual targeting ligand composition, adhesion is 
completely equilibrated across all particle moduli tested at one WSR, offering a route to improve 
binding of rigid particles at low WSR and deformable particles at high WSR. This unique work 
teases out the importance of multiple crucial physical properties of VTCs and targeted 
components to demonstrate the clear interplay of particle modulus, ligand kinetics, and ligand 
density to produce trends in particle adhesion. Using these findings, in conjunction with well-
defined disease hemodynamics and targeted disease receptor profiles, VTC systems can be more 
intelligently engineered for higher clinical efficacy and improved translation of VTC systems 
from the bench top to bedside.  
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: Evaluation of Receptor-Ligand Mechanisms of Dual-Targeted Chapter 5
Particles to an Inflamed Endothelium 
 
5.1 Publication Information 
This work is a collaboration with Dr. Catherine Fromen, all parts presented here are a 
direct result of my work. All the data in this chapter is published as: Fromen, Catherine A., 
Margaret B. Fish, Anthony Zimmerman, Reheman Adili, Michael Holinstat, and Omolola 
Eniola‐Adefeso. "Evaluation of receptor‐ligand mechanisms of dual‐targeted particles to an 
inflamed endothelium." Bioengineering & translational medicine 1, 1 (2016): 103-115. 
 
5.2 Abstract 
Vascular-targeted carriers (VTCs) are designed as leukocyte mimics, decorated with 
ligands that target leukocyte adhesion molecules (LAMs) and facilitate adhesion to diseased 
endothelium. VTCs require different design considerations than other targeted particle therapies; 
adhesion of VTCs in regions with dynamic blood flow requires multiple ligand-receptor (LR) 
pairs that provide particle adhesion and disease specificity. Despite the goal of leukocyte 
mimicry, the specificity of multiple LAM-targeted VTCs remains poorly understood, especially 
in physiological environments. Here, we investigate particle binding to an inflamed mesentery 
via intravital microscopy using a series of particles with well-controlled ligand properties. We 
find that the total number of sites of a single ligand can drive particle adhesion to the 
endothelium, however, combining ligands that target multiple LR pairs provides a more effective 
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approach. Combining sites of sialyl Lewis A (sLe
A
) and anti-intercellular adhesion molecule-1 
(anti-ICAM-1), two adhesive molecules, resulted in ~3-7-fold increase of adherent particles at 
the endothelium over single-ligand particles. At a constant total ligand density, a particle with a 
ratio of 75% sLe
A
: 25% anti-ICAM-1 resulted in more than 3-fold increase over all over other 
ligand ratios tested in our in vivo model. Combined with in vitro data, we find the best dual-
ligand design of a particle is heavily dependent on the surface expression of the endothelial cells, 
producing better adhesion with more particle ligand for the lesser-expressed receptor. These 
results establish the importance of considering LR-kinetics in intelligent VTC ligand design for 
future therapeutics.  
 
5.3 Background 
Particulate drug delivery was developed to package systemically toxic drugs into inert 
particle carriers, thereby selectively releasing active cargo to a diseased target. This approach 
should dramatically increase treatment efficacy by delivering more drug into the diseased tissue 
while eliminating systemic release, thereby mitigating toxic side effects. While this concept has 
not yielded a true “magic bullet” to date, packaging small molecule drugs into particles 
dramatically alters their pharmacokinetic/dynamic behavior and provides opportunities to direct 
drugs into diseased targets depending on their size, shape, and composition.
1,11,37,127
 Many 
diseases manifest in the upregulation or overexpression of certain cellular surface receptors; 
therefore, tissue specificity can be enhanced with use of LR pairs. Particulate drug carriers can 
be coated with ligands complimentary to these receptors, providing a lock and key approach to 
disease-specific delivery. In principle, the concept of LR pairs seems straightforward, however, 
implementation of actively targeted particles has proved challenging.
87
 Nanoparticle therapeutics 
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with applications in cancer have driven research in the field. Despite conflicting results in overall 
success,
87,192,193
 a handful of candidates are currently in the clinical trial pipeline for cancer 
applications.
192,194
 
VTCs are an emerging area of research within particulate drug delivery. We define VTCs 
as particles designed with surface adhesive ligands that mimic those of leukocytes. During 
inflammation, activated endothelial cells (ECs) upregulate surface LAMs, including selectins, 
intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-
1).
78
 Importantly, ECs shed their glycocalyx barrier, enabling leukocytes to interact directly with 
the EC surface.
195
 Surface ligands on circulating leukocytes facilitate rolling on and firm capture 
to activated ECs, and assist in extravasation into tissue to perform various immune functions.
79
 
This leukocyte adhesion cascade (LAC) is an important mechanism for normal immune function, 
but is also indicative of excessive cell recruitment that occurs early in many diseases.
78,79
 
Overexpression of LAMs represent potential targets for the design of particulate therapeutics; 
VTCs have been designed utilizing a wide range of LAM-LR pairs for novel therapeutic 
approaches in atherosclerosis,
196,197
 and cancerous tumors,
198
 among others.
192,199–202
 
Success of VTCs relies heavily on LR interactions with overexpressed LAMs on diseased 
ECs. VTCs are unique in that they must adhere to diseased ECs under rapid blood flow 
conditions, unlike other particles targeted to tissue spaces. Once localized to the endothelium, the 
interactions between LR pairs dictate adhesion and ultimate drug carrier efficacy. VTC and EC 
surface bonds must form rapidly to overcome particle momentum in flow. Capture and firm 
arrest at the surface will depend on the kinetics of the LR engaged pair and the aggregate 
strength of those interactions. Particle ligand total receptor avidity and specificity must be 
balanced; excessive avidity can lead to off target binding and immune responses due to rapid 
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opsonization of non-native proteins, while insufficient LR avidity can result in minimal 
binding.
86
 The design of VTC ligands must correspond with receptors in the targeted disease 
state; a ligand for the immediate onset of disease may not function efficiently in a chronic 
response.
203,204
 Given the fluctuation of receptors on ECs and the presence of blood flow, 
leukocytes achieve adhesion with multiple LR pairs, where each LR pair provides a unique 
benefit of capture, firm adhesion or transmigration, based on spatiotemporal expression on the 
diseased ECs. Notably, selectin receptors facilitate leukocyte capture and rolling, yet 
physiological levels of this LR pair are not enough to achieve firm adhesion on inflamed ECs. 
Firm adhesion requires secondary LR pairs, usually involving cell adhesion molecules (CAMs), 
which are expressed at a lower EC surface density with more favorable kinetics for firm 
adhesion.
78,79
 Through the synergistic effects of these two LR pairs, leukocytes efficiently 
respond to inflammation on diseased tissues in vivo.  
Despite the goal of LAC mimicry, the use of multiple LAM ligands on VTCs remains 
poorly understood. Most studies of VTCs have focused on particle designs with a single LR pair, 
with emphasis on the final disease outcome due to the delivered drug. Efficacy studies that have 
probed dual ligands are largely qualitative, comparing multi-ligand particles to the single ligand 
counterparts with minimal control over the total particle ligand presentation.
85–89
 Additional 
studies have probed the importance of ligand ratios between two LR pairs in static conditions, 
which fail to capture LR pair dynamics under physiologically relevant flows.
85,90
 To study LR 
kinetics under flow, multiple research groups have used protein-coated plates to study the 
adhesion and rolling of dual-targeted particles in vitro.
205–210
 However, these studies lack the 
complexity of a true diseased endothelium, as spatiotemporal LAM expression varies widely.
211
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To address these gaps in understanding, we have designed particles with controlled 
ligand densities and evaluated particle adhesion in physiological environments. We investigated 
both single and dual LR pairs, exploiting selectin and β2 integrin mediated paths of adhesion by 
designing particles with sLe
A
 and anti-ICAM-1. These two LR pairs drive leukocyte adhesion 
during inflammatory events, representing a synergistic therapeutic target for nanoparticle 
delivery.
78
 Furthermore, the carbohydrate-selectin LR pair and antibody-CAM LR pair have 
drastically different rates of interaction, which enables us to evaluate the role of LR pair kinetics 
in the nanoparticle design.
169,170
 Notably, we evaluated these particles in a model of inflamed 
mesentery using intravital microscopy to capture a dynamic in vivo environment. Our results 
show that controlling the design of particle ligand presentation is critical in optimizing delivery 
of VTCs. 
 
5.4 Results 
Density of sLe
A
 dictates particle adhesion in vitro and in vivo 
We utilized a parallel plate flow chamber (PPFC) assay to investigate the role of sLe
A 
density on particle adhesion under physiological blood flow conditions. A series of four particle 
types (A-D) was prepared with increasing sLe
A 
surface density (Figure 5.1A). SLe
A
 site densities 
were quantified by flow cytometry (Table 5.1), with representative gating shown in materials and 
methods (chapter 2) and reaction conditions are detailed in Figure 5.2. Human umbilical vein 
endothelial cell (HUVEC) monolayers were prepared and activated with TNF-α for 4 hours prior 
to experiments. Representative fluorescent images of particle binding in the PPFC assay are 
shown in Figure 5.1B. Minimal non-specific particle binding was observed for particles 
functionalized with an IgG-isotype control of varied densities, as shown in Figure 5.3. Particle 
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adhesion from sLe
A
 targeted particles was determined and non-specific binding from control 
particles at corresponding site densities were subtracted out to quantify target-specific adhesion 
(Figure 5.1C). Increasing the sLe
A
 density on 500 nm particles from 5,000 sites/µm
2
 to 40,000 
sites/µm
2 
resulted in increased particle adhesion. We observed a 2-fold increase in particle 
binding from A to B; additional sLe
A
 on C and D resulted in further increased adhesion (3- and 
6-fold increases over A, respectively).  
 
 
 
Figure 5.1 Particle adhesion to inflamed HUVEC monolayer as a function of total sLe
A
 
sites. 
(A) Diagram of four particle conditions A-D with increasing sLe
A
 ligand density (5,000, 10,000, 
20,000, and 40,000 sLe
A
 sites). (B) Representative fluorescence images of particle adhesion to in 
vitro inflamed HUVEC monolayer, corresponding to particles A-D from top to bottom. HUVEC 
activation was achieved via 4 hour TNF-α incubation. (C) Quantified particle adhesion. 
Statistical analysis was performed using one-way ANOVA with Fisher’s LSD test (*) indicates 
p<0.05, N=3 donors. Error bars represent standard error, scale bar 50 µm.  
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Figure 5.2 Reaction conditions for biotinylated ligand attachment of sLe
A
. 
Our highest site density used in subsequent studies was 40,000 ligands/µm
2
; further increases in 
the ligand reaction concentration resulted in increased in ligand site density. This indicates that 
the active avidin sites were never saturated. At 40,000 sites/µm
2
, the ligand occupies a parking 
area of 25 nm
2
 per targeting ligand. This is five times larger than hydrodynamic radius of avidin 
(5.4 nm), thus implying a distributed ligand landscape.
212
 
 
 
 
Figure 5.3 Non-specific particle adhesion to an inflamed HUVEC monolayer. 
Isotype control IgG (biotin-rat IgG2b, Biolegend) sites were varied on particles ranging from 
5,000, 10,000, 20,000, to 40,000. Using a PPFC, particle adhesion to in vitro inflamed HUVEC 
monolayer was determined HUVEC activation was achieved via 4 hour TNF-α incubation, N=3 
donors. Error bars represent standard error. 
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Table 5.1 Particle Ligand Quantification, Target Values Shown in Grey, with Actual 
Values Determined via Flow Cytometry 
 
Particle SLeA Site Density 
(#/µm
2
) 
ICAM-1Site Density 
(#/µm
2
) 
Total Site Density 
(#/µm
2
) 
A 5,000 0 5,000 
 5.642 +/- 929 0 5.642 
B 10,000 0 10,000 
 10,374 +/- 1,369 0 10,374 
C 20,000 0 20,000 
 19,623 +/- 1.920 0 19,623 
D 40,000 0 40,000 
 41,040 +/- 2,225 0 41,040 
E 0 5,000 5,000 
 0 4,526 +/- 1,892 4,526 
F 5,000 5,000 10,000 
 3,866 +/- 487 4,717 +/- 1,006 8,583 
G 0 10,000 10,000 
 0 10,938 +/- 2,536 10,938 
H 10,000 10,000 20,000 
 11,495 +/- 4,631 10,987 +/- 2,466 22,482 
I 7,500 2,500 10,000 
 6,792 +/- 911 2,976 +/- 675 9,768 
J 2,500 7,500 10,000 
 2,910 +/- 127 8,891 +/- 220 11,801 
 
We were interested if the increase in sLe
A
 site density could produce a similar increase in 
particle binding in vivo, which we observed with real-time intravital fluorescence microscopy. 
Fluorescent particle types A-D were visualized at the surface of the inflamed blood vessel in 
vivo, with qualitative differences in particle adhesion shown in representative still images of 
Figure 5.4A. The vessel walls of selected veins are indicated with black arrows; particles found 
 112 
in other vessels, including adjacent capillaries, were not included in the adhesion analysis. 
Particle adhesion and rolling densities were determined (Figure 5.4B) and the rolling velocities 
of corresponding particles are shown (Figure 5.4C). No particle binding or adhesion was 
observed for control particles with isotype-control IgG (Video 5.1). Movies of particles B & C 
rolling in vivo can be seen in Videos 5.2 and 5.3. 
 Particles A-D successfully adhered to the inflamed endothelium via both rolling and firm 
arrest. Particle A exhibited the fastest rolling velocity, which corresponded to the lowest 
occurrence of particles firmly arrested or rolling at the wall. Particle B exhibited a decreased 
rolling velocity compared to particle A (p<0.0001), which corresponded to an increased presence 
of particles at the wall. Particles C and D had similar low rolling velocities (p=0.2), which 
resulted in more firmly bound particles; Particle C was the most effective, with a ~30-fold 
increase of total adherent particles over A (p=0.014). This corresponded to a ~30-fold increase in 
rolling particles and a ~20-fold increase in firmly arrested particles (p=0.012 and p=0.042, 
respectively). Additionally, particle C produced a ~9-fold increase in total adherent particles over 
B (p=0.019), with a 7.5-fold increase in number of rolling particles and a ~10-fold increase in 
firmly arrested particles (p=0.019 and p=0.051 respectively). We observed no statistical 
difference between particles C and D for either rolling or firmly arrested particles, however the 
average number of adherent particles was less for particle D (p>0.05 for all interactions). As the 
average velocity of rolling particles decreased, more particles of that type firmly adhered to the 
inflamed vessel. Particle types C and D had the highest sLe
A 
surface densities and yielded the 
highest amount of firmly arrested and rolling particles. This suggests a sLe
A
 saturation point in 
vivo. 
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Figure 5.4 Particle adhesion to inflamed mesentery endothelium in vivo as a function of 
total sLe
A
 sites.  
(A) Representative fluorescence images of particle adhesion to inflamed mesentery, top images 
correspond particles A and B (left to right), bottom images correspond to particles C and D (left 
to right). Particle fluorescence shown in green, overlaid on the bright field image. (B) Quantified 
adherent density of firmly bound and rolling particles per representative # second imaging 
segment, n = 3 mice. Statistical analysis was performed using one-way ANOVA with Fisher’s 
LSD test between total adherent particles, where (*) indicates p<0.05, and two-way ANOVA 
with Fishers LSD test between groups ($) indicates p<0.05 between rolling groups, with all else 
non-significant (n.s.). (C) Velocity of rolling particles found at mesentery wall, n ≥ 50 particles 
from n = 3 mice. Statistical analysis was performed using one-way ANOVA with Fisher’s LSD 
test, with all interactions p<0.001 except where indicated. Error bars represent standard error, 
scale bar 50 µm. 
 
Use of dual-targeting ligands enhances particle binding in vivo 
We next explored how a mix of targeting ligands could further improve VTC adhesion in 
vivo. We compared a series of particles with varied sLe
A
 and anti-ICAM-1 ligand densities, as 
shown in Figure 5.5, to determine if particle adhesion from a dual-targeted particle is merely the 
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sum from the two individual ligands. The adhesion and rolling propensity of these particles were 
evaluated in the in vivo model of acute mesentery inflammation, as before.  
As shown in Figure 5.5A, particles A and E had 5,000 sites/µm
2
 of sLe
A
 or anti-ICAM-1, 
respectively, while particle F was the direct sum of the two ligands, for a total site density of 
10,000 sites/µm
2
 (Table 5.1). At a constant ligand density of 5,000 sites/µm
2
, varying the ligand 
type from sLe
A
 (A) to anti-ICAM-1 (E) resulted in a statistically insignificant increase in 
particles rolling or firmly arrested on the vessel wall (p=0.5). However, combining sites of sLe
A
 
and anti-ICAM-1 on the same particle (F) resulted in a significant increase of adherent particles 
at the wall (~7-fold increase over A, p=0.005, and ~3-fold increase over E, p=0.012). For particle 
F, the number of firmly arrested particles was a ~5-fold (p=0.034) and ~3-fold (p=0.049) 
increase over A and E, respectively. No differences were observed in the number of rolling 
particles between groups, however, there were differences in rolling velocities. Particle A had the 
fastest rolling velocity, while particle F had the slowest rolling velocity, corresponding to the 
most effective adhesion at the wall. A video of particle type F adhering in vivo can be found in 
Video 5.4. With particle types A, E, and F, a decrease in observed particle rolling velocity 
corresponded to more particle adhesion at the vessel wall in vivo.  
To probe the effect of total site density, we investigated particles B, G, and H, which each 
had twice the site densities of particles A, E, and F, respectively (Figure 5.5B). At these higher 
total site densities, varying the ligand from sLe
A
 (B) to anti-ICAM-1 (G) produced a minimal 
increase of particle presence at the wall, in either firmly arrested or rolling numbers, neither of 
which were significant from observation for particles A and E. Again, combining sites of sLe
A
 
and anti-ICAM-1 on the same particle (H) resulted in a significant increase of adherent particles 
at the wall (~2-fold increase over B, p=0.039, and ~3-fold increase over G, p=0.030). The 
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number of firmly arrested particles of type H resulted in a ~4.3-fold (p=0.007) and ~3-fold (p= 
0.011) increase over E and G, respectively. The relationship between rolling velocity and total 
particle adhesion was not linear in Figure 5.5B, owing to the fact that no particles were detected 
rolling for particle type G. Interestingly, increasing the total site density of dual-targeted particles 
from 10,000 (F) to 20,000 (H) sites/µm
2 
did not provide a significant increase in adhesion 
(p=0.5).  
 
 
Figure 5.5 Particle adhesion to inflamed mesentery endothelium in vivo as a function of 
combined sLe
A
 and anti-ICAM-1 sites. 
Comparison of dual-targeted particle designs with single ligand densities of (A) 5,000 
sites/µm
2
 and (B) 10,000 sites/µm
2
. Left: Diagram of particle conditions with varied amounts of 
sLe
A
 and anti-ICAM-1 ligand density. Middle: Quantified adherent density of firmly bound and 
rolling particles per representative imaging segment, n = 3 mice. Right: Velocity of rolling 
particles found at mesentery wall, n ≥ 50 particles from n = 3 mice. Statistical analysis of 
adherent density was performed using one-way ANOVA with Fisher's LSD test between total 
adherent particles: (*) indicates p < .05, (**) p < .01 and two-way ANOVA with Fishers LSD test 
between groups, (#) indicates p < .05, (##) p < .01 between firm groups, rolling groups n.s. 
Statistical analysis of rolling velocity was performed using one-way ANOVA with Fisher's LSD 
test, (***) indicates p < .001. Error bars represent standard error. 
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Particle adhesion of both dual-targeted particle types (F, H) indicate a more than additive 
effect of each individual-targeting ligand. We further compared the benefit of dual-targeting 
ligands on a single particle by keeping the total number of sites constant to eliminate any 
possible enhancement due to the change in total density (as studied in Figure 5.5). We developed 
a series of five particles with a constant total of 10,000 sites/µm
2
, given the lack of benefit when 
increasing to 20,000 sites/µm
2
 (F, H). We varied ratios of sLe
A
 and anti-ICAM-1 (Figure 5.6A 
and Table 5.1) and tested these in the model of acute mesentery inflammation. Figure 5.6B is a 
representative image of the highest dual-targeted fluorescent particle binding in vivo. 
Representative movies of particle types F, I, and J can be found in Videos 5.4-6, respectively. 
For all five particle types, the number density of both rolling and firmly arrested particles are 
quantified in Figure 5.6C. The ligand combination on particle I resulted in a significantly 
increased number of firmly arrested particles compared to all other combinations (p<0.001 for all 
comparisons), with at least a ~3-fold increase over all other ligand combinations. Similar 
numbers of rolling particles were observed with all five conditions; however as shown in Figure 
5.6D, slight decreases in rolling velocities were observed for particles I and F compared to B and 
J. 
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Figure 5.6 Particle adhesion to inflamed mesentery endothelium in vivo as a function of 
varied ratios of sLe
A
 and anti-ICAM-1 sites. 
(A) Diagram of five particle conditions with varied amounts of sLe
A
 and anti-ICAM-1 ligand 
density at a constant total site density of 10,000 sites/µm
2
. (B) Representative fluorescence 
image of particle I (7,500 sites/µm
2
 sLe
A
: 2,500 sites/µm
2
 anti-ICAM) adhesion to inflamed 
mesentery, scale bar 50 µm. (C) Quantified number of fixed or rolling particles on inflamed 
mesentery per representative imaging segment, n = 3 mice. Statistical analysis of adherent 
density was performed using one-way ANOVA with Fisher's LSD test between total adherent 
particles: (*) indicates p < .05 and two-way ANOVA with Fishers LSD test between groups 
(##) p < .01 between firm groups, rolling groups n.s. (D) Velocity of rolling particles found at 
mesentery wall, n ≥ 50 particles from n = 3 mice. Statistical analysis of rolling velocity was 
performed using one-way ANOVA with Fisher's LSD test, (*) indicates p < .05, n.d. indicates 
none detected and excluded from the analysis. Error bars represent standard error. 
 
Optimal dual ligand ratio on particle varies with EC surface expression 
 Given the dramatic increase in adhesion of particle I in vivo over all other ligand 
combinations in the particle series (Figure 5.6C), we investigated the dependence of particle 
adhesion on the corresponding surface expression of LAMs on the endothelium. As shown in in 
Figure 5.7A, TNF-α activation of HUVECs resulted in elevated levels of both ICAM-1and E-
selectin surface expression, albeit maximally at different times. Basal levels of ICAM-1were 
observed in all three conditions, while no basal E-selectin was observed. We further quantified 
these changes in expression level over time using flow cytometry (representative gating in Figure 
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5.8), with fold changes over unactivated cells shown in Figure 5.7B. Maximum E-selectin was 
observed between 4 and 8 hours, while maximum ICAM-1expression was observed at 24 hours. 
With maximum E-selectin expression, there was elevated ICAM-1expression, with the inverse 
true for E-selectin at time points of maximum ICAM-1expression. We explored particle adhesion 
of the panel of five particle types from Figure 5.6A in a PPFC with activated HUVECs at 4 hours 
(Figure 5.7C) and 24 hours (Figure 5.7D) to probe the importance of HUVEC surface expression 
on particle adhesion. At 4 hours, particle J resulted in superior particle adhesion, corresponding 
to ~1.5-fold more bound particles than all other particle types (p<0.05 between J and particles I, 
F, and G). At 24 hours, particle I resulted in maximal particle adhesion, with ~6-fold more bound 
particles over all other particle types (p<0.0001 between all particle types).  
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Figure 5.7 Particle adhesion to HUVEC monolayer as a function HUVEC surface 
expression. 
(A) Representative fluorescence images of HUVEC surface expression of E-selectin and ICAM-
1 at 4 hour and 24 hour post TNF-α activation. (B) HUVEC surface expression of E-selectin and 
ICAM-1 (left to right) over time determined via flow cytometry, representative gating in 
Supplemental Figure 2. Shown as fold increases of MFI over unactivated cells. Quantified 
particle adhesion following 5 minute PPFC assay after (C) 4 hour and (D) 24 hour TNF-α 
activation for particles at constant total site density but varied ligand ratios. Statistical analysis 
was performed using one-way ANOVA with Fisher’s Least Significant Difference (LSD) test (*) 
indicates p<0.05, (***) indicates p<0.001 between all groups, N=3 donors. Error bars represent 
standard error, scale bar 10 µm. 
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Figure 5.8 Representative gating of HUVEC surface expression. 
HUVEC cells were identified as single cells by forward (FSC) and side (SSC). Surface 
expression of CD45 (ICAM-1) and CD62E (E-selectin) were evaluated by MFI values in the 
FITC channel. Untreated cells shown in black, purple curve for 24 hour TNF-α activation, green 
curve for 4 hour TNF-α activation. 
 
 
 
Figure 5.9 Relative E-selectin and ICAM-1 expression of different endothelial cell types 
after 5 minutes of TNF-α activation. 
Surface expression of CD54 (ICAM-1) and CD62E (E-selectin) were evaluated via flow 
cytometry by comparing MFI values to standard curves. Surface expression was probed on 
primary mouse mesentery endothelial cells (MMEC), gated for CD106 positive cells only; 
cultured MMEC, gated by CD31 positive cells only; and (C) HUVEC.  
 
In Figure 5.9 we quantified the expression of three different EC types at the short, 5-
minute activation utilized in the intravital method. Of note, this time frame of activation is much 
shorter than the 4 and 24 hour activations utilized in vitro due to animal protocol limitations. Of 
key importance, the ICAM-1 expression dominates that of E-selectin for all 3 cell types tested. 
For the primary mouse mesentery endothelial cells (MMEC) this gap was the largest, with ~39 
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times more ICAM-1expressed than E-selectin. For both cultured cell types, MMEC and 
HUVEC, there was about ~10 times more ICAM-1expressed than E-selectin.  
 
5.5 Discussion 
Despite studies successfully employing dual-targeted particles for vascular delivery, gaps 
remain in understanding the effect of varied particle ligand densities and ratios. Here, we report a 
distinct interplay between endothelial receptor expression and particle ligand patterning that 
determines particle adhesion. To our knowledge, this is the first report of intravital microscopy 
investigations of dual-targeting VTCs in vivo, thus allowing evaluation of both particle rolling 
and firm adhesion. We find that increasing the number of sites of sLe
A
 on particles increases 
adhesion in vitro and in vivo. We also find that the dual-targeting particle designs result in 
adhesion superior to that of the linear addition of each individual ligand, indicating a 
multifaceted relationship in LR interactions. Overall, a 50%-50% split in ligand coverage, which 
is often studied, did not result in the best adhesion tendencies in vitro or in vivo under the 
conditions explored; rather, intermediate ligand regimes produced the best performance. 
Combined, these results indicate a balance required in LR kinetics, favoring particle designs with 
more ligands to the LAM receptor with the lower expression level. 
 Under flow conditions, many forces interact to prescribe the adhesion tendencies of 
VTCs. First, particles must marginate from bulk blood flow in order to interact with the 
vasculature of interest; only then does the targeting efficiency matter. Use of whole blood in our 
PPFC assay reproduces the conditions particles must overcome in vivo; particles must marginate 
to the surface, overcome collisions with blood cells, and be able to adhere in the presence of 
plasma proteins. Previous literature has demonstrated that 2-3 µm spherical particles are most 
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efficient at marginating from bulk human blood flow and concentrate in the cell free layer (CFL) 
near the wall, while 500 nm particles remain uniformly distributed.
10,46
 Smaller nano-sized VTCs 
are appealing for the ability to safely traverse capillaries and travel through intracellular and 
interstitial spaces in both mouse and human circulation. While 500 nm particles were used in our 
study, we anticipate the adhesion properties described here to follow similar trends when applied 
to a range particle sizes. Furthermore, polystyrene particles serve as a model VTC carrier; we 
anticipate ligand kinetics described here will be applicable to translatable particle formulations, 
such as poly(lactic-co-glycolic acid) (PLGA). As the particles used in this study were all the 
same size and material, margination dynamics, and thus interaction potential with the vascular 
wall, can be considered uniform across all trials; all effects observed are attributable to variations 
in the surface ligands. 
 In both our in vitro and in vivo results, increasing sLe
A
 densities produced increased 
adhesion. This increase in single ligand density also slowed the rolling velocity of particles, 
which has previously been demonstrated for sLe
A
 functionalized particles over a coated 
surface.
182
 As more LR pair interactions occur, the aggregate LR interaction forces overcome the 
wall shear force to establish firm adhesion. Avidin’s multivalency increases the likelihood of 
clustered targeting ligands, yet our surface densities never saturated the available avidin sites 
(Figure 5.2). General increases in ligand density increases the likelihood of a viable spatial 
orientation that favors LR interactions. However, there were diminishing returns to adding more 
sLe
A
 on the particle surface in vivo. Other researchers have discussed the steric hindrance limit 
of antibody ligands, such that too many antibodies on a particle surface block each other from 
successful interaction with endothelial receptors.
185,186
 Though sLe
A
 is a small carbohydrate 
unlikely to cause steric hindrance, our results indicate a similar trend, showing a clear limit of 
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diminishing returns of particle adhesion with increasing site density. Adding more sites of sLe
A 
did not significantly hinder particle adhesion over the range of densities tested, these data 
disprove the mantra that “the more, the better” for particle ligands.  
The dual-ligand VTC particles studied here target both the selectin and β2 integrin 
mediated paths of adhesion to inflamed endothelium. Most previous work in dual ligand particles 
explores targeting inflammatory surface molecules with mixes of antibodies.
85,86,88,213
 Our work 
aims to explore a dynamic mixing of a carbohydrate-selectin LR pair with an antibody-CAM LR 
pair, which have drastically different kinetics.
170,188
 We first explored the benefit of having two 
ligands on a single particle, to determine if particle adhesion from a dual-targeted particle is 
merely the sum from the two different ligands. To answer this, we evaluated the series of 
particles shown in Figure 5.5. In vivo, increasing the total ligand density of either sole ligand 
type from 5,000 sites/µm
2 
to 10,000 sites/µm
2
 resulted in non-significant increases in either 
firmly arrested (A-B, E-G) or rolling (A-B, E-G) particles. When we compare these individual 
ligand types to dual-targeted particles F and H, we can conclude that there is a more than 
additive effect when blending the two ligand types. For example, the total number of adhesive 
particles for dual-targeted particle F is more than the addition of particle A and E; this is also true 
when comparing particle H to the sum of adhesion from B and G. Particles F and H resulted in 
increased rolling and adhesive densities compared to both single-ligand particle types. As 
explained with the rolling velocities, this is likely due to the synergistic activity of the two 
ligands; sLe
A
 facilitates initial adhesion, but the rapid off rate guarantees some level of particle 
rolling,
188
 while anti-ICAM-1 facilitates firm adhesion after an initial interaction.
170
 When both 
ligands are present, the behaviors blend to allow initial rolling and eventual firm capture, similar 
to leukocytes. Various investigations into leukocyte adhesion in vivo have demonstrated the 
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importance of endothelial expression of both selectins and CAMs on cell rolling and 
adhesion.
214–217
 Providing a variety in the ligand presentation on particles corresponding to 
physiological ratios of endothelial receptors provides additive benefits for VTCs targeting a 
dynamic endothelium.  
As Figures 5.1 and 5.4 demonstrate, increasing the total site density can increase particle 
adhesion both in vitro and in vivo. To eliminate the suspicion that comparative observations in 
Figure 5.5 are purely due to the increased total site density, we compared particles of the same 
total ligand density (10,000 sites/µm
2
), as shown in Figures 5.6 & 5.7. Our results show that an 
optimal particle ligand ratio exists based on the surface expression of the endothelium, where the 
most effective particle type has a blend of both ligands and a ratio favoring the least expressed 
receptor. These results were initially counter-intuitive. At maximum expression of E-selectin (4 
hours, Figure 5.7C), we hypothesized that the sLe
A
/E-selectin interaction would control particle 
adhesion, with greater amounts of sLe
A
 resulting in greater adhesion to the dominant receptor. 
Instead, our results show the most adhesion for particle J, with 25% sLe
A
:75% anti-ICAM-1. A 
parallel trend was observed at maximum expression of ICAM-1(24 hours, Figure 5.7D), where 
the most adhesion was achieved with particle I, with 75% sLe
A
:25% anti-ICAM-1. Furthermore, 
the in vivo results shown in Figure 5.6C match this adhesion trend in Figure 5.7D. Initially, the 
receptor profile was not explicitly quantified in the mesentery, but it was known that rapid 
inflammation induced by topical TNF-α results in P-selectin expression within minutes of 
stimulation, in addition to omnipresent basal levels of ICAM.
140,141
 SLe
A
 binds non-specifically 
to all selectins, facilitating the adhesive sLe
A
-selectin LR pair interaction. Though initially 
uncharacterized, the total number of ICAM-1receptors is likely higher than selecting within our 
short, 5 minute activation.
218
 In order to confirm this hypothesis, Figure 5.9 shows that in all 3 
 125 
live cell types tested, ICAM-1expression far outweighs that of E-selectin, from 10 to 39 times, 
depending on the cell type. Indeed, basal levels of ICAM-1expression dominate at short, 5 
minute activation times, as hypothesized. Combined, these in vitro and in vivo data support the 
conclusion that the best ligand design of a particle is dependent on the surface expression of the 
ECs, showing better adhesion with more ligand for the lesser-expressed receptor. Fewer ligands 
to the more abundant receptor are required to maximize the benefit of that LR pair (rolling or 
firm adhesion, for sLe
A
 and ICAM, respectively). Additionally, more ligands lesser-expressed 
receptor increases the likelihood that the ligands find the LR pair for an adhesive interaction.  
Few studies have delved deeply into the direct effect of each LR pair on multi-targeted 
particles.
170,210,213
 Of those, there has been in vitro research corroborating that particle adhesion 
and rolling velocities depend on both the receptor density, as represented by coated plate 
coverage, and the particle ligand density.
170,219
 In these coated plate studies, particles with 
increasing amounts of anti-ICAM-1 provided improved firm binding regardless of dominant 
plate receptor composition.
208
 Particles functionalized in these studies had ligand site densities 
typically less than 1,000 sites/µm
2
.
170
 Our in vitro findings differ in three key ways: utilizing 
TNF-α activated ECs rather than receptor coated plates, 500 nm particles instead of 6 µm, and 
whole blood in place of buffer flow, all of which more closely capture the physiological 
dynamics at the surface of the vascular wall. Our in vitro findings are also supported by recent 
work with 2 µm particles coated with variable ratios of the antibody ligands anti-ICAM-1 and 
anti-E-selectin, where optimal binding was achieved by a particle of 70:30 anti-ICAM-1:anti-E-
selectin ligand composition following 4 hour HUVEC activation.
213
 Unfortunately, the total 
ligand site density was not evaluated in this study. Here, we attribute the success of this particle 
combination to the surface receptor expression, rather than the cited geometry of the flow 
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channel. This work on larger, 2 µm particles suggests that the same optimal presentation of 
ligands on the particle can be extended to particles of different sizes.  
Optimization of VTC particle designs that utilize dual targeting is expected to provide 
improved delivery to the vascular wall. As demonstrated via intravital microscopy, the dual-
targeted VTCs studied here rapidly and efficiently adhere to the inflamed endothelium. 
Importantly, these combinations of ligands provided minimal off target adhesion, resulting in 
high targeting specificity. Our work suggests that cargo-loaded VTCs with these ligand 
decorations can provide highly efficient binding to the vascular endothelium, especially when 
optimized towards the known receptor profiles of the target disease. In addition to this 
application towards drug delivery, there are possible diagnostic applications of this work. 
Particle adhesion with dual-targeted particles could help determine the surface expression of 
diseased endothelium, providing a diagnostic tool to determine stage of a disease with a simple 
IV injection of a blend of dual-targeted particles. 
 
5.6 Conclusions 
Overall, the work presented here represents a truly novel demonstration of particle 
binding to an inflamed mesentery via intravital microscopy. We have shown that the adhesive 
abilities of 500 nm particles, which are not preferentially excluded to the vascular wall from 
blood flow, can be significantly improved by targeting ligand design. While the total number of 
sites of a single ligand can drive particle adhesion to the endothelium, combining LR pairs from 
multiple LAM interactions provides a more powerful approach. These dual-targeted ligand 
designs should be optimized based on the surface endothelium, with ligand coating densities 
favoring the less-predominant adhesive receptor, as driven by the LR pair kinetics. The 
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knowledge presented here about the importance of the LR pair matching will help in the 
intelligent particle ligand design for future applications in all diseases benefitting from VTCs, 
including atherosclerosis, cancer, inflammation, and many more.  
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: Impact of Targeting Ligands on Circulation Time and Chapter 6
Accumulation at Inflammatory Sites 
 
6.1 Publication Information 
 This data is not published. This chapter has been merged with chapter 7 into a 
manuscript, which will be submitted in the coming weeks. It will be entitled: “A Paradigm Shift 
in Vascular-Targeted Drug Delivery: Hydrogel Microparticles as Carriers for Nanoparticles to 
the Vascular Wall.” The author list will be as follows: Fish, Margaret B., Catherine A. Fromen, 
Margaret Braunreuther, William J. Kelley, Alison L. Banka, and Omolola Eniola-Adefeso. 
 
6.2 Abstract 
 Vascular-targeted drug delivery aims to increase the amount of drug that arrives at the 
disease site, while decreasing side effects that arise due to systemic exposure. In order to achieve 
this intended objective, the particle carriers with targeting ligands must evade immune uptake 
and circulate in the vasculature long enough to establish firm adhesion in the diseased area. After 
adhering, the particles must stay bound sufficiently long enough to release their cargo and 
achieve a therapeutic effect. We have previously shown that targeted hydrogel particles are able 
to bind to inflamed mesentery in vivo. In this work, we directly compare the pharmacokinetic 
(PK) behavior of hydrogel particles both with and without targeting ligand. We then determined 
the capacity of targeted hydrogels to stay adhered over time in vivo with two different models of 
inflammation. We show that for polymerized poly(ethylene glycol) (PEG)-based particles, 
deformable hydrogels  maintain targeted adhesion over an hour in the mesentery, while rigid 
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hydrogel adhesion drops to less than 50% in this time frame. Over longer time windows, 
deformable microparticles are able to achieve a targeting window of up to 8 hours, significantly 
longer than nanoparticles. All PEG-based particles have similar plasma circulation times, 
regardless of the presence of a targeting ligand. This work directly investigates how adding 
targeting ligand affects particle PK parameters and the direct translation into targeted particle 
adhesion and accumulation. Overall, this work demonstrates the importance of particle modulus 
and size as design considerations for controlling the targeting timeline of different hydrogel 
systems. These results emphasize the importance of choosing the particle size and modulus for 
maximizing the targeting time horizons, and has the potential to improve treatments for a variety 
of diseases, including cardiovascular disease, cancer, diabetes, and more. 
 
6.3 Background 
Free pharmaceutical agents, whether administered orally or intravenously, distribute 
throughout the human body in a pharmacokinetically problematic manner; minimal amounts of 
drug reach the intended tissues and cells. Depending on the drug properties, there tends to be a 
small therapeutic window, also known as therapeutic index, between the dose-limiting toxicity 
and the minimal therapeutically effective concentration.
220,221
 This issue initially inspired the 
field of particulate drug carriers, with hopes to skew the pharmacokinetic parameters of drug 
delivery.
222–224
 As an additional benefit, particles have the ability to protect free drug from 
degradation in the blood stream while shifting the drug biodistribution and interaction with the 
immune system versus free drug dosing. Over decades many research groups have investigated 
particles of widely varying physical properties with a whole host of proposed disease 
applications, resulting in surprisingly little clinical success.
225
 Particles include but are not 
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limited to liposomes, micelles, hydrogels, polymeric particles, dendrimers, and polymersomes.
226
 
Unfortunately, even though these carriers are proposed as magic bullets, it has been shown that 
in cancer specifically, less than 1% of the particles arrive at the intended site of accumulation, 
the tumor.
166,227,228
 Intravenously administered particles must navigate complex blood flow to 
arrive at the site of disease. Particle size and modulus have been firmly established as important 
particle properties that determine the transport, circulation time, immune interactions, and 
biodistribution of these carriers. Briefly, more deformable particles evade immune uptake and 
circulate longer than rigid counterparts. Additionally, microparticles (MPs) have been shown to 
be more efficient at binding from whole blood flow, but are more readily phagocytosed than 
nanoparticles (NPs).
29,38,39,46,106,229
 Another crucial property of particulate drug delivery systems 
is the presence or absence of surface-bound ligands that target particles, thereby changing the 
whole particle biodistribution and potential accumulation at the targeted site.  
 Vascular-targeted drug carriers (VTCs) are particulate carriers that have targeting ligands 
on the surface that specifically bind to receptors on endothelial cells, which line the luminal side 
of all blood vessels. By strengthening the affinity of particles preferentially to inflamed cells, the 
field has aimed to increase the local therapeutic exposure while decreasing systemic exposure 
and toxicity. However, it is debated in the literature whether these targeting ligands can provide a 
benefit versus bare particle surfaces; the ligands are often proteins, which significantly decrease 
the circulation time of certain types of particles.
32,33,94
 Some use this fact alone as rationale to 
abandon the targeted particle strategy- these researchers tend to focus on extending the 
circulation time of particles, even if they lack targeting ligands to direct them to the specific 
disease site. Those in the targeting camp have thought that if particles rapidly bind, the 
circulation time should not be considered the only defining particle characteristic. Yet, many 
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targeting studies look at final time points of less than an hour, which is not long enough to 
address whether targeting produces the sustained adhesion required to outperform the dosing of 
free drug and non-targeted particles. These competing paradigms have yet to be tested 
experimentally in an extended clinical window, meaning we do not know the true potential that 
VTCs have to deliver sustained release in comparison to untargeted particle and free drug 
administration. 
 To address this deliberation in the literature, we explore the behavior of both targeted and 
untargeted particles for their ability to specifically adhere to cells or tissues, using a range of 
inflammatory models. We explore how particles of varying moduli and size can adhere to a 
targeted tissue and how that targeting evolves over time. We approach the question of whether it 
is worth it to target polymeric PEG-based particles by looking at the circulation time, adhesion in 
intravital microscopy (IVM) for an hour, and targeting to the lung in an acute lung injury (ALI) 
model for 24 hours. Our data demonstrate that for polymerized PEG particles, the circulation 
times are very short, independent of particle modulus, size, and targeting state. However, we 
found that larger particles bind more in general, as shown by comparing VTCs of 2 µm and 500 
nm diameters. Furthermore, rigid VTCs begin to detach within an hour, whereas the deformable 
counterparts stay bound. Finally, we found that targeting to the lung in an ALI model is 
dependent on the PEG particle size and modulus; we define clear targeting windows, when 
targeted particles outperform non-targeted counterparts, of up to 8 hours depending on the 
combination of VTC modulus and size. This work is the first to approach the question of whether 
particulate drug carriers, after having minimal success clinically for decades, should be 
developed as targeted entities, based on how long they sustain targeting after being cleared from 
circulation. Overall, our results provide an unprecedented perspective on the length of time that 
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targeted PEG particles, based on size and modulus, are able to maintain adhesion for targeted 
drug delivery. 
 
6.4 Results  
Targeting time IVM: larger, softer particles are best at maintaining adhesion for 1 hour 
We first evaluated the ability for targeted particles to adhere at an inflammation site and 
stay bound for up to 1 hour, using real-time imaging of an inflammation model: mesentery vein 
IVM. Four PEG-based, spherical particle types were utilized throughout this work, including 2 
different sizes and 2 different moduli. 2 µm diameter particles of 15% PEG and 100% PEG 
composition were designated as MPS and MPH, respectively. 500 nm diameter particles of 15% 
PEG and 50% PEG composition were designated as NPS and NPH, respectively, designating 
both the size and either “soft” or “hard” modulus. The “T” at the end designate the targeted 
status of the particle type. Anti-P-selectin antibody was used as the targeting ligand to bind P-
selectin induced by topical application of TNF-α on the mesentery vessels. All particle types 
were conjugated with the same targeting ligand density of 30,000 anti-P-selectin/µm
2
 so that 
trends were independent of ligand effects. These site densities were confirmed via flow 
cytometry and have been previously shown to produce firm particle adhesion in this model.
106
 
We dosed all four particle types by equivalent mass, 30 mg particles/kg mouse (~0.6 mg 
of particles), and captured the adhesion in five distinct locations of the mesentery veins every 
five minutes for an hour. Figure 6.1A and 6.1B shows representative images of the adhesion to 
an inflamed mesenteric vein 5, 30, and 60 minutes after particle injection for 2 µm and 500 nm 
particles, respectively. Figure 6.1C shows the adhesion of MP of both moduli over 60 minutes, 
displayed as both the number per vessel area and that scaled to the mass of particle per vessel 
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area. Figure 6.1D shows the same but for NP of both moduli, with the y-axis zoomed in to 
highlight the trend. Two very clear trends emerged, one by size and one by modulus. First, 2 µm 
diameter MPs bound significantly better than 500 nm diameter NPs for all moduli tested, as 
highlighted by the different y-axes, varying by a full order of magnitude. In fact, the adhesion 
over the entire hour was significantly better for both MPs than for both NPs tested; NPs never 
matched or surpassed MPs in targeted adhesion efficiency in this time frame. Interestingly, both 
hard particle sizes began to detach within 20 minutes of the particle injection, dropping to about 
half of the maximal adhesion achieved by the final hour time point (38.6% of max for MPHT 
and 49.3% of max for NPHT). All the while, soft particles of both sizes were able to at least 
maintain the adhesion; the soft MPs maintained adhesion while the soft NPs adhesion increased 
through the hour time frame. Therefore, the superiority of soft particles versus the hard 
counterparts increased over the hour time window tested. Despite the uniform ligand density 
employed on the particle surfaces, there are key differences in the ability of particles to sustain 
targeted adhesion in the acute mesentery vein inflammation model based on both particle size 
and modulus.  
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Figure 6.1 IVM to evaluate MP and NP adhesion over time. 
(A) Representative images of MPST and MPHT at 5, 30, and 60 minutes post particle injection. 
(B) Representative images of NPST and NPHT at 5, 30, and 60 minutes post particle injection. 
The adhesion of particles on an inflamed mesentery vein of both (C) 2 µm and 500 nm diameters 
over a full hour. (D) Is the same data as (C), but for just the 500 nm particle data zoomed in on 
the y-axis. Error bars represent standard error for N=3.    
 
Lung accumulation of VTCs in ALI mice 
To extend the time window of targeting experiments, we shifted to a different 
inflammation model, known as the acute lung injury (ALI) model. For this, lipopolysaccharide 
(LPS) was instilled into the mouse airways to induce a local inflammation event, and one hour 
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later an equivalent mass of particles (30 mg particles/kg mouse, ~0.6 mg of particles), were 
injected via the tail vein. We then quantified accumulation in the targeted organ of interest, the 
lung. The same particles were as used for IVM, excluding MPH for its known short circulation 
times in the literature, poor performance versus MPS in IVM, and increased risk of producing 
pulmonary embolism.
38,150
 The “T” or “U” at the end of each particle type designates the 
targeting status of the particle, either targeted or untargeted; anti-intercellular adhesion molecule-
1 (anti-ICAM-1) was employed as the targeting ligand for these experiments. ICAM-1 is highly 
upregulated by the lung endothelium through 48 hours post instillation with LPS, producing a 
more sustained inflammatory response compared to the IVM method,
75,173,175,230
 whereas P-
selectin was the VTC target of choice in the IVM because of the rapid expression of P-selectin 
within minutes of exposure to agonists.
140,141
 All particle types were loaded with near-infrared 
dye to quantify the lung accumulation over time. 
Of note, the average vessel size in the lung is much smaller than that evaluated via 
mesentery IVM method in Figure 6.1. Additionally, higher shear is expected in the lung 
capillaries versus the mesentery due to physiological differences between capillaries and veins, 
including vessel diameter and blood flow rate.
117
 The particle accumulation in the lung is 
reported as µg particles/mg lung tissue for Figure 6.2A-C. Figure 6.2A shows a direct 
comparison between MPSU and MPST to elucidate any benefits of targeting the exact same 
particle type. Targeting the MPS particle induced statistically increased accumulation in the lung 
for both the 2 and 4 hour time points, which was resolved by the 8 hours after the particle 
injection. Thus, the targeting window, which we define here as the time when targeted particles 
accumulate significantly more in the lung versus the untargeted counterparts, was established 
between 4-8 hours. Figure 6.2B shows the same comparison for NPS between targeted and 
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untargeted particles. There was a statistically increased amount of NPST as compared to NPSU 
for 2 hours after the initial particle injection, which resolved by the 4 hour time point, 
establishing a targeting window of 2-4 hours. We then investigated NPHT and NPHU, as shown 
in Figure 6.2C; in line with the results from Figure 6.1D, the hard NPs did not deliver any 
targeting benefit at the initial 2 hour time point, designating no targeting window in this model. 
Figure 6.2D-F shows this same data and particle comparisons but represented at % of total 
fluorescence recovered rather than a particle mass per lung tissue mass. With this representation 
of the data, the benefit of targeting looks smaller in magnitude overall, but is still maintained 
statistically through 4 hours in Figure 6.2D. 
Area under the curve (AUC) is a PK parameter typically used in the context of blood 
circulation to compare the exposure of particles to the body; in Figure 6.2G we applied this 
concept to particle mass accumulation in the lung, representing the particle exposure of each type 
to the targeted organ. The AUC of MPST is significantly higher than that of MPSU, designating 
an overall higher exposure of particles in the lung over the time window tested. The same is true 
of NPST versus NPSU, whereas for NPH there is no increased exposure to the lung by adding 
targeting functionality. These data establish the difference between targeted and untargeted 
particles, as a way to measure targeting specificity over time. These results are consistent with 
the findings of Figure 6.1, where deformable VTC adhesion persisted over time and more rigid 
VTC adhesion decreased to about 50% in one hour. Yet, we are interested in how the overall 
biodistribution and circulation of these particles in blood compares to targeted adhesion in both 
inflammation models over time. 
 
VTCs in ALI mice: circulation time, biodistribution and PK parameters 
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The experimental setup of Figure 6.2 was repeated, with the same LPS instillation, dosing 
schedule, and same particle types, but evaluated in the context of blood circulation and 
biodistribution over 24 hours. Shown in Figure 6.3A-C, the data was collected as the actual 
concentration in blood by particle mass (mg/mL), which was also represented as the % of the 
total particle dose in the blood, shown in Figure 6.3D-F. From Figure 6.3, we show that the 
circulation of all particles is short-lived and qualitatively similar across particle types. By the 30 
minute time point, less than 1% of all particle types were still circulating in the blood (Figure 
6.3D-F), and MPST and MPSU dropped the fastest, to less than 0.1% in 30 minutes. 
The pharmacokinetic parameters of AUC and initial concentration (C0), obtained from 
fitting bi-exponential curves using PKSolver to the particle concentrations in blood over time, 
are shown in Table 6.1. Data was evaluated with both one- and two-compartment models, with 
comparison of the Akaike information criterion (AIC) determining the two-compartment model 
as the best fit for all particle types. The AUC is a representation of the body exposure to the 
injected VTCs, the higher the AUC, the more opportunity for the particles to interact with the 
targeted vasculature. AUCs ranged from 0.011 to 0.141 [(mg*hour)/mL], for MPST and NPSU, 
respectively, with the AUCs of untargeted particles are all marginally larger than their targeted 
counterparts. The C0 calculated by the model was smaller than the actual injection of 0.6 mg for 
all particle types, as shown in Figure 6.4, with a significant disparity between the targeted and 
untargeted of each particle type. The initial concentrations of the targeted particles were 
calculated as lower by the bi-exponential model, given the blood concentration inputs in Figure 
6.3A-C, due to the targeted particle’s more rapid clearance in the first 5 minutes prior to the first 
blood draw. Because of this, the absolute value of the concentrations of the targeted particles 
were lower at the initial time point of the circulation plots in Figure 6.3. The model uses C0 as the 
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initial concentration, even though a uniform, and higher concentration of all particle types were 
dosed.
231,232
  
 
After determining pharmacokinetic parameters for PEG-based spherical particles, we 
analyzed overall biodistribution of all particle types at all time points (2, 4, 8, and 24 hours) in 
the organs of interest as shown in Figure 6.5. The head to head comparisons of MPST and 
MPSU, NPST and NPSU, NPHT and NPHU are shown consecutively in Figure 6.5A, 6.5B, and 
6.5C in units of µg particle per mg of organ tissue. This measure gives a good idea of a 
hypothetical drug density delivered in each organ. Over time, all particle types increasingly 
accumulate in organs of the reticuloendothelial system, namely the liver and spleen, after they 
have been cleared out of circulation. Any accumulation in the lung in the early time points later 
shifts to that in the liver and spleen. There is little accumulation in the kidney and heart for all 
particle types and all time points; by 24 hours there is little accumulation in either. For all time 
points and all organs, except MPST at 2 hours, most of the particles accumulate in the liver than 
any other organ due to its sheer size. The relative amount in the spleen is significantly less than 
how the data was presented in Figure 6.5 because of the spleen’s small size. Finally, as expected 
based on the circulation curves and PK parameters, there were few particles remaining in the 
blood across all time points tested here.  
Figure 6.6 is focused on the accumulation of particles into the liver over time in the ALI 
model, with all time points included in A-C for all particle types, in units of µg particles per mg 
of liver. As expected, over time the accumulation of all particle types increases as they are 
cleared out of the blood stream and from the lungs to the liver. There is a clear trade off in 
accumulation in the liver and lung; as particles leave the lung they traffic to the liver as a 
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clearance mechanism. The micron-sized particles accumulated in the liver the most by the final 
time point of 24 hours. Figure 6.7 is a head to head comparison of two different methods of the 
ALI model 2 hours post particle injection, either with lung perfusion or without before 
evaluating the amount of particle fluorescence in the lungs. All comparisons between the two 
methods for one particle type are non-significant, indicating the similarity between the results 
obtained with the different methods. Figure 6.7 shows the raw differences in adhesion between 
the two methods; again, all were non-significant, but the MPSU were most affected by the 
perfusion of the lungs, designating some amount of non-specific entrapment in the lung that is 
eliminated by perfusion. 
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Figure 6.2 Accumulation of PEG-based particles in the lungs of ALI mice. 
2 hours, 4 hours, 8 hours, and 24 hours post particle injection. Left to right: (A) MPS (B) NPS 
(C) NPH. (D-F) Is the same particle sequence, but the data is represented at the % of total dose 
recovered in the lungs. (G) The Area Under the Curve (AUC) represents the exposure of the 
organ to each particle type by mass, in units of (µg particles/mg lung tissue)*hour. Bars represent 
the standard error for N=4 for all plots. Statistical analysis was performed using one-way 
ANOVA with Fisher’s Least Significant Difference (LSD) test (*) indicates p<0.05 with targeted 
lung accumulation over non-targeted lung accumulation. 
 
 
Figure 6.3 Blood circulation profile of PEG-based particles over time in ALI mice.  
The concentration of particles remaining in the blood stream of C57BL/6 mice after orotracheal 
instillation with LPS. Plots are shown for (A) MPS, (B) NPS, and (C) NPH both targeted (T) and 
untargeted (U). (D-F) Is the same particle sequence, but the data is represented at the % of total 
dose recovered in the blood. Blood samples were collected at 5, 30, 60 and 180 minutes after the 
particle injection. Bars represent the standard error from N=4. Statistical analysis was performed 
using one-way ANOVA with Fisher’s Least Significant Difference (LSD) test (*) indicates a 
higher untargeted concentration in the blood versus targeted, with p<0.05. 
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Table 6.1 Pharmacokinetic Parameters from Two-Compartment Model Fit of Blood 
Concentration Data in ALI Mice 
 
 
 
 
 
Figure 6.4 The fit parameter C0, as determined by PKSolver, in the ALI model.  
The calculated initial concentration of particles in the blood, based on the biexponential fit of the 
two-compartment model. N=4 for all circulation plots used to fit this model. Statistical analysis 
was performed using one-way ANOVA with Fisher’s Least Significant Difference (LSD) test (*) 
indicates p<0.05 versus targeted of the same particle group. 
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Figure 6.5 Biodistribution of PEG-based particles in ALI mice by mass. 
Each row represents a different time point after particle injection: 2 hours, 4 hours, 8 hours, and 
24 hours, respectively. The columns represent the different particle types, from left to right: (A) 
MPS (B) NPS (C) NPH. Bars represent the standard error for N=4. Statistical analysis was 
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performed using one-way ANOVA with Fisher’s Least Significant Difference (LSD) test (*) 
indicates p<0.05 versus targeted particle of the same type. 
 
 
 
 
Figure 6.6 Accumulation of PEG-based particles in the livers of ALI mice over time. 
2hours, 4hours, 8hours, and 24 hours post particle injection. Left to right: (A) MPS (B) NPS (C) 
NPH. Bars represent the standard error for N=4. 
 
 
 
Figure 6.7 Impact of lung perfusion on particle lung accumulation in ALI model. 
(A) Head to head comparison of particle accumulation in the lung obtained when the lungs are 
perfused or not perfused, 2 hours post injection. Within each particle type, there is no statistical 
difference between perfused and non-perfused; statistical analysis of lung accumulation was 
performed using one-way ANOVA with Fisher’s LSD test between perfusion conditions. (B) 
Difference in µg particles/mg lung tissue from non-perfused to perfused. The particle types 
MPST, MPSU, NPST, and NPSU are included. N=3 for all and error bars represent the standard 
error.  
 
6.5 Discussion 
To date, no study has extensively evaluated the time horizon of targeting functionality for 
biocompatible PEG-based particles, especially for VTCs in the MP size range. For vascular 
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targeting to deliver a clear benefit over free drug administration, targeted particles must be able 
to bind to inflamed vasculature and stay bound longer than untargeted particles, to release the 
loaded cargo.  This work confirms the ubiquitous superiority of MPs over NPs for targeting 
efficiency, as found in our previous in vitro and in vivo work.
122,138,229
 Additionally, we found 
that in two different models of inflammation, including blood vessels of varying diameter, soft 
VTCs were better than rigid counterparts at maintaining targeted adhesion, and soft MPs 
delivered the largest targeting window of all, up to 8 hours. Others’ have utilized a large range of 
hydrogel moduli for drug delivery applications,
38,105,144–149
 but have not established a true 
targeting window to inform VTC and dosing design. There is a critical need to determine and 
understand the targeting windows of particles developed with the intention to translate into the 
clinic; this information is vital in the engineering of particles, their loading, release, and dosing 
schemes.   
In this work, we utilized a range of particle size and modulus, including 2 µm and 500 
nm diameters and 15%, 50%, or 100% PEG compositions. We wanted to know how both 
targeted particles interact with inflamed endothelium in real time. In our IVM results in Figure 
6.1, the MPs adhere better than all NPs because of the superior ability of MPs to marginate to 
vessel wall versus NPs in hemodynamic conditions.
10,46,106
 A range of mechanisms could explain 
the difference in adhesion behavior after particles of different moduli are bound to the vessel 
wall. Of note, the differences in circulation time between rigid and soft PEG particles is not 
enough to explain these differences; all particle types are cleared in a statistically similar fashion 
and the phenomena is removal of rigid particles after initially bound. Leukocytes have the 
potential to disrupt particles in two ways: by physically colliding with them on the vascular wall 
and dislodging them, or by actively phagocytosing them off the vessel wall. Alternatively, the 
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surface receptors of endothelial cells are extremely dynamic and the constant recycling and 
resolution of expression could affect particle binding over time.
75,233,234
 This would decrease the 
number of ligand-receptor pairs engaged, decreasing the adhesive force holding the particle on 
the wall, allowing the hemodynamic force of flow to shear the particles off. In looking at Figure 
6.1, the soft particles maintain their binding, therefore we do not expect that the recycling of 
surface receptors is the dominant mechanism driving this behavior. Yet, these less rigid particles 
are able to deform once bound, allowing more ligand receptor interactions per particles and 
lessening the stress on each bond due to particle deformation.
181,235
 As for the contribution of 
leukocytes, it is likely a combination of both physical collisions and phagocytosis; indeed, 
leukocytes are known to be a substantial player in particle clearance,
236,237
 and rigid particles are 
more readily removed by phagocytic cells.
39,106
 The trend of particle targeting over an hour was 
clear by both size and modulus in IVM, but to evaluate VTC behavior for clinically-relevant, 
longer time windows we moved to a different experimental method. Overall, these results 
indicate that softer particles have maximal potential to maintain any adhesion achieved, with 
MPs significantly better than NPs. 
The lung ALI model was introduced to investigate longer time points to overcome the 
protocol-imposed time constraints of IVM. There are significant differences between the IVM 
and ALI models; most importantly are the inflammatory prompt of TNF- versus LPS and the 
difference in targeted vessel size. In the mesentery we selected veins of about 150-250 µm in 
diameter, whereas in the lung the majority of the vasculature is capillaries with diameters less 
than 20 µm.
238
 This difference in vessel size dictates different forces experienced by particles in 
blood flow and bound to the vessel wall. Figure 6.2 highlights the key results from this ALI 
study, the accumulation of particles in the inflamed lung over a 24-hour time frame. MPST are 
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again better than all NP conditions, like the IVM model in Figure 6.1, especially in the 2 to 8-
hour time window; for these times, MPST are the best performers.  
We define the targeting window in the ALI study as the time frame where the targeted 
particles result in significantly more lung accumulation than the untargeted counterparts. In line 
with the mesentery IVM, the hard particles, down-selected to NPHT and NPHU for this 
inflammation model from a combination of safety and performance perspectives, showed no 
ability to target in the 2 to 24-hour time window; this aligns with the particles binding being 
reduced to only 50% of the max binding within 1 hour after injection in the IVM method. MPH 
resulted in significantly less adhesion than MPS previously, so was not included here for its poor 
performance and increased risk of causing lung emboli and non-specific accumulation in 
capillaries, which would confound results. Together, these data suggest that rigid PEG-based 
hydrogel particles, though orders of magnitude less rigid than often-used biocompatible materials 
such as poly(lactic-co-glycolic acid) or polycaprolactone,
239
 are still not soft enough to deliver 
targeting over an extended time window needed to make intravenous particle drug delivery 
clinically viable. We show a difference for the soft particles of the same modulus but two 
different sizes, 2 µm and 500 nm. The NPST particles deliver a targeting window between 2 and 
4 hours, whereas MPST deliver an extended targeting window between 4 and 8 hours. Again, the 
same possible mechanisms can be driving the reduction in targeted particle accumulation in the 
lung as were in the mesentery. We know that in the ALI model the targeted receptor, ICAM-1, 
persists and increases in EC density through 24 hours, longer than the time frame of our 
experiments.
125,240
 Therefore, the decrease in targeting over time must be due to the physical 
collision and phagocytic action of leukocytes in the inflamed lung vasculature. Additionally, 
neutrophils, a particular subset of leukocytes, are known to be hyperactive in ALI models with 
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regards to accumulation and action such as phagocytosis in the lung in response to 
inflammation.
125
 Therefore, we hypothesize that the behavior seen in lung accumulation and 
clearance is heavily correlated to the behavior of neutrophils occupying and functioning in the 
same vascular and tissue space as our PEG-based particles. In the context of phagocytosis, 
researchers have shown that deformable particles are phagocytosed significantly slower than 
rigid particles of the same composition,
101,104,150,241
 which bolsters the argument that leukocyte 
phagocytosis is the driving mechanism that creates the key differences between soft and rigid 
particles. 
For all particle types tested through the longer 24 hour experimental time window, we 
found extremely short circulation times. The known benefit of “PEGylation” is manifested when 
it is grafted onto the surface, either in mushroom or brush conformation, to resist protein 
opsonization.
32,33
 Of note, our particles are composed of polymerized PEG, which has been 
previously shown to have short circulation times in vivo, even at relatively low moduli and 
corresponding crosslinking densities.
38
 Additionally, our targeted particles had either anti-P-
selectin or anti-ICAM-1 on the surface; proteins on the surface of particles are known to increase 
immune recognition and therefore decrease circulation times.
32,33,91
 Since the circulation time of 
our untargeted particles is short to begin with in Figure 6.3, the addition of targeting ligands 
keeps these values low, but does not significantly change the amount circulating. It is key to 
remember that particles may exit the blood stream with two different destinations: the targeted 
lung, which is a positive event, or the RES, which is still considered negative clearance.  The 
removal of MPs from the blood stream and into the lungs likely dropped the MP concentrations 
in the blood, as seen in Figure 6.3.  
 148 
The predicted initial concentrations are significantly lower for those targeted particles, as 
shown in Table 6.1 and plotted in Figure 6.4. This C0 can be thought of a representation of what 
happens before the first experimental blood draw at 5 minutes; the lower the C0 value, the more 
that is cleared in the short 5 minute window. Namely, more of the targeted particles are cleared 
faster, as corroborated by the smaller C0 values. This could be due to a phenomenon known as 
target-mediated drug disposition, where the pharmacokinetics of an entity with high affinity is 
affected by binding to the targeted site.
242
 Even with these very short circulation times, the 
recirculation time of a whole mouse is only 6 seconds, meaning the particles have multiple 
passes through the targeted vasculature before clearance.
243
 Our short circulation times align 
with values of crosslinked PEG in the literature, where Merkel noted that a 10% crosslinked 
hydrogel particles had a half-life of 0.038 hours in vivo.
38
 It is important to note that large 
differences in circulation times arise between particles that are either targeted or surface grafted 
with PEG, rather than simply bare.
33,91
 Overall, our intravenously injected particles circulate for 
short times whether there or not there is targeting ligand on the surface. Thus, any targeted 
accumulation found after a few minutes is overcoming the rapid clearance mechanisms found in 
vivo.  
 Our work provides an interesting perspective on the ability of PEG-based particles of 
different sizes and moduli to target inflamed tissue and the resulting quantitative benefit of this 
targeting over time. Importantly, the circulation times of particles is not the most significant 
indication of particle accumulation, rather, the targeting and retention in the organ of interest is 
more indicative of VTC system success. Again, even though our particles were cleared within 
the order of 10 minutes, they were able to stay bound in the targeted organ for up to 8 hours. This 
conclusion will inform the intelligent engineering of VTCs for intravenously delivery and will 
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allow further development of particle systems that have short circulation times. Researchers have 
shown that the targeted adhesion and resulting biodistribution heavily depends on the targeting 
ligand density and mix of multifunctional targeting ligands.
33,46,122,244
 For each engineered 
system, our work builds a framework of expected targeting window, but this and the 
biodistribution will undoubtedly change with changes in ligand number, ligand type, disease, and 
endothelium expression. Thus, future work in the field should investigate each VTC system 
carefully in the best disease models possible. We hypothesize that multifunctional targeting 
would simultaneously increase the initial targeting specificity achieved and the immune 
recognition, thereby slightly decreasing the circulation time but allowing for the possibility of 
more targeted accumulation in the first 5 minutes that has the potential to stay for hours. 
Lessening the amount of targeting ligand would decrease the overall adhesion in the areas of 
inflammation, thereby skewing the targeted biodistributions closer to those of the untargeted 
particles.  
 This study provides clear guidelines for and conclusions about the resulting timeline of 
particle adhesion once adhered to the vessel wall. In general, using particles instead of free 
intravenous drug alters this pharmacokinetic profile in the blood serum. In the context of 
maintaining a drug dose in the therapeutic window in the body, between the minimally effective 
dose and toxicity threshold, our work gives detailed biodistribution and circulation data that will 
help inform and predict systemic and organ-specific toxicity. Of course, all of this is very drug 
molecule and release mechanism dependent. Particles can be designed to degrade in the time 
window of targeting via mechanisms such as ester hydrolysis,
245,246
 or enzymatic release,
247–249
 
thereby maximizing the amount of drug that reaches the target cell before the majority is 
trafficked to the liver and spleen. Indeed, the information presented here will allow much tighter 
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control of future VTC systems and better pharmacokinetic understanding. We highly encourage 
this sort of work be expanded for many other types of VTCs in development today. 
 
6.6 Conclusions 
The work presented here is the first demonstration that the ability of particles to maintain 
targeting to inflamed vasculature is heavily dependent on both the particle size and bulk 
modulus. For VTCs to deliver the theorized benefit of extended release profiles over free drug, 
the particles must stay bound near the disease site. This work represents a comprehensive study 
of PEG-based particles, with and without targeting ligand, to understand the true targeting 
benefit delivered in vivo. First, our findings confirm that micron-sized particles of all moduli are 
significantly better than all of our nano-sized particles tested at maintaining adhesion once 
bound, which ultimately controls the amount of cargo that is delivered to the vessel wall. The 
circulation time of all polymerized PEG particles employed is low, and yet, in both models, a 
significant number of particles remain bound after most the particle dose is cleared, indicating 
that circulation time is not the deterministic parameter. These modular hydrogel particles can 
target the vasculature in a variety of diseases, and have the potential to be utilized for a range of 
treatments in widespread diseases such as cardiovascular disease, cancer, diabetes, and more. 
This work emphasizes the importance of choosing the particle size and modulus for maximizing 
targeting over long time horizons and encourages the continued examinations of VTC systems in 
this manner. 
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: A Paradigm Shift in Targeted Drug Delivery: Hydrogel Chapter 7
Microparticles as Carriers for Nanoparticles to the Vascular Wall 
 
7.1 Publication Information 
 This data is not published. This work has been merged with chapter 6 into a manuscript, 
which will be submitted in the coming weeks. It will be entitled: “A Paradigm Shift in Vascular-
Targeted Drug Delivery: Hydrogel Microparticles as Carriers for Nanoparticles to the Vascular 
Wall.” The author list will be as follows: Fish, Margaret B., Catherine A. Fromen, Margaret 
Braunreuther, William J. Kelley, Alison L. Banka, and Omolola Eniola-Adefeso. 
 
7.2 Abstract  
 Vascular-targeted drug carriers (VTCs) must localize and bind to a targeted, diseased 
endothelium to achieve clinical utility. There is a great need to improve the proportion of 
injected particle dose that ultimately reaches the targeted tissue. Frequently used nanoparticles 
(NPs) are limited in their ability to marginate to the vessel wall from blood flow versus 
microparticles (MPs). However, NP drug carriers remain attractive as they can better take 
advantage of the enhanced permeation and retention (EPR) effect for uptake by targeted cells and 
intracellular drug delivery, and can also more easily transcytose into key tissue spaces compared 
to MPs. Here, we propose the use of biocompatible hydrogel MPs as carriers for smaller NPs to 
the vessel wall. We previously showed that hydrogel MPs adhered significantly more efficiently 
than NPs, and that deformable MPs adhered best in low shears, while rigid MPs adhered best at 
high shears. The engineered VTC system in this work leverages the size and modulus of two 
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particle types to increase NP delivery. We investigate how bulk hydrogel properties and NP 
loading determine the adhesion of VTCs to the vascular wall under physiological blood flow 
conditions and the resulting NP payload delivered. In general, deformable hydrogel MPs bound 
better under low shear and more rigid MPs under high shear, with the hydrogel modulus being 
the key variable. More importantly, at a fixed dose of NPs in vitro, deformable particles 
delivered a larger NP payload at the low wall shear rates and rigid particles delivered more NPs 
at the high wall shear rate tested. In vivo, the deformable particles far outperformed free 50 nm 
NPs, where the loading density into hydrogel MPs did not change the overall number of NPs 
delivered. Overall, this work is a key paradigm shift in targeted drug delivery: hydrogel MPs can 
be used to more efficiently traffic smaller NPs to the inflamed endothelium of interest, proposing 
a new way to greatly improve clinical theranostics with applications for many diseases.  
 
7.3 Background 
VTCs are engineered to adhere and accumulate at sites of disease, producing localized 
delivery of drugs with the goal of increasing the local therapeutic payload and decreasing 
systemic toxicity. Current research in the targeted drug delivery field has established that 
physical properties of the carriers, including size, and modulus, affect the ability of particles to 
marginate from bulk blood flow to adhere at the site of disease or inflammation.
10,106
 These 
physical parameters can greatly impact the final performance of a VTC system, as successful 
margination from bulk blood flow is a prerequisite for the final adhesion of the particles; active 
ligand-receptor interactions must occur for the particle to adhere. Upon firm interaction, VTCs 
can release their drug payload to the diseased endothelium and into the adjacent tissue. 
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Biocompatible, biodegradable NPs are often cited as appealing drug delivery candidates 
for both targeted and non-targeted applications for a variety of reasons. Non-targeted particles in 
the 20-80 nm range avoid immune recognition and clearance, minimizing cellular phagocytosis 
and enabling long circulation half lives in the bloodstream.
250,251
 Their high surface area to 
volume ratio makes them ideal drug carriers, with drug loading near the particle surface enabling 
rapid release from the carrier,
252
 and allowing for a more finely tuned pharmacokinetic release 
versus a single intravenous dose. Once near the vascular wall, although NPs are typically too 
large for paracellular diffusion, they are able to transcytose more readily than MPs into the 
adjacent tissues beneath endothelium.
71,253,254
 Furthermore, NPs in the 20-80 nm range are able 
to passively diffuse through disordered vasculature often present in tumors, taking advantage of 
the EPR effect.
255,256
 However, recent work and reviews have revealed that less than 1% of 
injected doses make it to the tumor site, far from the “magic bullet” name so often used.166,227,228 
A main issue with this is the diminished ability of nano-sized particles to marginate and bind to a 
vessel wall from whole blood.
10,46
 Instead, research has shown that 2-5 µm particles marginate 
much more effectively than NPs.
10
 However, rigid, polymeric particles in the micrometer size 
range optimal for margination could produce dangerous capillary occlusions in vivo and lack 
many of the benefits detailed for NPs. In parallel to the VTC size work, researchers have 
established particle modulus as a key physical property and shown that lower VTC modulus both 
decreases non-specific particle entrapment and increases circulation time in vivo, due to slower 
filtration rates and phagocytosis by immune cells.
38,39,104,150,153
 Furthermore, we have recently 
demonstrated that the targeting ability of MPs is dependent on both the MP modulus and the 
local shear rate. Soft, more flexible particles are more efficient at margination under low shear 
 154 
conditions found typically in veins, while stiffer, more rigid MPs are more efficient under higher 
shear conditions found in arteries or partially blocked, diseased vessels.  
In this work, we sought to leverage the benefits of two different sizes and different 
moduli, by loading rigid NPs into deformable hydrogel MPs for delivering NPs to the endothelial 
cell (EC) wall. Recent studies have explored the use of bulk hydrogels loaded with NPs for a 
broad range of applications, including the controlled release of insulin,
257
 bone tissue 
proteins,
258,259
 glaucoma therapeutic,
260
 local anti-inflammatories,
261–263
 oral anti-
inflammatories,
264
 and antibacterials
265,266
. In these studies, NPs were released from bulk 
hydrogels via a variety of mechanisms, including non-specific hydrolysis, pH and thermos-
specific hydrolysis, and infrared light-triggered release. A few others have loaded NPs into larger 
MPs in the range of 100 µm diameter, and studied the resulting encapsulation
267
 mainly for 
increased solubility of poorly soluble drug-loaded NPs.
268,269
 Some work has developed NP-
embedded MPs for treatment of lung disorders via inhalation,
270,271
 while others have shown 
favorable release kinetics via oral delivery,
272
 while some have only tested on the bench top.
273
 
Most of these formulations involve spray drying of powders, which results in polydisperse 
collections of non-spherical MPs. Some call these methods a type of “Trojan Horse”, in that NPs 
can be covertly delivered to the tissue of interest without recognition by the immune system.
269
 
While these studies demonstrate the feasibility of loading NPs into a hydrogel carrier, to date, no 
one has loaded NPs into hydrogel MPs in the 2 µm size range for intravenously administrated 
vascular-targeted drug delivery and evaluated the system both in vitro and in vivo. This is the 
first known work that proposes the use of deformable hydrogel MPs as carriers for rigid NPs to 
directly improve margination to the vessel wall. We propose the exploitation and sequential 
harnessing of complementary characteristics of the different particle types employed for the 
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increased trafficking of rigid NPs to inflamed endothelium. To address this deficiency in the 
research field, we investigate 2 µm hydrogel particles of varying moduli loaded with polystyrene 
(PS) NPs (500 nm and 50 nm). We explore how modulus and the molecular weight of highly 
biocompatible, FDA-approved poly(ethylene glycol) (PEG) used in the fabrication of the 
hydrogel MPs affect loading efficiency by comparing relative fluorescence of the loaded MPs 
under controlled fabrication conditions. We investigate the impact of two different variables: the 
bulk material modulus and the number of loaded NPs, on margination and adhesion both in vitro 
in human blood flow assays and in vivo via intravital microscopy. Our data demonstrate that the 
loading of rigid NPs into deformable MPs slightly affects the modulus of the MPs, but in a way 
that would not alter the in vivo circulation time of low modulus VTCs. Importantly, our work 
shows that head to head, delivering NPs loaded into hydrogel MPs is between 630% and 5,450% 
more efficient than free NPs alone, depending on the hemodynamic conditions. For small NPs 
that do not marginate well, we report a dramatic increase in NP delivery to the inflamed vessel 
wall. This is the first study to examine the possibilities of loaded MPs as a method to increase 
margination and adhesion of NPs, and therefore offers important insight into utility of loaded 
MPs as carriers for NPs, and exciting improvements for many therapeutic applications. 
 
7.4 Results 
NP loading dictated by NP size, PEG molecular weight, and % solids in composition 
We first investigated how different parameters in the emulsion fabrication system 
impacted the loading of PS NPs into spherical hydrogel MPs of 2-µm diameter. Loading of NPs 
into hydrogel MPs was evaluated by flow cytometry; all PS NPs utilized were fluorescent green 
and the number of NPs per particle directly correlated to the quantified median fluorescent 
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intensity (MFI). Fabrication of PEG-based hydrogel MPs was as previously reported,
106
 using 
PEG diacrylate (PEGDA) of 700 Da molecular weight (MW), with the addition of varying 
amounts of PS NPs, except where the PEG MW is noted as varied. Lyophilized NPs were 
suspended in predetermined volumes of PEG hydrogel precursor solution so that upon 
photopolymerization, the NPs were physically entrapped in the hydrogel matrix. Reaction 
conditions for the PEG hydrogels are detailed with the resulting physical properties in Figure 
7.1; the hydrogel pores are only 3.5 nm and 0.3 nm for the 15% and 50% PEG conditions, 
respectively; thus, we do not expect any diffusion of the NPs out of the MPs. Flow cytometry 
gating ensured characterization of only hydrogel MPs, with exclusion of free NPs based on their 
small diameter.  
 To determine how different parameters affected NP loading, we evaluated the importance 
of PS NP size, PEGDA MW and PEGDA composition in the final NP loading into hydrogel 
MPs. We tested both 500 nm and 50 nm NPs diameter in Figure 7.2A, fabricated at initial 
equivalent volume fractions as specified in the methods. The 50 nm particle loading increased 
linearly with increased volume percent of NPs. The 500 nm particle loading also increased with 
the volume percent of NPs, except for the 15.6% v/v, where the MFI dropped significantly and 
fewer hydrogel MPs total were formed. We hypothesize that this was due to the larger NPs 
inhibiting the end group proximity required to initiate the crosslinking and formation of hydrogel 
MPs. In summary, we successfully loaded a range of NPs into 2 µm hydrogel MPs. We found 
the saturation limit for the 500 nm particles at 15% v/v. Conversely, we achieved a linear loading 
for 50 nm particles across the studied range. Next, we were interested if varying the PEGDA 
MW would increase NP loading due to different crosslinking dynamics of varying length 
monomers. Figure 7.2B shows the importance of PEGDA MW in the loading of 50 nm NPs with 
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250, 700, and 10,000 Da PEG monomer. Higher MW PEGDA delivered the highest loading 
efficiencies, followed by the low MW PEGDA, and the intermediate PEGDA MW produced the 
least loading. In all cases, loading of the 50 nm NPs increased with increased % v/v NPs, 
indicating that loading saturation had not been reached for any conditions tested. Next, we 
explored whether the number of NPs loaded changes with MP modulus by varying the PEGDA 
composition within the emulsion to achieve MPs with varied crosslinking density and modulus, 
but the same loading of NPs. Figure 7.2C shows a plot of NP loading into hydrogels MPs with 
varying amounts of PEG composing the hydrogel matrix. In Figure 7.2C, the higher % solids on 
the x-axis means more PEGDA and crosslinking present during fabrication, which resulted in 
higher modulus particles. We found that with the same number of NPs in the formulation prior to 
polymerization, more heavily crosslinked particles loaded and retained more NPs in the hydrogel 
MP. This is likely because with a set volume of NPs and increasing amount of polymer present, 
more end groups are readily available to polymerize together and encapsulate more NPs.  
 From this work, we elected to study delivery of 50 nm NPs, as both a larger number and 
more volume can be loaded into a single hydrogel MP. Additionally, the 50 nm size is more 
amenable to endothelial transcytosis, intracellular delivery, and the EPR effect than the 500 nm 
diameter NPs.
71,253–256
 We focused our evaluation on two different % solids of PEGDA, to 
determine how the overall MP modulus may impact NP delivery to the vascular wall. All MPs 
were fabricated using the 700 Da MW PEGDA monomer. Finally, for each of the MP of varied 
moduli, we evaluated different NP loading to assess if more NPs per MP was more efficient at 
delivering NPs to the vessel wall. In Figure 7.2D, we report the MFI of the particles selected and 
utilized for the remainder of this work. We find that with the loading and PEG formulations 
employed, we obtained a range of NPs/MP. Subsequent in vitro and in vivo experiments will be 
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performed with “soft” 15% PEG particles with 2 different amounts of NPs loaded, and one 
“hard” 50% PEG particle with NP loading. A schematic of these particles is shown in Figure 
7.2E, along with designations of how they will be discussed moving forward. This set of 
different particle types will help determine what level of loading and which hydrogel bulk 
modulus are optimal for each hemodynamic condition tested. 
 
 
 
Figure 7.1 Hydrogel fabrication conditions and characterization. 
(A) Tabulated fabrication conditions and calculated bulk material properties of unloaded 
hydrogel materials. (B) Swollen shear moduli of hydrogel particle conditions without loaded 
NPs. 
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Figure 7.2 Characterization of PS NP loading into hydrogel MPs by emulsion. 
PS NPs were loaded into hydrogel MPs under varying conditions. All other variables held 
constant, the NP loading is represented by the median fluorescent intensity (MFI) and plotted by 
varying (A) NP size with constant “hard” hydrogel and 700 Da PEG, (B) PEGDA MW with 
constant “soft” hydrogel and 50 nm PS NPs, (C) % Solids PEG with 500 nm PS NPs and 700 Da 
PEG. The MFI of the NP-loaded hydrogel MPs used throughout the remainder of the paper is 
shown in (D). (E) Schematic of five hydrogel particles and free nanoparticles utilized throughout 
this work.  
 
Loading of NPs into hydrogels alters the bulk modulus 
Figure 7.3A shows fluorescent images of hydrogel MP (in red), 50 nm PS NPs (in green) 
and the two overlain to show both the co-localization of the NPs into the PEG and the varying 
amount of NP loading by condition. VTC modulus has been shown to affect particle adhesion 
efficiency in vitro and in vivo, as well as circulation time in vivo.
38,39,149
 Therefore, we tested 
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how the physical loading of PS NPs affected the bulk material modulus of the hydrogels used in 
this work. We hypothesized that loading of rigid NPs would impact the overall modulus of the 
hydrogel MPs because PS is very rigid with an elastic modulus of about 2 GPa.
155
 We fabricated 
bulk hydrogels with same composition as the MPs utilized for the in vitro and in vivo 
experiments and tested them via rheometry. The bulk conditions correspond to 0, 3, or 25 of the 
50 nm PS NPs loaded into each 2 µm hydrogel MP, which we defined as unloaded, low, and 
high NP loading, respectively. In Figure 7.3B, we show that both amounts of NP loading into 
“soft” hydrogels significantly increased the shear modulus versus the unloaded hydrogel, as 
measured on swollen bulk hydrogels via an AR-G2 rheometer. Specifically, the shear modulus 
increased from 5600 +/- 700 Pa for unloaded hydrogel to 8600 +/- 420 Pa for the low NP loading 
to 9800 +/- 290 Pa for the high NP loading. Thus, at high NP loading, we observe a 75% 
increase in the bulk shear modulus. We then fabricated “hard” 50% PEG hydrogels both 
unloaded and with high NP loading, corresponding to 16 PS 50 nm NPs per 2 µm hydrogel MP. 
Physically loading 50 nm PS NPs into a bulk hydrogel for this composition did not significantly 
increase the bulk shear modulus (72,500 +/- 300 Pa to 78,400 +/- 280 Pa), as shown in Figure 
7.3C, corresponding to an only 8% increase in shear modulus. Overall, despite the significant 
impact of NP loading on the rigidity of the “soft” hydrogel, these hydrogels are still considerably 
more deformable than the “hard” hydrogels.  
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Figure 7.3 Material properties of NP-loaded hydrogel MPs. 
(A) Schematic of five hydrogel MP with varied modulus and NP loading, with representative 
fluorescence images of each particle type via confocal microscopy. Red is MP hydrogel, green is 
50 nm PS NPs, and the two are overlaid to show co-localization of NPs and hydrogel MPs. 
Swollen shear moduli of all hydrogel particle conditions; influence of adding different amounts 
of NPs on bulk material rheometry for (B) 15% PEG and (C) 50% PEG hydrogels. Statistical 
analyses were performed using one-way ANOVA with Fisher’s LSD test, where (***) indicates 
p<0.001 in comparison to the non-loaded hydrogels. Error bars represent standard error for N=3. 
 
Hydrogel MPs outperform free NPs in an experimental blood vessel model  
 Next, we evaluated the ability of our NP-loaded hydrogel MPs to bind to an inflamed 
vessels wall in blood flow via an in vitro model of blood flow in a parallel plate flow chamber 
(PPFC) with activated human umbilical vein endothelial cell (HUVEC) monolayer serving as the 
inflamed vessel wall.  Our key interest here is to determine if MPs can deliver a better NP load to 
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the vascular wall than free NPs.  Using the PPFC assay,
106
 we are able to quantify the number of 
both MP and NPs trafficked to the vessel wall. We evaluated the adhesion of our particles in two 
different dosing schemes. First, we maintained a fixed hydrogel MP concentration in human 
blood and characterized the resulting adhesion of anti-ICAM-1 targeted particles in Figure 7.4A. 
The surface of each particle type was characterized to ensure a constant 5,000 sites of anti-
ICAM/µm
2 
and all experiments were at a low WSR of 200 s
-1
. This shear rate represents that of 
veins and venules, which is often where leukocytes are captured for rapid response to 
inflammation.
117
 The “soft” 15% PEG particles adhered equivalently independent of NP loading 
(unloaded, low, and high), whereas the “hard” 50% PEG MPs adhered less than all “soft” 
conditions. Thus, the difference in modulus produced by loading of NPs within each of the “soft” 
and “hard” particle groups did not produce significant differences in adhesion of hydrogel MPs, 
as shown in Figure 7.4A. 
The MFIs, representing the number of 50 nm PS NPs loaded per hydrogel MP, were used 
to scale from the number of hydrogel MPs bound to the inflamed HUVEC to the number of NPs 
delivered. More specifically, we compared the loaded hydrogel MPs to free NPs on a plate 
reader to determine the average number of NPs loaded per hydrogel MP. We translated results 
from Figure 7.4A to the number of 50 nm NPs delivered in NPs/mm
2
 vessel wall using the MFIs, 
with the results shown in Figure 7.4B. In these experiments, the concentration of hydrogel MPs 
was fixed in blood, therefore those with higher NP loading delivered a significantly higher NP 
payload to the vessel wall. In order to determine which particle type is most efficient at 
delivering NPs, we next dosed MPs by a fixed concentration of NPs in the flow, i.e. more 
hydrogel MPs/mL for those loaded with fewer NPs. The adhesion of hydrogel MPs in the fixed 
NP concentration dosing scheme are shown in Figure 7.4C; the 15% PEG particles with low 
 163 
loading adhere significantly more because the concentration was much higher per mL of human 
blood perfused. The unloaded hydrogel conditions were excluded as no NPs were loaded, so 
there was no logical dosing equivalent. We again translated these results to the delivery of NPs 
to the vessel wall in Figure 7.4D and compared to adhesion quantified from experiments which 
utilized free 50 nm PS particles of the same concentration in flow. We find that the low loading 
of “soft” 15% PEG particle delivered significantly more NPs to the vessel wall than any other 
condition tested, including the soft hydrogel MPs with higher loading. This is in line with the 
softer particles adhering significantly better at low WSRs. Of note, the free NPs were 
significantly worse than all other particle types tested at delivering 50 nm PS NPs to the vessel 
wall. Quantitatively, in the order that they are presented in Figure 7.4D, the hydrogel MPs 
delivered 5,450%, 3,300%, and 630% increases in number of NPs delivered to the vessel wall 
versus free NPs themselves, all massive increases.  
 After determining the most efficient combination of hydrogel formulation and NP 
loading at a low WSR of 200 s
-1
, we then evaluated the particles in a high WSR of 1000 s
-1 
in the 
same PPFC assay. This shear rate represents the higher end of the range that occurs in the body, 
typically found in healthy arterioles and stenotic large arteries in atherosclerosis.
117
 We again 
employed the two different dosing schemes of fixed hydrogel MP concentration (Figure 7.5A-B) 
and fixed NP concentration (Figure 7.5C-D). At a fixed hydrogel MP concentration under high 
shear conditions, the “hard” 50% PEG particles adhered significantly more than the “soft” 15% 
PEG particles, consistent with previous results from our lab that find hydrogel binding is heavily 
shear dependent in vitro (Figure 7.5A).
106
 The difference in modulus produced by loading of NPs 
within each of the “soft” and “hard” particle groups again did not produce significant differences 
in adhesion. We translated these hydrogel MP adhesion results to the delivery of NPs to the 
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vessel wall in Figure 7.5B and the “hard” 50% PEG particle delivered the most NPs under high 
WSR. Like the low shear assays, we then dosed a fixed number of NPs by altering the number of 
hydrogel MPs per mL of human blood in the PPFC assay. Again, shown in Figure 7.5C, the 
lowest loaded hydrogel MP, composed of 15% PEG, adhered the best due to being dosed with 
more hydrogel MPs per mL of human blood. However, the 50% PEG “hard” particles, though 
dosed at a significantly lower concentration, achieved similar binding under these conditions. We 
then translated this adhesion to the NPs delivered to the vessel wall in Figure 7.5D and found 
that at a high WSR of 1000 s
-1
, the rigid particles delivered significantly more NPs to the vessel 
wall then all other conditions tested, including free NPs. Within the soft hydrogel MPs, the low 
loading again produced more NP delivery to the wall versus the high loading equivalent. Again, 
every NP-loaded hydrogel MP condition was significantly better at delivering NPs to the vessel 
wall than free NPs perfused at the same concentration. Quantitatively, in the order that they are 
presented in Figure 7.5D, the hydrogel MPs delivered 310%, 170%, and 1,550% increases in 
number of NPs delivered to the vessel wall versus free NPs themselves. In summary, the 
adhesion efficiency is the driving variable of final NP delivery. 
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Figure 7.4 Adhesion of NP-loaded hydrogels to an inflamed HUVEC monolayer at 200 s
-1
 
wall shear rate. 
Quantified VTC adhesion for all particle types with a (A) fixed concentration of hydrogel MPs 
and scaled in (B) to the number of NPs delivered by this hydrogel adhesion. (C) Shows hydrogel 
MP binding at a fixed NP concentration, scaled in (D) to the number of NPs delivered. For all, 
adhesion was quantified after 5 minutes of laminar blood flow over an IL-1β activated HUVEC 
monolayer. N=3 human blood donors per particle condition. Statistical analysis of adherent 
density was performed using one-way ANOVA with Fisher’s LSD test where (*) indicates 
p<0.05 and (****) indicates p<0.0001 versus the first bar in each plot. Error bars represent 
standard error. 
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Figure 7.5 Adhesion of NP-loaded hydrogels to an inflamed HUVEC monolayer at 1000 s
-1
 
wall shear rate. 
Quantified VTC adhesion for all particle types with a (A) fixed concentration of hydrogel MPs 
and scaled in (B) to the number of NPs delivered by hydrogel adhesion. (C) Shows hydrogel MP 
binding at a fixed NP concentration, scaled in (D) to the number of NPs delivered. For all, 
adhesion was quantified after 5 minutes of laminar blood flow over an IL-1β activated HUVEC 
monolayer. N=3 human blood donors per particle condition. Statistical analysis of adherent 
density was performed using one-way ANOVA with Fisher’s LSD test where (*) indicates 
p<0.05, (**) indicates p<0.01, (***) indicates p<0.001 and (****) indicates p<0.0001 versus the 
first bar in each plot. Error bars represent standard error. 
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 To better understand how these results may translate into the clinical setting, we 
evaluated the vessel wall adhesion of “soft” 15% PEG particles of both high and low NP loading 
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has been shown previously that more rigid hydrogel MPs have shorter circulation times in vivo 
and are significantly worse than deformable hydrogels at adhering to inflamed endothelium.
106
 
Therefore, we directly compared our “soft” hydrogels MPs with two different amounts of NPs to 
free NPs. We utilized an intravital microscopy method to facilitate live imaging of inflamed 
mesentery veins in an anesthetized mouse. We dosed the mice with a fixed number of NPs, 
meaning a variable number of hydrogel MPs, all with a constant surface targeting ligand site 
density of 30,000 anti-P-selectin/µm
2
. Anti-P-selectin has been previously shown to ensure 
rapid, firm capture of particles in vivo.
106
 Figure 7.6A is representative images of each hydrogel 
particle type used, broken out by hydrogel MP binding in red, NP binding in green, and all 
merged to observe the overlap. Of note, there is no red image for free 50 nm particles because 
there was no hydrogel material. Figure 7.6B shows the hydrogel adhesion to a mesentery vein, 
after 3 minutes of TNF-α activation, followed by the injection of particles, and 5 minutes of 
circulation time. The results portrayed as the adhesion of hydrogel MPs per mm
2
 of vessel in 
vivo. As with Figures 7.4C and 7.5C, the low loaded hydrogel MP produced the best hydrogel 
MP adhesion simply because more particles were injected into the mouse than the other hydrogel 
MP type. In Figure 7.6C we then translated these results to the number of NPs delivered, and 
found that in vivo, the loading density of NPs does not significantly change the number of NPs 
trafficked to the vessel wall within the “soft” 15% PEG particle type. Free 50 nm PS NPs 
resulted in significantly less adhesion versus both high and low loading into 15% PEG particles 
after 5 mins of particle circulation in vivo. Specifically, the two hydrogel conditions delivered at 
minimum a 3,630% increase in the number of NPs that arrive on the vessel wall. Overall, it is 
very clear that in vivo, 15% PEG particles are significantly more efficient at delivering 50 nm PS 
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NPs to an inflamed mesentery versus free NPs, within the experimental window that we dosed, 
regardless of the number of NPs loaded and small variations in bulk modulus. 
 
 
 
Figure 7.6 Delivery of NPs to an inflamed mesentery endothelium as a function of loading 
into hydrogel MPs. 
(A) Representative brightfield and fluorescence images of particle adhesion to inflamed 
mesentery. (B) Quantified adherent density of three different particle conditions, 15% PEG low 
loading hydrogel MP, 15% PEG high loading hydrogel MP, and free NPs. Particles were dosed 
by equivalent NP payload, therefore a different number of hydrogel MPs for each bar. (C) Data 
scaled by the number of NPs to show efficiency of NP delivery by each VTC system. N = 3 mice 
per group and statistical analysis was performed using one-way ANOVA with Fisher’s LSD test. 
(**) indicates p<0.01 and (***) indicates p<0.001 compared to the low NP loaded 15% PEG 
particle binding. Error bars represent standard error. 
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that binding of particles to a vessel wall depended heavily on both size and modulus of the 
particles. Therefore, we next evaluated whether the binding of 50 nm NPs increased over time to 
approach the binding of NP-loaded hydrogels. We utilized the same method as in Figure 6.4 and 
quantified the binding of 50 nm NPs, targeted with anti-P-Selectin, to an inflamed mesentery 
wall with IVM. In Figure 7.7, the binding of 50 nm particles increases slightly over an hour time 
frame, but does not come near closing the gap in Figure 7.6. Therefore, we can be sure that the 
adhesion of 50 nm NPs will not catch that of hydrogel MPs over time; after an hour binding 
increased 54% from the initial, 5 minute time point, but leveled off and stopped increasing after 
25 minutes. Figure 7.7B shows a head to head comparison of the two particle types, scaled to the 
mass of particles delivered to the vessel wall. The binding of 50 nm NPs is nominal compared to 
that of 2 µm hydrogels. 
 
 
Figure 7.7 Delivery of NPs to an inflamed mesentery endothelium as a function of loading 
into hydrogel MPs. 
(A) The adhesion of 50 nm PS particles targeted with anti-P-Selectin to an inflamed mesentery 
vein of over a full hour. (B) Is the same data as (A), but with data from Figure 6.4C to give an 
idea about the difference in binding between hydrogel MPs and 50 nm PS NPs. Error bars 
represent standard error for N=3.    
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7.5 Discussion 
 To date, no study has extensively evaluated how loading NPs into targeted hydrogel MPs 
affects the overall transport and adhesion of NPs in vascular targeting. It has been shown that a 
very small percent, about 0.7% on average, of intravenously delivered VTCs arrive at the 
targeted tissue or vasculature of interest in cancer applications, where the VTCs are labeled as 
“magic bullets”.166,227,228 It is imperative that VTCs make adhesive contact with the endothelium 
of interest, otherwise all potential benefits of targeting are negated. While different NP-
embedded MP systems have been developed for proposed theranostic applications,
267–273
 none 
have targeting moieties, nor are they tailored in modulus and NP loading to optimize targeted NP 
delivery and adhesion. In this work, we show that targeted hydrogel MPs deliver significantly 
more NPs to the vessel wall than free NPs themselves, for all hemodynamic conditions tested, 
and for up to an hour. This suggests that there are major improvements yet to be made in the 
delivery of NPs to disease sites in vascular-targeted drug delivery. Our findings shed light on 
hydrogel modulus as the key physical property that controls the number of loaded NPs delivered 
to the vessel wall. There is a critical need to thoroughly evaluate the ability of smaller NPs to 
bind to the vessel wall in inflammatory disease, and to understand how loading into hydrogel 
MPs directly affects their transport to the vessel wall. This work elucidates the untapped 
potential of smaller NPs loaded into hydrogel MPs for clinical treatment of many diseases 
involving with inflammatory responses, including cancer, diabetes, atherosclerosis, and many 
more.  
Motivated by others’ results showing that NPs of different compositions and sizes can be 
loaded into varying types of MPs, we engineered a simple emulsion system to fabricate NP-
loaded hydrogel MPs and then target inflamed vascular wall. By loading rigid NPs into hydrogel 
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MPs, we have developed a system that exploits the benefits of each respective size and modulus 
in two subsequent steps. The larger, deformable MP has improved margination dynamics in 
blood flow versus 50 nm PS NPs. Upon release, the loaded rigid NPs can more readily 
transcytose into the tissue, travel intracellularly to deliver a therapeutic, or diffuse through leaky 
vasculature via EPR effect more rapidly than a MP.
71,253–256
 Thus, this proposed 2 step vascular 
targeting strategy has the potential to revolutionize the efficiency and overall targeted delivery 
efficacy of NPs for broad applications in difficult to treat diseases. Many studies have 
investigated the loading of NPs into bulk hydrogels for varied applications,
257–266,274
 but haven’t 
exploited the potential of using a PEG-based hydrogel MP as a Trojan horse through blood to 
transport rigid NPs to the vessel wall. This work is a paradigm shift in the way to think about 
VTC size; namely, two different particle sizes are used for two different transport length scales. 
Larger particles are used to traffic smaller particles to the vessel wall from bulk blood flow, and 
then the smaller particles can perform their functionality more efficiently at the cellular level.  
We chose to work with PEG because it is highly biocompatible due to its hydrophilicity 
and is a highly modular building block for VTCs. We show in this work that a variety of PEG 
hydrogel formulations may be employed to load different numbers of NPs into the crosslinked 
VTC. Our previous work has shown the overall particle modulus controls the final binding of 
hydrogel MPs, thus, loading NPs has the potential to alter the particle modulus and therefore the 
final adhesion.
106
 Overall, we find that the physical properties of the emulsion system, PEG, and 
NPs determine the final encapsulation of PS NPs into the hydrogel crosslinked matrix (Figure 
7.1). The 50 nm NPs were more easily encapsulated in MPs than the 500 nm NPs, which is likely 
due to inability of the PEG to crosslink around high concentrations of the larger NPs; this limit 
was not reached for the conditions tested with 50 nm NPs, highlighting the fact that a higher % 
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v/v of 50 nm NPs can be loaded versus 500 nm NPs. As for the influence of PEG properties, 
PEGDAs of varying MW have very similar chemical properties, including solubility and 
hydrophilicity, but the solution viscosity can increase greatly with increasing MW, which has the 
potential to affect emulsion dynamics.
275
 In Figure 7.2B, the higher PEG MW loaded 
significantly more NPs than the lower MWs, due to both the higher viscosity droplets retaining 
more of the solid NPs and the flexibility of the much longer PEGDA monomers that can bend 
around NPs to make covalent bonds. Within the two lower MWs, which were very similar in 
size, the crosslinking was likely controlled by crosslinking dynamics; with 250 Da PEG, there 
are significantly more acrylate groups, which increases the probability that polymerization 
around the particle is completed. The 700 Da PEG is also small, but has significantly fewer end 
groups, making it harder to polymerize around the NPs, leading to the lowest amount of loading. 
The higher loading of NPs with increasing amount of PEG in the formulation can be attributed to 
a tighter hydrogel matrix that again allows less diffusion out during and after loading. As 
anticipated, adding NPs to the PEG formulations has an overall larger effect on modulus of softer 
hydrogels than that of rigid hydrogels (Figure 7.3). Since the NPs are physically entrapped rather 
than covalently crosslinked into the hydrogel backbone, even though they are very rigid PS NPs, 
they move with the material under shear force. Importantly, these differences in modulus 
produced by NP loading are not enough to produce difference in circulation time in vivo.
38
 
We hypothesized that by loading small NPs into larger 2 µm hydrogel MPs, we would be 
able to deliver significantly more to a vessel wall, based on our previous work studying particle 
size and margination. We know that particles of different sizes respond differently to the 
presence of the RBC core in flow; micron-sized particles present a near-wall excess whereas NPs 
do not, meaning NPs have a diminished probability of binding compared to MPs.
46
 We designed 
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this study to compare the importance of two different variables on determining the final NP 
delivery to inflamed vasculature: NP loading, and PEGDA crosslinking (baseline modulus 
without loading). We varied NP loading because researchers have shown that VTCs surprisingly 
deliver more total drug, when less drug was loaded per particle, and more particles were dosed in 
vivo. This is due to saturation of the mononuclear phagocyte system (MPS) with a larger number 
of particles,
276
 therefore, we explored different amounts of loading in our system to see if we 
produced the same effect. We explored bulk hydrogel modulus, controlled by PEGDA 
crosslinking, as it has been extensively shown that particle modulus controls the overall 
circulation time of drug delivery particles, with deformable particles circulating significantly 
longer than rigid counterparts.
38,39,104,150,153
 In addition, particle modulus has been established as 
a physical property that dictates VTC adhesion, a vital step in overall targeted cargo 
delivery.
39,106
 Between these two variables, we worked to optimize the delivery of NPs under 
physiological, hemodynamic conditions.  
Both these and previous results show that rigid particles adhered better at high WSR 
while more deformable particles were better at low WSR.
106
 At low WSR this behavior by 
modulus directly produced most efficient NP delivery with the most deformable hydrogel, with 
the inverse being true at high WSR. These results are clear evidence that hydrogel modulus is the 
most important property to consider when designing a NP loaded hydrogel system. In vivo, the 
soft 15% PEG particles loaded with different amounts of NPs delivered statistically the same 
number of NPs to the vessel wall, 3,630% more than free NPs, meaning the disparity in hydrogel 
number dosed was mostly equilibrated by the different number of NPs per particle. We 
hypothesize that this difference between in vitro and in vivo results, where the lower loaded 
particles produced better adhesion, arises due to the complexity of the in vivo environment; the 
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higher loaded particles were only slightly more rigid than the low loading, likely not enough to 
alter circulation times. Therefore, the same number of NPs were delivered by both systems 
because all MPs had a similar number of opportunities to bind to the inflamed endothelium.  
We applied concepts and experimental methods from Chapter 6 to this project, and 
evaluated how long 50 nm NPs could target a vessel wall. Of importance, 50 nm particles are 
known to circulate for longer times, due to their ability to evade uptake by the liver and spleen, 
or organs of the reticuloendothelial system. Therefore, one could conceive that 50 nm NPs may 
continue to accumulate on a vessel wall in vivo, like the NPS in Chapter 6. Our findings showed 
the opposite- 50 nm NPs maintained and slightly increased their adhesion over an hour, but this 
leveled off after 25 mins. Therefore, it is possible to conclude that the transport of 50 nm NPs to 
the vessel wall will always be significantly better when loaded into hydrogel MPs, rather than 
free NPs. This data allows extrapolation to longer time points and allows us to definitively 
conclude that the superiority of NP-loaded hydrogels over free NPs will be maintained for long 
times in vivo, in clinical settings. 
By showing that the loading density into deformable hydrogel MPs does not change the 
overall delivery of NPs to the inflamed vessel wall in vivo, we propose that this system can be 
engineered to have tailored release kinetics based on the design parameter of NP loading density. 
For instance, higher loading could facilitate a burst release while lower loading could produce a 
depot-like NP extended release. As an example, chronic inflammation implicated in 
cardiovascular disease could be treated with low loaded hydrogel MPs while a more acute 
disorder, such as sepsis, could benefit from the release profile produced with higher loading of 
NPs. If the active pharmaceutical ingredient is poorly loaded into the NPs, as is often then 
case,
11,277,278
 then loading more NPs into the MPs would facilitate higher overall dosing. In order 
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to release these NPs additional functionality will need to explored in these particles. In addition 
to non-specific hydrolysis to degrade MPs, researchers have utilized materials functionalized to 
impart the triggered degradation of hydrogel-based materials upon exposure to changes in pH,
245
 
certain wavelengths of light,
274
 and certain enzymes.
11,249
 Future work to tune the hydrolytic or 
protease-induced degradation of PEG-based hydrogels is will further optimize the clinical 
functionality of these particles. 
Our work is not the first to conceive the general idea of loading NPs into MPs for drug 
delivery, yet, our particles vary from previous studies in a few key ways. Rather than focusing on 
synthesis and characterization,
267,268,270,273
 our research is highly comprehensive, starting with 
fabrication and continuing through both in vitro and in vivo applications. Rather than suggesting 
certain clinical outcomes in certain animal models,
269,271,272
 we propose that this system is widely 
applicable to diseases involving inflammation for systems dosed intravenously. We use MPs of a 
size that will not cause dangerous capillary occlusions after intravenous administration, 
especially because they are deformable. Others’ have shown that hydrogels with similar moduli 
are able to navigate small capillary diameters.
38
 Because we chose an emulsion method of 
fabrication, our particles are highly spherical and smooth, in stark contrast to particles that are 
spray dried.
269–271
 Overall, in the context of other work, we are able to provide a holistic view of 
the potential of NP-loaded PEG based hydrogel systems.    
 
7.6 Conclusions 
The loading of NPs into hydrogel MPs has great potential to revolutionize the delivery of 
smaller NPs for the many broad clinical situations amenable to targeted drug delivery. Loading 
NPs can impact the resulting bulk materials, but not in a way that impacts the final delivery of 
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NPs. The hydrogel composition is the driver dictating final adhesion both in vitro and in vivo. 
For all experiments hydrogel MPs were significantly better than free NPs, by at least an order of 
magnitude, if not two, designating a massive advantage gained by loading NPs into hydrogels in 
trafficking them to the vessel wall. This advantage was maintained for over an hour time 
window, indicating a sustained advantaged delivered by hydrogel MPs. An immense 
improvement over free NPs that has potential to revolutionize the clinical delivery of NPs. A 
very thorough review shows that less than 1% of NPs dosed intravenously ever make it to the 
intended site of delivery;
227
 if the same number of NPs were encapsulated into hydrogel MPs, 
this efficacy could be increased over 10%, and our study suggests, to up to 25% of the dose. 
Overall, this work will inform the engineering of VTCs moving forward such that smaller NPs 
may be tremendously more efficiently delivered to the site of disease.  
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: Conclusions and Future Directions  Chapter 8
 
8.1 Overall Dissertation Conclusions 
This dissertation embodies a few important projects that highlight the potential of 
vascular  targeted carrier (VTC) development into the clinic. Understanding the properties and 
dynamics that control VTC behavior in physiological blood flow is key to contributing 
fundamental knowledge to the field, that can then be used to engineer next generation VTCs for 
clinical use. It is imperative that the characteristics of the target tissue and cells are well-
understood, including the local hemodynamics, vessel geometry, and diseased surface protein 
expression pattern. In addition, the physical properties of VTCs can be manipulated to alter their 
behavior, including the size, shape, modulus, targeting ligand regime, composition, surface 
coating, density, and much more. Our original hypothesis, that multiple physical properties of 
particles interplay with physiological considerations to determine specific optimized conditions 
for each disease state, was confirmed by our experiments. The body of work presented here, 
which accomplishes the original goal of establishing how different particle properties interact 
with physiological parameters of disease to produce VTC adhesion, delivers the key knowledge 
that working together, particle modulus, size, and ligand regime have a massive impact on the 
final efficacy of VTCs in blood flow. 
In chapter 3, we found a coupled influence of particle modulus and size in determining 
VTC adhesion both in vitro and in vivo. In our experimental work, 2 µm particles were 
significantly better than all 500 nm particles when tested head to head, regardless of modulus. 
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For 2 µm hydrogel particles of varying deformabilities, a shear-dependent adhesion trend arose. 
At a low wall shear rate (WSR), more deformable particles performed better, whereas at a high 
WSR, more rigid particles delivered maximal adhesion. We find that this trend primarily arose 
due to collisions with leukocytes, where rigid particle produced more elastic collisions, which 
push them preferentially toward the vessel wall for enhanced adhesion.  
In chapter 4 we expanded the work from chapter 3 and investigated how ligand kinetics 
intersect with particle modulus to determine overall adhesion. We found consistency with the 
overarching trend of rigid particles performing better at higher WSR, with more targeting ligand 
unable to equilibrate the binding across all moduli. Deformable particles with a single ligand, 
regardless of site density or ligand type, were not able to match the binding of rigid particles in 
high shear environments. The complex involvement of leukocytes drove the observed trends at 
both low (300 sites/µm
2
) and high (5,000 sites/µm
2
) site densities, and for both ligands sialyl 
Lewis
A
 (sLe
A
) and anti-intercellular adhesion molecule-1 (anti-ICAM-1). The removal of white 
blood cells (WBCs) elucidates their key role in altering VTC adhesion from blood flow. With 
low site densities and adhesive forces, WBCs disrupted particle binding via competition at low 
WSRs, whereas with high site densities WBCs increased particle binding via productive 
collisions in the red blood cell-free layer. Interestingly, optimal dual targeting of the particles 
resulted in uniform adhesion across all particle moduli.  
In chapter 5, we aimed to enhance the poor margination and adhesion of 500 nm 
polystyrene (PS) spheres by comparing different ratios of two targeting ligands, sLe
A
 and anti-
ICAM-1. We found that by adding more sLe
A
, adhesion increased both in vitro and in vivo, but 
with overall diminishing returns. The mixing of the two ligand types provided a more than linear 
addition boost in the adhesion produced by the two individual ligands alone. For all experimental 
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conditions tested, particles with a 25%-75% mix of the two ligands performed best; with the 75% 
as the ligand of the lesser expressed receptor. For the more prevalent receptor present on the 
targeted cells, less ligand was needed to achieve the benefit of that ligand receptor (LR) 
interaction. We confirmed these findings in vivo in our mesentery inflammation model. 
Therefore, given a known cell surface protein pattern, we suggested a ligand configuration to 
maximize the binding of 500 nm PS spheres.  
In chapter 6, we combined the findings from the previous chapters and investigated the 
duration for which VTCs can stay bound in vivo. We examined the circulation times in mice 
plasma for a rigid and soft NP and MP, all composed of PEG. All particles had extremely short 
plasma circulation times in a mouse, independent of size, modulus, or presence of targeting 
ligand. Over the time frame of an hour, the soft MP and NP maintained or increased binding over 
time in our mesentery inflammation intravital method, whereas the rigid MP and NP detached to 
about half the maximum binding after an hour. In line with the intravital results, only the soft MP 
and NP showed significant targeting in our acute lung injury model, and the soft MP delivered 
the maximum particle dose and specificity to the lung for up to 8 hours. Therefore, we 
experimentally demonstrated that the ability of particles to target and stay bound to a vessel wall 
does not require extremely long circulation times in vivo, which was achieved with particles used 
in previous chapters.  
In chapter 7, we proposed the use of 2 µm PEG hydrogel MPs as Trojan Horses for the 
delivery of 50 nm NPs to the vascular wall. Physical entrapment of the NPs in to the PEG 
hydrogel did not alter the material modulus enough to expect a change in MP behavior, such as 
adhesion in vitro or circulation time in vivo. We found that in terms of the number of NPs 
delivered to the vascular wall, it was significantly more efficient to load these NPs into the 
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hydrogel MPs versus direct NP dosing in the free blood stream, both in vitro and in vivo. When 
dosed by a constant number of NPs, it did not matter if many hydrogel MPs were used with low 
loading, or fewer with high loading, a similar number of NPs were transported to the vessel wall. 
Overall, the driving characteristic of this system was the bulk modulus of the hydrogel MP, in 
line with our previous findings. This suggested that loading density of NPs could be tailored to 
desired release kinetics. 
In conclusion, we found that particle modulus is a key physical property to consider in 
the engineering of particulate drug delivery systems, especially for MP VTCs. We found that the 
adhesion of VTCs was often limited by ligand kinetics, which could be tuned to improve final 
binding efficiency based on known surface protein patterns. We proposed the use of hydrogel 
MPs as Trojans Horses for smaller NPs, with great success . This work contributes to the 
fundamental knowledge base that is necessary to design modular, optimized VTCs for broad 
applications in clinical settings. With this, we hope to provide continually better vascular-
targeted therapies for challenging-to-treat diseases.  
 
8.2 Impact and Future Directions 
This dissertation lays the ground work for many more potential projects, both 
experimental and computational in nature. Given the status of and improvements needed in the 
vascular targeted drug delivery field, we highlight the impact of our work and propose the 
following are areas of interest to pursue.  
The work presented in chapter 3 is the first study to systematically investigate a broad 
range of particle moduli, in conjunction with size, for targeted adhesion both in vitro and in vivo. 
With all the work around deformable, biocompatible, PEG-based particles,
150
 it is imperative to 
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understand exactly how modulus dictates different physiological processes necessary for 
vascular-targeted drug delivery. Our work delivers well-controlled particle and physiological 
conditions, including pertinent blood flow, to shed valuable insight into how modulus affects 
particle binding. 
Chapter 3 emphasizes the importance of modulus, and how that interplays with WSR to 
dictate final adhesion. In my mind, the follow up on this chapter is three-fold. First, would be to 
push the lower limits of deformability to more completely explore the modulus parameter space. 
Second, while our in vitro results were corroborated under low shear conditions in vivo, the high 
shear trend has not been confirmed in vivo. Therefore, an experimental method should be 
developed to image the targeted adhesion of hydrogels in high shear arteries in real time. Of 
note, the blood flow in large arteries is pulsatile rather than laminar in nature, making the arteries 
more challenging to image. The pulsatility of the blood flow can produce differences in targeted 
adhesion versus equivalent laminar conditions.
46,168
 High shear areas are the most relevant for 
targeting in atherosclerosis and cardiovascular disease, meaning this work would be high impact 
and extremely pertinent. A model could be developed to image the carotid artery of anesthetized 
mice; methods are currently being explored in the literature to establish stabilization of the artery 
sufficient to facilitate imaging.
279,280
 Other arteries could be explored, again, so long as they can 
be sufficiently stabilized for imaging. For these experiments, the endothelial cells should be 
characterized to provide as much physiologically pertinent information as possible. Finally, in 
chapter 3 we showed computationally via finite element analysis that hydrogels MPs in the 
modulus range we tested did not deform in the physiological shear forces of free blood flow. It 
would be of key interest to model the deformation of these same particles, but anchored to a 
vascular wall via LR pairs. It is expected that more deformation will arise, as the shear forces are 
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larger in magnitude near the vessel wall, especially if the anchored velocity of the particle is 
zero.
119
 These simulations would contribute to the understanding and expectations of how 
deformable VTCs should behave once bound to a blood vessel wall. Overall, these three projects 
would continue to build key knowledge about deformable hydrogel VTCs.   
Chapter 4 is a unique study that combines the investigation of key physical VTC 
properties including modulus, targeting ligand type, and ligand amount, to deliver insight into 
how two different VTC properties work together to deliver targeted adhesion. This kind of work 
is key for developing understanding of how all VTC properties must be engineered in concert to 
produce maximal adhesion and specificity. The work in chapter 5 is the first systematic variation 
of the ratio of two different ligands on VTCs for adhesion to cells under truly physiological 
blood flow conditions. It is imperative to design studies that mimic physiological conditions, 
otherwise results may differ when translated from an oversimplified system to an animal model. 
Overall, these studies deliver key knowledge that will impact the engineering of VTC systems 
targeted to many common diseases.  
 In chapters 4 and 5, we look at ligand kinetics, and in chapter 5 we focus on the dual 
targeting of 500 nm PS spheres. While this was a good model drug carrier to establish the 
importance of ligand kinetics, more work should be done with biocompatible particles. The dual 
targeting work should be expanded to larger particles still relevant for drug delivery (2 µm) and 
across the parameter space of particle moduli, using a range of materials. It is well known that 
particles composed of different materials absorb different plasma protein opsonins, which alter 
the way in which the VTCs bind.
92,281
 Additionally, larger particles will experience more 
efficient margination and offer a larger surface for adhesive contact, but will experience greater 
shear removal forces.
37,65,229
 Therefore, it is of key interest to investigate at how size and material 
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interact with targeting ligand composition and blood vessel size to produce maximal targeted 
adhesion. Additionally, our conclusion of more ligand is needed to the lesser expressed receptor 
should be tested for different LR pairs, relevant to disease, with different individual kinetics. It is 
imperative to keep in mind that the over-expressed receptor or protein must be expressed on the 
luminal side of the blood vessel, otherwise known as on the endothelial cells, or else the ligand 
will never find the intended counter receptor. For example, folic acid and hyaluronic acid, 
ligands to folate receptors and CD44 on cancer cells, respectively, may seem attractive for 
intravenous drug delivery, but will require that the cancerous cells protrude into the vasculature, 
which is not a given; the receptors are not present at high levels on endothelial cells.
248,282
 As one 
example, platelet mimetics have arisen as targeted therapeutic particles in the recent years, but 
the ratio of ligands to collagen and von Willebrand factor could be studied in more detail to 
optimize the clotting capabilities of the VTCs.
283
 
Chapter 6 is the first work to investigate how the circulation time of particles in vivo 
produces targeted adhesion over time. We were able to show that circulation time is not 
indicative of how long particles will stay bound at an intended inflammatory site, but rather, 
deformable particles are able to maintain adhesion for hours despite short circulation times for all 
particle types. Indeed, we are the first to show that once particles bind to endothelial cells in vivo, 
which happens within minutes, they no longer need to circulate for targeted adhesion to be 
maintained. This work has an immense impact, indicating that circulation time should not be 
used as a proxy for the possible success of a VTC system, but rather, accumulation at the target 
site over time is key. 
In chapter 6, we investigate the duration for which VTCs maintain targeted adhesion 
once injected intravenously. This chapter can certainly be expanded to more particle moduli 
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and different biocompatible materials. While our “rigid MP” was the most rigid condition 
tested, it is nowhere near the rigidity of other polymeric materials such as poly(lactic-co-
glycolic acid) (PLGA) or polycaprolactone, therefore this study could continue in this direction. 
This work can also be expanded to investigate targeting duration in pulsatile, high shear vessels 
in vivo, which may prove very different environments for particle adhesion than the low shear 
mesenteric veins. In addition to looking at targeting time, this project can be extended into a 
model with more complete clinical relevance, including drug loading and optimized release 
mechanisms to compare the clinical outcomes are over time. We hypothesize that deformable 
MPs will deliver the best clinical outcome in most disease models, because it has the longest 
targeting window, and therefore time to release the drug locally. Proteins such as hemoglobin 
have been loaded into PEG-based particles with high loading capacities and non-specific 
release mechanisms.
102
 Other drugs have been loaded into hydrogels, such as insulin,
257
 bone 
tissue proteins,
258,259
 glaucoma therapeutics,
260
 and anti-inflammatories.
261–263
    
To fully understand the possible clinical impacts of these loaded VTC systems, it is 
critical that the drug loading capacity and release kinetics be studied in the context of multiple 
disease models. Then the targeting ligand regime on the deformable PEG-based particle should 
be optimized to the known diseased endothelium, to maximize adhesion at the disease site and 
minimize accumulation in healthy tissue. I propose tracking the development of atherosclerotic 
plaque over time in apolipoprotein E–deficient (ApoE−/−) mice dosed daily with statin-loaded 
PEG particles.
284
 Statins lower the amount of lipids present and accumulating in vivo, thereby 
decreasing the development cardiovascular disease. This class of medications has a dose 
limiting toxicity due to the systemic side effects such as muscle pain, fever, and digestive 
problems.
285
 With the proposed targeting of particles loaded with statins to areas inflammation, 
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which manifests due to high lipid levels in ApoE
−/−
 mice, I hypothesize that a higher level of 
local statin concentration can be maintained with decreased systemic side effects. All results 
with targeted, loaded particles should be compared head to head with the same free drug 
dosage. A higher local statin concentration would decrease the size of atherosclerotic plaque 
developed, which should be evaluated histologically at the end of the experiment. If the 
targeted statin treatment functions more locally than free statin dosing, fewer inflammatory 
cytokines should be detected circulating in the blood stream, which can be sampled more 
regularly throughout the experiments on the same mice and quantified via ELISA kits. I 
suggest the testing of interleukin-1, interleukin-6, tumor necrosis factor-α and interferon-, 
due to the known involvement in development and modulation of cardiovascular disease.
286
 
Additionally, the concentrations of different lipids and lipid by-products can be monitored for 
their ability to mediate chronic inflammation.
287
 This model will give a complete picture of the 
clinical utility of statin-loaded hydrogel MPs and will show the importance of maintaining 
particle adhesion to the disease vessel site. 
Chapter 7 is the first study to explore the parameter space of NP loading into hydrogel 
MPs for targeted delivery to an inflamed vascular wall. We employed well-controlled ligand 
kinetics, and directly compared how delivering the same number of NPs, either in free solution 
or in different numbers of 2 µm PEG hydrogels, resulted in adhesion to the vascular wall. This 
work highlighted the huge impact that loading smaller NPs into deformable hydrogels can have, 
and the untapped potential for using polymerized PEG as a Trojan horse to get NPs to the disease 
site. This work has the potential to impact and greatly improve the overall efficacy of VTC 
systems involving small NPs, including many already in development for the clinic. 
 186 
Chapter 7 finds that loading 50 nm PS NPs into PEG hydrogel MPs delivers significantly 
more to the vessel wall than free NPs themselves. This should be developed in the direction of 
biocompatibility, using NPs composed of PLGA or polycaprolactone. Of interest, PLGA suffers 
from a significant plasma effect, where any exposure to protein opsonins in the blood 
significantly decreases the targeted adhesion.
92
 Loading PLGA NPs into the highly hydrophilic 
PEG hydrogel will provide a shield to the detrimental opsonins, and decrease the overall plasma 
effect. Once released, the PLGA NPs will need to bind very quickly to fight the rapid 
opsonization, and therefore, must too be conjugated with targeting ligand. As the NPs are 
released from the hydrogel, they must stay bound locally, otherwise all NPs and their cargo will 
wash away, overturning any targeting functionality. Therefore, the MPs and NPs should both be 
targeted to ensure extreme proximity to the diseased cells of interest.  
The next critical step in NP-loaded VTC development is to optimize a mechanism for NP 
release from hydrogel MPs. In the degradable polymer field, non-specific hydrolytic degradation 
is often utilized as a mechanism of cargo release, typically by inclusion of ester linkages in the 
hydrogel backbone or mesh.
288,289
 However, by definition, hydrogels are comprised of a high 
water content, facilitating rapid hydrolysis in solution and under physiological conditions, 
making this strategy not feasible for targeted delivery. Other mechanisms of hydrogel 
degradation/release include changes in pH, temperature, or enzymatic degradation. Finally, a 
zymogen could be loaded into the hydrogel MP, which would be converted into an active 
protease for an autocatalytic approach that feeds back for amplified degradation with enzyme 
exposure.
290
 If the delivery site is acidic in pH, such as a tumor environment, pH sensitivity can 
be incorporated into the hydrogels via hydrazine, acetal, or oxime bonds in the polymer mesh, 
which degrade in acidic pHs.
248
 This body of work discusses vascular targeting, where a shift in 
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pH is likely not large enough to facilitate the development of site-specific degradation. 
Therefore, enzymatic degradability offers the best avenue for disease site-specific degradation of 
VTC systems. 
Proteases are known to play an active role in the complex development of atherosclerotic 
plaques and exhibit enhanced expression and activity surrounding the associated inflamed 
endothelial cells (ECs).
291
Atheromas on arterial walls, have characteristically increased 
expression and activity of matrix metelloproteinases (MMPs), which are secreted by infiltrating 
macrophages, surrounding inflamed ECs, and smooth muscle cells (SMCs);
292
 the high 
expression of these MMPs has been associated with vulnerable plaques,
293
 and may offer an 
avenue for targeted cargo release in cardiovascular disease. MMP-9, also known as Gelatinase B, 
is a protease that is minimally expressed by healthy cells but is highly expressed by luminal ECs 
and SMCs near atherosclerotic plaques.
292
 It is key that there is a sizeable increase in protease 
expression near the intended site of release versus healthy tissue. MMP-9 is a prime example, 
with the healthy serum level reported as 0.2–0.4 nM (20-40 ng/mL) in healthy tissues and 
cells,
294,295
 and approximately 100 times that level near vulnerable regions of atherosclerotic 
plaques.
292
 We hypothesize that upon successful inclusion of protease-degradable cross-linkers 
within a hydrogel matrix, loaded NPs, or any desired cargo, can be locally released at the site of 
disease upon contact with proteases that are upregulated by the inflamed endothelium. An ideal 
MP for the delivery of cargo (NP, drug, imaging agent) to the vascular wall must both 
specifically and rapidly degrade once in contact with the endothelium, and also stay intact in the 
free stream of blood flow and elsewhere in the body.   
If hydrogel particles are rendered enzymatically degradable for NP release, then final NP 
adhesion and functionality requires that any particle and corresponding ligand system must be 
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stable in the presence of high concentrations of enzymes. A protocol must be established to 
synthesize custom peptides in house, to render our hydrogel VTCs enzymatically cleavable. 
Significantly more work is required to tailor the degradation kinetics for the time scales of 
degradation required in vivo. These time scales are dictated by the targeting windows established 
in Chapter 6; once the VTCs wash away, degradation is no longer relevant or site-specific.  
It has been previously shown in the literature that the degradation kinetics of bulk 
materials can be tuned based on hydrogel crosslinking density, the kinetics of the degradation of 
the linker, and the mode of degradation, including but not limited to: non-specific diffusion, 
hydrolysis, enzymatic cleavage, and response to changes in pH.
257–260,262–266
 The potential impact 
of this system lies with diseases that involve over activity of specific proteases as part of the 
clinical manifestation. For these systems, the specificity will be two-fold, including both the 
adhesion aspect and targeted degradation and release.  
If pursuing enzymatically-triggered NP release, the amount of peptide in the hydrogel 
back bone should be optimized to allow the particle to stay intact everywhere, except with 
atherosclerotic plaque levels of disease associated proteases, which should produce degradation. 
First, a quantitative method needs to be developed to determine the concentration of peptide that 
is crosslinked into the backbone of the hydrogel matrix. Once a reliable method is developed, 
well-varied amounts of peptide should be incorporated into either bulk hydrogels, hydrogel MPs, 
or both. I can fathom four ways of determining the rate of degradation over time. Smaller NPs, 
larger than the pore size of the hydrogel mesh, can be physically entrapped into the material. As 
the hydrogel degrades upon exposure to disease associated proteases, the NPs will be released 
into solution, which can be quantified with a plate reader. Else, the mass of a bulk hydrogel can 
be weighed over time in an enzymatic solution, with an eventual decrease in mass signifying 
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significant degradation. This has limitations as the hydrogel will eventually break into too small 
of pieces to measure. Otherwise, once enzymes cleave the peptide at a peptide bond, both a free 
carboxyl and amine group will be exposed. Therefore, colorimetric assays to determine the 
concentrations of free amines may be used with a hydrogel MP solution.
296,297
 Alternatively, MP 
degradation can be observed by automated microscopic imaging of samples from the degradation 
solution, to monitor the concentration of particles in solution over time. Based on the findings in 
chapter 6 that VTCs can stay bound for up to 8 hours, the site specific degradation should be 
optimized to occur in hours, upon exposure to elevated levels of disease associated protease. 
There are many formulation variables that may be altered to tune the enzymatic 
degradation kinetics of the hydrogels to the intended disease application. The PEG mesh will 
determine how quickly the bulk hydrogels or MPs degrade.  The molecular weight of the PEG 
monomer can have a huge impact on the molecular mesh formed, and therefore, the degradation 
kinetics.
152
 All else constant, higher molecular weight PEG increases the degradation rate of the 
overall gel. The number of arms on the PEG can also greatly impact degradation kinetics; more 
arms on each PEG molecule means a tighter hydrogel mesh and slower degradation rate.
152,298
  
The work in chapter 7 establishes the ability of targeted hydrogel particles to deliver NPs 
to the vascular wall with much higher efficiency than free NPs. Upon determining degradation 
kinetics in vitro with disease associated proteases, the system should be evaluated in more 
physiological environments, which could include cultured cells or many animal models of 
inflammation that involve over activity of disease associated proteases.  
 After testing degradability, researchers should evaluate the ability of these particles to be 
conjugated covalently with targeting ligands. Once maximal site densities are determined via 
secondary staining and flow cytometry, the MPs should be tested via parallel plate flow chamber 
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assay to ensure that rendering hydrogel degradable does not significantly alter the adhesion 
characteristics of the MPs prior to degradation. At this stage in development the particles will 
have both degradation and targeting built in or onto the surface, and so their overall functionality 
can be tested in many ways. Different experimental models should be used to fully investigate 
this system’s functionality both in vitro and in vivo, including degradation kinetics, uptake of 
released NPs by target cells, biodistributions of both hydrogel MPs and loaded NPs, and 
treatment of inflammatory models in vivo. 
The possible success of this enzymatically-degradable system will require the tuning of 
many variables, including the loading density of NPs, the peptide concentration, and the MP size, 
to name a few. This system can be tested with many animal models, such as with atherosclerotic 
ApoE
−/−
 mice
299
 or with atherosclerotic Ldlr
-/-
 Apob
100/100 
mice,
300
 which have both shown 
increased activity of disease-associated proteases such as MMPs near plaque development areas. 
Additionally, and more broadly, this system could be applied to a range of cancer models, as 
specific proteases are highly active in tumor environments.
290
 The entire design of the 
enzymatically-degradable hydrogel system would need to be tailored to each, unique tumor 
environment. The concentration of disease associated enzymes will be different in a tumor versus 
and atherosclerotic plaque, and hence, the kinetics should be tailored to the local concentrations 
and desired rate of overall hydrogel particle degradation. The intersection of all three chapters 
(6-8) should deliver a well-developed system with high clinical utility for a broad application of 
diseases. 
These last chapters should be combined to deliver a fully optimized system in vivo. By 
this, I mean that enzymatically degradable, NP-loaded hydrogel MPs should be injected 
intravenously and evaluated for delivery of small NPs to target endothelial cells. Of key interest, 
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an assay should be developed to determine the rate of retention on the vascular wall when the 
NPs are released. This should give an idea of how many are being swept back into the 
bloodstream, which will determine the true viability of this system. This can be visualized in real 
time, using intravital microscopy, as demonstrated throughout my dissertation. If most of the 
NPs rinse away from the vessel wall back into the blood stream, then the added complexity of 
adding NPs into hydrogel MPs did not deliver a significant benefit and the system must be 
reevaluated for clinical utility.  
 
8.3 Overall Outlook 
 I maintain a strong scientific conviction that targeted drug delivery will have an immense 
impact on many diseases in the not-so-distant future. Here, I give my insight on the current state 
of the art in vascular-targeted drug delivery, and my outlook as to where the field is going from 
here. I also propose a few more creative ideas to help propel the field forward with the ultimate 
goal of clinical translation. 
 Regarding the deformability of particles in blood flow, there is a crucial need to better 
understand how particles will behave in the dynamic environment of blood vessels in vivo, full of 
different cell types, constant collisions, varying vessel geometries, and variable shear forces and 
profiles. Atomic force microscopy has been used to study the different components of blood 
extensively, including RBCs, WBCs, and platelets.
133,134,178,301
 This work with blood cells helped 
elucidate the mechanics that govern the development of a RBC core in vivo. While rheometry 
has proven a good way to compare different elastic materials, it has been difficult to dive into the 
more micro-mechanics and hemodynamics of micro-sized particles in complex blood flow. I 
propose that the development of atomic force microscopy methods to better characterize the 
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detailed mechanics of deformable VTCs, would better inform computational models to more 
accurately predict the margination and adhesion of hydrogel VTCs in blood flow. Recent 
computational work has begun to elucidate the transport mechanisms of cell types with different 
physical properties in blood flow,
40,135,302
 yet there are many challenges to modeling such highly 
complex fluid flow, such as human blood, accurately. Recent computational work has underlined 
the major impact of cell size and rigidity on blood margination, however, little experimental 
work focuses on the effects particle physical properties in full blood flow. In summary, I propose 
a concerted effort to much more expansively use atomic force microscopy to better inform 
simulations involving complex, whole blood dynamics. This would allow for the better screening 
of particle behavior in vivo. 
 There has been a surge in clinical nanomedicines recently, with 40% of all current 
clinical trials involving particles having started in the last three years.
13,14
 The term 
“nanomedicine” is defined rather loosely, and can apply to systems from polymer-drug 
conjugates to bare or targeted, polymeric particles.
14
 While there are many clinical trials 
involving either particle or antibody drug candidates, there are very few that involve antibody 
targeting on a particle. BIND therapeutics has one of the fastest developing platforms of 
PLGA/PEG targeted particles, with indications for many cancer types showing promising 
results.
13
 Some of the key hurdles remaining for VTCs, from my perspective, are regulatory and 
manufacturing in nature. The US Food and Drug Administration has stringent clinical trial 
requirements, such as exact control over the number of antibodies per warhead on an antibody-
drug conjugate. That is easy to manage when there are only one or two active sites for linking 
between the two. When particles have the potential for thousands or millions of targeting ligands, 
controlling the exact number of molecules on the surface has proven either too costly (top-down 
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manufacturing) or generally impossible in the window required (bottom up manufacturing). In 
terms of the particles themselves, methods that are the highest throughput typically offer the least 
amount of control over particle size, shape, and morphology. Well-designed top-down 
manufacturing is cost prohibitive on a clinical trial or commercial scale. Taken together, there is 
not quite a happy medium between manufacturing capabilities and the US Food and Drug 
Administration clinical trial requirements. In my opinion, once we are able to tweak those 
requirements for particle systems, rather than trying to apply those in place from molecular 
systems to VTCs, the field will take off rapidly into the clinic. 
 In general, there are still creative emerging concepts when it comes to targeted drug 
delivery. For instance, researchers have proposed the use of zwitterions as either particle 
coatings or as the bulk particle material itself to evade immune recognition. Zwitterions have 
shown massively successful initial results, delivering huge increases in circulation times versus 
conventional polymers such as PEG and PLGA.
303,304
 More creative methods to control cargo 
release, including enzymatically cleavable hydrogels, has allowed for more finely tuned, and 
even sequential release,
305
 of different active molecules. There are hugely comprehensive 
reviews that cover all of the different physical and chemical design parameters to be considered 
in the design of a particulate drug carrier.
6,11
 Based on my experience, I believe that the key is to 
keep it simple. Not to stop innovating, but to drive towards the most elegant solutions that 
provide the required outcomes to translate into the clinic, rather than racing to a new idea that 
adds an undue level of complexity. For example, the complex synthesis of zwitterions has 
slowed the research and development of such molecules. That said, to the high levels of success 
with zwitterions, I propose that the field collaborate with chemists to find the simplest, most 
stable synthesis route possible. I strongly believe that these collaborations will produce the 
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elegant solutions required in academic research to accomplish the maximal impact in the medical 
world.  
 In general, it is key that work in the vascular-targeted drug delivery field becomes more 
systematic and concerted across research groups, to be able to establish guiding principles for 
designing VTCs with entire physiological process in mind. Far too much work is conducted in a 
scientific silo, when a more collaborative effort would inform the development of more 
efficacious VTCs. By working together, there is potential to provide working guidelines for what 
to consider when choosing a VTC system for a specific disease. To date, many studies evaluate 
one specific parameter of VTCs in only one experimental model in vitro or in vivo, making it 
difficult to see the big picture of how the biology interfaces with all the different design 
parameters of VTCs. Moving forward, the intersection of all the different physical properties of 
VTCs must be combined and studied, to create understanding that will propel both the general 
field and clinical trials forward.  
 
 
 195 
References 
 
1. Brannon-Peppas, L. & Blanchette, J. O. Nanoparticle and targeted systems for cancer 
therapy. Adv. Drug Deliv. Rev. 6, 206–212 (2012). 
2. Faraji, A. H. & Wipf, P. Nanoparticles in cellular drug delivery. Bioorg. Med. Chem. 17, 
2950–62 (2009). 
3. Misset, J. L. et al. Original article Dose-finding study of docetaxel and doxorubicin in 
first-line treatment of. Ann. Oncol. 10, 553–560 (1999). 
4. Perhamon Press, L. The Collected Papers of Paul Ehrlich, vol III. (1960). 
5. Strebhardt, K. & Ullrich, A. Paul Ehrlich’s magic bullet concept: 100 years of progress. 
Nat. Rev. Cancer 1–8 (2008). doi:10.1038/nrc2394 
6. Torchilin, V. P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58, 1532–55 (2006). 
7. Santos, L. A. & Akil, E. M. Drug Delivery Formulations of Ordered and Nonordered 
Mesoporous Silica: Comparison of Three Drug Loading Methods. J. Pharm. Sci. 100, 
3294–3306 (2011). 
8. Zhang, L. et al. Nanoparticles in Medicine : Therapeutic Applications and Developments. 
Clin. Pharmacol. Ther. 83, 761–769 (2008). 
9. Mehta, D. & Malik, A. B. Signaling Mechanisms Regulating Endothelial Permeability. 
Physiol. Rev. 86, 279–367 (2006). 
10. Charoenphol, P. et al. Targeting therapeutics to the vascular wall in atherosclerosis-
Carrier size matters. Atherosclerosis 217, 364–370 (2011). 
11. Torchilin, V. P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 64, 302–315 (2012). 
12. Cheng, Z., Zaki, A. Al, Hui, J. Z., Muzykantov, V. R. & Tsourkas, A. Multifunctional 
Nanoparticles : Cost and Versus Benefit of Adding Targeting and Imaging Capabilities. 
Science (80-. ). 338, 903–910 (2012). 
13. Anselmo, A. & Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 1, 10–29 
(2016). 
14. Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J. & Corrie, S. R. Nanoparticle-Based 
Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm. 
 196 
Res. 33, 2373–2387 (2016). 
15. Mitragotri, S. & Lahann, J. Physical approaches to biomaterial design. Nat. Mater. 8, 15–
23 (2009). 
16. Tao, L. et al. Shape-specific polymeric nanomedicine: emerging opportunities and 
challenges. Exp. Biol. Med. (Maywood). 236, 20–9 (2011). 
17. Decuzzi, P., Pasqualini, R., Arap, W. & Ferrari, M. Intravascular delivery of particulate 
systems: does geometry really matter? Pharm. Res. 26, 235–43 (2009). 
18. Nel, A. E. et al. Understanding biophysicochemical interactions at the nano-bio interface. 
Nat. Mater. 8, 543–57 (2009). 
19. Owens, D. E. & Peppas, N. a. Opsonization, biodistribution, and pharmacokinetics of 
polymeric nanoparticles. Int. J. Pharm. 307, 93–102 (2006). 
20. Jiskoot, W., van Schie, R. M. F., Carstens, M. G. & Schellekens, H. Immunological risk of 
injectable drug delivery systems. Pharm. Res. 26, 1303–14 (2009). 
21. Fromen, C. et al. Neutrophil–Particle Interactions in Blood Circulation Drive Particle 
Clearance and Alter Neutrophil Responses in Acute Inflammation. ACS Nano (2017). 
22. Longmire, M., Choyke, P. L. & Kobayashi, H. Clearance properties of nano-sized 
particles and molecules as imaging agents: considerations and caveats. Nanomedicine 
(Lond). 3, 703–17 (2008). 
23. Boulikas, T. Clinical overview on Lipoplatin: a successful liposomal formulation of 
cisplatin. Expert Opin. Investig. Drugs 18, 1197–1218 (2009). 
24. Pinto-Sietsma, S.-J. et al. Urinary Albumin Excretion Is Associated with Renal Functional 
Abnormalities in a Nondiabetic Population. J Am Soc Nephrol 11, 1882–1888 (2000). 
25. Smith, D. A., Waterbeemd, H. van de & Walker, D. K. Pharmacokinetics and Metabolism 
in Drug Design. (2006). 
26. Mebius, R. E. & Kraal, G. Structure and function of the spleen. Nat. Rev. Immunol. 5, 
606–16 (2005). 
27. Cesta, M. F. Normal structure, function, and histology of the spleen. Toxicol. Pathol. 34, 
455–65 (2006). 
28. Moghimi, S. M. Mechanisms of splenic clearance of blood cells and particles: towards 
development of new splenotropic agents. Adv. Drug Deliv. Rev. 17, 103–115 (1995). 
29. Merkel, T. J. et al. The effect of particle size on the biodistribution of low-modulus 
hydrogel PRINT particles. J. Control. Release 162, 37–44 (2012). 
30. Tomlinson, E. Theory and practice of site-specific drug delivery. Advanced Drug Delivery 
 197 
Reviews 1, 87–198 (1987). 
31. Bilzer, M., Roggel, F. & Gerbes, A. L. Role of Kupffer cells in host defense and liver 
disease. Liver International 26, 1175–1186 (2006). 
32. Perry, J. L. et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein 
binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 12, 
5304–10 (2012). 
33. Reuter, K. G. et al. Targeted PRINT Hydrogels: The Role of Nanoparticle Size and 
Ligand Density on Cell Association, Biodistribution, and Tumor Accumulation. Nano 
Lett. 15, 6371–6378 (2015). 
34. Goldberg, M., Langer, R. & Jia, X. Nanostructured materials for applications in drug 
delivery and tissue engineering. J. Biomater. Sci. Polym. Ed. 18, 241–268 (2007). 
35. Yoo, J.-W., Doshi, N. & Mitragotri, S. Adaptive micro and nanoparticles: temporal 
control over carrier properties to facilitate drug delivery. Adv. Drug Deliv. Rev. 63, 1247–
56 (2011). 
36. Doane, T. & Burda, C. Nanoparticle mediated non-covalent drug delivery. Adv. Drug 
Deliv. Rev. 65, 607–21 (2013). 
37. Albanese, A., Tang, P. S. & Chan, W. C. W. The effect of nanoparticle size, shape, and 
surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14, 1–16 (2012). 
38. Merkel, T. J. et al. Using mechanobiological mimicry of red blood cells to extend 
circulation times of hydrogel microparticles. Proc. Natl. Acad. Sci. U. S. A. 108, 586–91 
(2011). 
39. Anselmo, A. C. et al. Elasticity of Nanoparticles Influences Their Blood Circulation, 
Phagocytosis, Endocytosis, and Targeting. ACS Nano 9, 3169–3177 (2015). 
40. Kumar, A. & Graham, M. D. Mechanism of Margination in Confined Flows of Blood and 
Other Multicomponent Suspensions. Phys. Rev. Lett. 109, 108102 (2012). 
41. Crowl, L. M. & Fogelson, A. L. Computational model of whole blood exhibiting lateral 
platelet motion induced by red blood cells. Int. j. numer. method. biomed. eng. 26, 471–
487 (2010). 
42. Eckstein, E. C., Tilles, A. W. & Millero, F. J. Conditions for the occurrence of large near-
wall excesses of small particles during blood flow. Microvasc. Res. 36, 31–39 (1988). 
43. Lee, T.-R. et al. On the near-wall accumulation of injectable particles in the 
microcirculation: smaller is not better. Sci. Rep. 3, 2079 (2013). 
44. Tilles, A. W. & Eckstein, E. C. The near-wall excess of platelet-sized particles in blood 
flow: its dependence on hematocrit and wall shear rate. Microvasc. Res. 33, 211–223 
 198 
(1987). 
45. Namdee, K., Thompson, A. J., Charoenphol, P. & Eniola-Adefeso, O. Margination 
propensity of vascular-targeted spheres from blood flow in a microfluidic model of human 
microvessels. Langmuir 29, 2530–2535 (2013). 
46. Charoenphol, P., Huang, R. B. & Eniola-Adefeso, O. Potential role of size and 
hemodynamics in the efficacy of vascular-targeted spherical drug carriers. Biomaterials 
31, 1392–1402 (2010). 
47. Dell’Orco, D., Lundqvist, M., Oslakovic, C., Cedervall, T. & Linse, S. Modeling the time 
evolution of the nanoparticle-protein corona in a body fluid. PLoS One 5, e10949 (2010). 
48. Mahmoudi, M. et al. Protein À Nanoparticle Interactions : Opportunities and Challenges. 
5610–5637 (2011). 
49. Lundqvist, M. et al. Nanoparticle size and surface properties determine the protein corona 
with possible implications for biological impacts. Proc. Natl. Acad. Sci. U. S. A. 105, 
14265–14270 (2008). 
50. Monopoli, M. P., Aberg, C., Salvati, A. & Dawson, K. a. Biomolecular coronas provide 
the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779–86 (2012). 
51. Zalipsky, S. Chemistry of polyethylene glycol conjugates with biologically active 
molecules. Adv. Drug Deliv. Rev. 16, 157–182 (1995). 
52. Kentworthy, A. K., Hristova, K., Needham, D. & Mcintosh, T. J. Range and Magnitude of 
the Steric Pressure Between Bilayers Containing Phospholipids with Covalently Attached 
Poly(ethylene glycol). Biophys. J. 68, 1921–1936 (1995). 
53. Gombotz, W. R., Guanghui, W., Horbett, T. A. & Hoffman, A. S. Protein adsorption to 
poly (ethylene oxide) surfaces. J. Biomater. Res. 25, 1547–1562 (1991). 
54. Gref, R. et al. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol 
(PEG): influences of the corona (PEG chain length and surface density) and of the core 
composition on phagocytic uptake and plasma protein adsorption. Colloids Surfaces B 
Biointerfaces 18, 301–313 (2000). 
55. Cui, J. et al. Engineering Poly (ethylene glycol ) Particles for Improved Biodistribution. 
ACS Nano 9, 1571–1580 (2015). 
56. Canelas, D. A., Herlihy, K. P. & Desimone, J. M. Top-down particle fabrication : control 
of size and shape for diagnostic imaging and drug delivery. 1, 391–404 (2009). 
57. Fattahi, P., Borhan, A. & Abidian, M. R. Microencapsulation of chemotherapeutics into 
monodisperse and tunable biodegradable polymers via electrified liquid jets: control of 
size, shape, and drug release. Adv. Mater. 25, 4555–60 (2013). 
 199 
58. Discher, D. E. & Ahmed, F. Polymersomes. Annu. Rev. Biomed. Eng. 8, 323–341 (2006). 
59. Lahann, J. Recent Progress in Nano-biotechnology : Compartmentalized Micro- and 
Nanoparticles via Electrohydrodynamic Co-jetting. Small 7, 1149–1156 (2011). 
60. Vehring, R. Pharmaceutical Particle Engineering via Spray Drying. Pharm. Res. 25, 999–
1022 (2008). 
61. Gonçalves, C., Pereira, P. & Gama, M. Self-Assembled Hydrogel Nanoparticles for Drug 
Delivery Applications. Materials (Basel). 3, 1420–1460 (2010). 
62. Srivastava, A. et al. Polymers in Drug Delivery. J. Biosci. Med. 4, 69–84 (2016). 
63. James, H. P., John, R., Alex, A. & Anoop, K. R. Smart polymers for the controlled 
delivery of drugs– a concise overview. Acta Pharm. Sin. B 4, 120–127 (2014). 
64. Müller, K., Fedosov, D. a & Gompper, G. Margination of micro- and nano-particles in 
blood flow and its effect on drug delivery. Sci. Rep. 4, 4871 (2014). 
65. Toy, R., Hayden, E., Shoup, C., Baskaran, H. & Karathanasis, E. The effects of particle 
size, density and shape on margination of nanoparticles in microcirculation. 
Nanotechnology 22, 115101 (2011). 
66. Dasgupta, S., Auth, T. & Gompper, G. Shape and orientation matter for the cellular uptake 
of nonspherical particles. Nano Lett. 14, 687–93 (2014). 
67. Champion, J. a & Mitragotri, S. Role of target geometry in phagocytosis. Proc. Natl. 
Acad. Sci. U. S. A. 103, 4930–4 (2006). 
68. Champion, J. a, Walker, A. & Mitragotri, S. Role of particle size in phagocytosis of 
polymeric microspheres. Pharm. Res. 25, 1815–21 (2008). 
69. Champion, J. a & Mitragotri, S. Shape induced inhibition of phagocytosis of polymer 
particles. Pharm. Res. 26, 244–9 (2009). 
70. Champion, J. A. & Mitragotri, S. Shape induced inhibition of phagocytosis of polymer 
particles. Pharm. Res. 26, 244–249 (2009). 
71. Kulkarni, S. A. & Feng, S. Effects of Particle Size and Surface Modification on Cellular 
Uptake and Biodistribution of Polymeric Nanoparticles for Drug Delivery. Pharm. Res. 
30, 2512–2522 (2013). 
72. Chen, L. et al. Development and Characterization of Lecithin-based Self-assembling 
Mixed Polymeric Micellar (saMPMs) Drug Delivery Systems for Curcumin. Sci. Rep. 
(2016). doi:10.1038/srep37122 
73. Chen, W., Palazzo, A., Hennink, W. E. & Kok, R. Effect of Particle Size on Drug Loading 
and Release Kinetics of Gefitnib-Loaded PLGA Microspheres. Mol. Pharm. 14, 459–467 
 200 
(2017). 
74. Yang, L. & Fassihi, R. Zero-order release kinetics from a self-correcting floatable 
asymmetric configuration drug delivery system. J. Pharm. Sci. 85, 170–3 (1996). 
75. Muro, S., Gajewski, C., Koval, M. & Muzykantov, V. R. ICAM-1 recycling in endothelial 
cells : a novel pathway for sustained intracellular delivery and prolonged effects of drugs. 
Blood 105, 650–659 (2017). 
76. Granger, D. N. & Kubes, P. The microcirculation and inflammation: modulation of 
leukocyte-endothelial cell adhesion. J. Leukoc. Biol. 55, 662–75 (1994). 
77. Eldika, N., Yerra, L., Chi, D. S. & Krishnaswamy, G. Atherosclerosis as an inflammatory 
disease: implications for therapy. Front. Biosci. 9, 2764–2777 (2004). 
78. Ley, K., Laudanna, C., Cybulsky, M. I. & Nourshargh, S. Getting to the site of 
inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678–89 
(2007). 
79. Schmidt, S., Moser, M. & Sperandio, M. The molecular basis of leukocyte recruitment 
and its deficiencies. Molecular Immunology 55, 49–58 (2013). 
80. Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 
1135–1143 (2002). 
81. Mann, A. P. et al. Identification of Thioaptamer Ligand against E-Selectin: Potential 
Application for Inflamed Vasculature Targeting. PLoS One 1–14 (2010). 
82. Schardt, J. S. et al. Engineered Multivalency Enhances Affibody-Based HER3 Inhibition 
and Downregulation in Cancer Cells. Mol. Pharm. 14, 1047–1056 (2017). 
83. Omolola Eniola, A. & Hammer, D. a. In vitro characterization of leukocyte mimetic for 
targeting therapeutics to the endothelium using two receptors. Biomaterials 26, 7136–44 
(2005). 
84. Barthel, S. R., Gavino, J. D., Descheny, L. & Dimitroff, C. J. Targeting selectins and 
selectin ligands in inflammation and cncer. Expert Opin. Ther. Targets 11, 1473–1491 
(2008). 
85. Gunawan, R. C., Almeda, D. & Auguste, D. T. Complementary targeting of liposomes to 
IL-1?? and TNF-?? activated endothelial cells via the transient expression of VCAM1 and 
E-selectin. Biomaterials 32, 9848–9853 (2011). 
86. Papademetriou, I., Tsinas, Z., Hsu, J. & Muro, S. Combination-targeting to multiple 
endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo 
biodistribution of drug nanocarriers and their therapeutic cargoes. J. Control. Release 188, 
87–98 (2014). 
 201 
87. Howard, M. et al. Vascular targeting of nanocarriers: Perplexing aspects of the seemingly 
straightforward paradigm. ACS Nano 8, 4100–4132 (2014). 
88. McAteer, M. A. et al. Magnetic resonance imaging of endothelial adhesion molecules in 
mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler. 
Thromb. Vasc. Biol. 28, 77–83 (2008). 
89. Sun, D. et al. Superior sensitivity of novel molecular imaging probe: simultaneously 
targeting two types of endothelial injury markers. FASEB J. 24, 1532–40 (2010). 
90. Gunawan, R. C. & Auguste, D. T. The role of antibody synergy and membrane fluidity in 
the vascular targeting of immunoliposomes. Biomaterials 31, 900–907 (2010). 
91. McNeeley, K. M., Annapragada, A. & Bellamkonda, R. Decreased circulation time offsets 
increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. 
Nanotechnology 18, (2007). 
92. Sobczynski, D. J. et al. Plasma protein corona modulates the vascular wall interaction of 
drug carriers in a material and donor specific manner. PLoS One 9, e107408 (2014). 
93. Onyskiw, P. J. & Eniola-adefeso, O. Effect of PEGylation on Ligand-Based Targeting of 
Drug Carriers to the Vascular Wall in Blood Flow. Langmuir 29, 11127–11134 (2013). 
94. Saw, P. E. et al. Effect of PEG Pairing on the Efficiency of Cancer-Targeting Liposomes. 
Theranostics 5, 746–754 (2015). 
95. Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G. & Richette, P. Antibodies 
against polyethylene glycol in healthy subjects and in patients treated with PEG-
conjugated agents. Expert Opin. Drug Deliv. 1319–1323 (2012). 
doi:10.1517/17425247.2012.720969 
96. Peppas, N. A., Hilt, J. Z., Khademhosseini, A. & Langer, R. Hydrogels in Biology and 
Medicine: From Molecular Principles to Bionanotechnology. Adv. Mater. 18, 1345–1360 
(2006). 
97. Knop, K., Hoogenboom, R., Fischer, D. & Schubert, U. S. Poly(ethylene glycol) in drug 
delivery: Pros and cons as well as potential alternatives. Angew. Chemie - Int. Ed. 49, 
6288–6308 (2010). 
98. Olabisi, O. & Adewale, K. Handbook of Thermoplastics. (2016). 
99. Yoo, J., Irvine, D. J., Discher, D. E. & Mitragotri, S. Bio-inspired, bioengineered and 
biomimetic drug delivery carriers. Nat. Rev. Drug Deliv. 10, 521–535 (2011). 
100. Meyer, R. A., Sunshine, J. C. & Green, J. J. Biomimetic particles as therapeutics. Trends 
Biotechnol. 33, 514–524 (2015). 
101. Balmert, S. C. & Little, S. R. Biomimetic Delivery with Micro- and Nanoparticles. Adv. 
 202 
Mater. 24, 3757–3778 (2012). 
102. Chen, K. et al. Low modulus biomimetic microgel particles with high loading of 
hemoglobin. Biomacromolecules 13, 2748–2759 (2012). 
103. Cui, J. et al. Super-Soft Hydrogel Particles with Tunable Elasticity in a Microfluidic 
Blood Capillary Model. Adv. Mater. 26, 7295–7299 (2014). 
104. Beningo, K. A. & Wang, Y. Fc-receptor-mediated phagocytosis is regulated by 
mechanical properties of the target. J. Cell Sci. 115, 849–856 (2002). 
105. Modery-Pawlowski, C. L. et al. Biomaterials Approaches to synthetic platelet analogs. 
Biomaterials 34, 526–541 (2013). 
106. Fish, M. B. et al. Exploring deformable particles in vascular-targeted drug delivery: Softer 
is only sometimes better. Biomaterials 124, 169–179 (2017). 
107. Dawidczyk, C. M. et al. State-of-the-Art in Design Rules for Drug Delivery Platforms: 
Lessons from FDA-approved Nanomedicines. J. Control. Release 133–144 (2014). 
doi:10.1016/j.jconrel.2014.05.036.State-of-the-Art 
108. Zhang, Y., Chan, H. F. & Leong, K. W. Advanced Materials and Processing for Drug 
Delivery: The Past and The Future. Adv. Drug Deliv. Rev. 65, 104–120 (2014). 
109. Fairbanks, B. D., Schwartz, M. P., Bowman, C. N. & Anseth, K. S. Photoinitiated 
polymerization of PEG-diacrylate with lithium phenyl-2,4,6-trimethylbenzoylphosphinate: 
polymerization rate and cytocompatibility. Biomaterials 30, 6702–6707 (2009). 
110. Majima, T. & Schnabel, W. Phenyl-2,4,6-trimethylbenzoylphosphinates as water-soluble 
photoinitiators. Generation and reactivity of O=P(C6H5)(O-) radical anions. Makromol. 
Chem. 192, 2307–2315 (1991). 
111. Anseth, K., Bowman, C. N. & Brannon-peppas, L. Mechanical Properties of Hydrogels 
and Their Experimental Determination. Biomaterials 17, (1996). 
112. Stenekes, R. J. et al. Pore sizes in hydrated dextran microspheres. Biomacromolecules 1, 
696–703 (2000). 
113. Charoenphol, P., Onyskiw, P. J., Carrasco-Teja, M. & Eniola-Adefeso, O. Particle-cell 
dynamics in human blood flow: implications for vascular-targeted drug delivery. J. 
Biomech. 45, 2822–8 (2012). 
114. Huang, R. B. & Eniola-Adefeso, O. Shear stress modulation of IL-1-induced E-selectin 
expression in human endothelial cells. PLoS One 7, 1–11 (2012). 
115. Huang, A. D. A. J. et al. Effects of Human Neutrophil Chemotaxis Across Human 
Endothelial Cell Monolayers on the Permeability of These Monolayers to Ions and 
Macromolecules. J. Cell. Physiol. 135, 355–366 (1988). 
 203 
116. Ducusin, R. J. T., Sarashina, T., Uzuka, Y., Tanabe, S. & Ohtani, M. Phagocytic response 
of bovine polymorphonuclear leukocytes to different incubation conditions and following 
exposure to some effectors of phagocytosis and different anticoagulants in vitro. Can. J. 
Vet. Res. 65, 38–44 (2001). 
117. Papaioannou, T. G. & Stefanadis, C. Vascular wall shear stress: basic principles and 
methods. Hellenic J. Cardiol. 46, 9–15 (2005). 
118. Lipowsky, H. H., Usami, S. & Chien, S. In vivo measurements of ‘apparent viscosity’ and 
microvessel hematocrit in the mesentery of the cat. Microvasc. Res. 19, 297–319 (1980). 
119. Papaioannou, T. & Stefanadis, C. Vascular wall shear stress: basic principles and 
methods. Hell. J Cardiol (2005). 
120. Wang, Y. et al. Plasma fibronectin supports hemostasis and regulates thrombosis. J. Clin. 
Invest. 124, 4281–4293 (2014). 
121. Reheman, A. et al. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual 
role in platelet aggregation. J. Thromb. Haemost. 3, 875–883 (2005). 
122. Fromen, C. A. et al. Evaluation of Receptor-Ligand Mechanisms of Dual-Targeted 
Particles to an Inflamed Endothelium. Bioeng. Transl. Med. 1, 2–41 (2016). 
123. Fromen, C. A. et al. Controlled analysis of nanoparticle charge on mucosal and systemic 
antibody responses following pulmonary immunization. Proc. Natl. Acad. Sci. 112, 488–
493 (2015). 
124. Fromen, C. A. et al. Nanoparticle surface charge impacts distribution , uptake and lymph 
node trafficking by pulmonary antigen-presenting cells. Nanomedicine Nanotechnology, 
Biol. Med. 12, 677–687 (2016). 
125. Grommes, J. & Soehnlein, O. Contribution of Neutrophils to Acute Lung Injury. Mol. 
Med. 17, 293–307 (2011). 
126. Hsu, C. W. & Chen, Y. L. Migration and fractionation of deformable particles in 
microchannel. J. Chem. Phys. 133, (2010). 
127. Fish, M. B., Thompson, A. J., Fromen, C. A. & Eniola-Adefeso, O. Emergence and Utility 
of Non-Spherical Particles in Biomedicine. Ind. Eng. Chem. Res. 54, 4043–4059 (2015). 
128. Sen Gupta, A. Role of particle size, shape, and stiffness in design of intravascular drug 
delivery systems: insights from computations, experiments, and nature. WIREs 8, 255–270 
(2016). 
129. Geng, Y. et al. Shape effects of filaments versus spherical particles in flow and drug 
delivery. Nat. Nanotechnol. 2, 249–55 (2007). 
130. Skotheim, J. M. & Secomb, T. W. Red blood cells and other nonspherical capsules in 
 204 
shear flow: Oscillatory dynamics and the tank-treading-to-tumbling transition. Phys. Rev. 
Lett. 98, (2007). 
131. Crowl, L. M. & Fogelson, A. L. Computational model of whole blood exhibiting lateral 
platelet motion induced by red blood cells. Int. j. numer. method. biomed. eng. 26, 471–
487 (2010). 
132. Geislinger, T. M. & Franke, T. Hydrodynamic lift of vesicles and red blood cells in flow 
— from Fåhræus & Lindqvist to microfluidic cell sorting. Adv. Colloid Interface Sci. 208, 
161–176 (2014). 
133. Dulinska, I. et al. Stiffness of normal and pathological erythrocytes studied by means of 
atomic force microscopy. J. Biochem. Biophys. Methods 66, 1–11 (2006). 
134. Radmacher, M., Fritz, M., Kacher, C. M., Cleveland, J. P. & Hansma, P. K. Measuring the 
Viscoelastic Properties of Human Platelets with the Atomic Force Microscope. Biophys. J. 
70, 556–567 (1996). 
135. Kumar, A., Rivera, R. G. H. & Graham, M. D. Flow-induced segregation in confined 
multicomponent suspensions : effects of particle size and rigidity. J. Fluid Mech. 423–462 
(2014). doi:10.1017/jfm.2013.592 
136. Haga, J., Beaudoin, A., White, J. & Strony, J. Quantification of the Passive Mechanical 
Properties of the Resting Platelet. Ann. Biomed. Eng. 26, 268–277 (1998). 
137. Namdee, K., Carrasco-Teja, M., Fish, M. B., Charoenphol, P. & Eniola-Adefeso, O. Effect 
of Variation in hemorheology between human and animal blood on the binding efficacy of 
vascular-targeted carriers. Sci. Rep. 5, (2015). 
138. Namdee, K. et al. In vivo evaluation of vascular-targeted spheroidal microparticles for 
imaging and drug delivery application in atherosclerosis. Atherosclerosis 237, 279–286 
(2014). 
139. Winter, H. H. & Chambon, F. Analysis of Linear Viscoelasticity of a Crosslinking 
Polymer at the Gel Point. J. Rheol. (N. Y. N. Y). 30, 367–382 (1986). 
140. Kansas, G. Selectins and Their Ligands: Current Concepts and Controversies. Blood 88, 
3259–3287 (1996). 
141. Foreman, K. E. et al. C5a-induced expression of P-selectin in endothelial cells. J. Clin. 
Invest. 94, 1147–1155 (1994). 
142. Gao, T. & Hu, H. H. Deformation of elastic particles in viscous shear flow. J. Comput. 
Phys. 228, 2132–2151 (2009). 
143. Chen, Y. Intertia- and deformation-driven migration of a soft particle in confined shear 
and Poiseuille flow. RSC Adv. 4, 17908–17916 (2014). 
 205 
144. Doshi, N., Zahr, A. S., Bhaskar, S., Lahann, J. & Mitragotri, S. Red blood cell-mimicking 
synthetic biomaterial particles. Proc. Natl. Acad. Sci. U. S. A. 106, 21495–9 (2009). 
145. Modery-pawlowski, C. L., Tian, L. L., Pan, V. & Sen Gupta, A. Synthetic Approaches to 
RBC Mimicry and Oxygen Carrier Systems. Biomacromolecules 14, 939–948 (2013). 
146. Doshi, N. et al. Platelet mimetic particles for targeting thrombi in flowing blood. Adv. 
Mater. 24, 3864–9 (2012). 
147. Anselmo, A. C. et al. Platelet-like nanoparticles: mimicking shape, flexibility, and surface 
biology of platelets to target vascular injuries. ACS Nano 8, 11243–53 (2014). 
148. Brown, A. C. et al. Ultrasoft microgels displaying emergent platelet-like behaviours. Nat. 
Mater. 13, 1108–1114 (2014). 
149. Su, J. et al. Long Circulation Red-Blood-Cell-Mimetic Nanoparticles with Peptide-
Enhanced Tumor Penetration for Simultaneously Inhibiting Growth and Lung Metastasis 
of Breast Cancer. Adv. Funct. Mater. 26, 1243–1252 (2016). 
150. Anselmo, A. C. & Mitragotri, S. Impact of particle elasticity on particle-based drug 
delivery systems. Adv. Drug Deliv. Rev. (2016). 
151. Wang, J., Byrne, J. D., Napier, M. E. & Desimone, J. M. More Effective Nanomedicines 
through Particle Design. Small 7, 1919–1931 (2011). 
152. Zustiak, S. P. & Leach, J. B. Hydrolytically Degradable Poly ( Ethylene Glycol ) 
Hydrogel Scaffolds with Tunable Degradation and Mechanical Properties. 
Biomacromolecules 11, 1348–1357 (2010). 
153. Hu, Y., Xie, J., Tong, Y. & Wang, C.-H. Effect of PEG conformation and particle size on 
the cellular uptake efficiency of nanoparticles with the HepG2 cells. J. Control. Release 
118, 7–17 (2007). 
154. Cheuvront, S. N., Kenefick, R. W., Heavens, K. R. & Spitz, M. G. A Comparison of 
Whole Blood and Plasma Osmolality and Osmolarity. J. Clin. Labratory Anal. 28, 368–
373 (2014). 
155. Guo, D., Li, J., Xie, G., Wang, Y. & Luo, J. Elastic Properties of Polystyrene Nanospheres 
Evaluated with Atomic Force Microscopy: Size Effect and Error Analysis. Langmuir 30, 
7206–7212 (2014). 
156. Addio, S. M. D. et al. Effects of block copolymer properties on nanocarrier protection 
from in vivo clearance. J. Control. Release 162, 208–217 (2012). 
157. Kutscher, H. L. et al. Threshold size for optimal passive pulmonary targeting and 
retention of rigid microparticles in rats. J. Control. Release 143, 31–37 (2010). 
158. Koutsiaris, A. G. et al. Volume flow and wall shear stress quantification in the human 
 206 
conjunctival capillaries and post-capillary venules in vivo. Biorheology 44, 375–386 
(2007). 
159. Nagaoka, T. & Yoshida, A. Noninvasive Evaluation of Wall Shear Stress on Retinal 
Microcirculation in Humans. Investig. Ophthalmol. Vis. Sci. 47, 1113–1119 (2006). 
160. Simon, S. I., Hu, Y., Vestweber, D. & Smith, W. C. Neutrophil Tethering on E-Selectin 
Activates β 2 Integrin Binding to ICAM-1 Through a Mitogen-Activated Protein Kinase 
Signal Transduction Pathway. J. Immunol. 164, 4348–4358 (2000). 
161. Müller, K., Fedosov, D. A. & Gompper, G. Understanding particle margination in blood 
flow – A step toward optimized drug delivery systems. Med. Eng. Phys. 38, 2–10 (2016). 
162. Yoo, J., Chambers, E. & Mitragotri, S. Factors that Control the Circulation Time of 
Nanoparticles in Blood: Challenges , Solutions and Future Prospects. Curr. 
Pharamceutical Des. 16, 2298–2307 (2010). 
163. Marshall, B. T. et al. Direct observation of catch bonds involving cell-adhesion molecules. 
Nature 423, 190–193 (2003). 
164. Kim, S., Ong, P. K., Yalcin, O., Intaglietta, M. & Johnson, P. C. The cell-free layer in 
microvascular blood flow. Biorheology 46, 181–189 (2009). 
165. Pillai, G. Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those 
under Various Stages of Development. SOJ Pharm. Pharm. Sci. 1, 13 (2014). 
166. Bae, Y. H. & Park, K. Targeted drug delivery to tumors: Myths, reality and possibility. J. 
Control. Release 153, 198–205 (2011). 
167. Charoenphol, P. et al. Targeting therapeutics to the vascular wall in atherosclerosis-
Carrier size matters. Atherosclerosis 217, 364–370 (2011). 
168. Thompson, A. J., Mastria, E. M. & Eniola-Adefeso, O. The margination propensity of 
ellipsoidal micro/nanoparticles to the endothelium in human blood flow. Biomaterials 34, 
5863–71 (2013). 
169. Beauharnois, M. E. et al. Affinity and Kinetics of Sialyl Lewis-X and Core-2 Based 
Oligosaccharides Binding to L- and P-Selectin. Biochemistry 44, 9507–9519 (2005). 
170. Eniola, A. O., Willcox, P. J. & Hammer, D. A. Interplay between rolling and firm 
adhesion elucidated with a cell-free system engineered with two distinct receptor-ligand 
pairs. Biophys. J. 85, 2720–31 (2003). 
171. Thompson, A. J., Mastria, E. M. & Eniola-Adefeso, O. The margination propensity of 
ellipsoidal micro/nanoparticles to the endothelium in human blood flow. Biomaterials 34, 
5863–5871 (2013). 
172. Bevilacqua, M. P. Enodthelial-Leukocyte Adhesion Molecules. Annu. Rev. Immunol. 11, 
 207 
767–804 (1993). 
173. Haraldsen, G., Kvale, D., Lien, B., Farstad, I. N. & Brandtzaeg, P. Cytokine-Regulated 
Expression of E-Selectin, Intercellular Adhesion Molecule-1 (ICAM-1), and Vascular Cell 
Adhesion Molecule-1 (VCAM-1) in Human Intestinal Microvascular Endothelial Cells. J. 
Immunol. 156, 2558–2565 (1996). 
174. Kobuchi, H. et al. Quercetin inhibits inducible ICAM-1 expression in human endothelial 
cells through the JNK pathway. Am. J. Physiol. 304, 403–411 (1999). 
175. Panes, J. et al. Regional differences in constitutive and induced ICAM-1 expression in 
vivo. Am. Physiol. Soc. 269.6, H1955–H1964 (1995). 
176. Springer, T. a. Traffic signals for lymphocyte recirculation and leukocyte emigration: The 
multistep paradigm. Cell 76, 301–314 (1994). 
177. Augustin, H., Kozian, D. & Johnson, R. Differentiation of Endothelial Cells: Analysis of 
the constitutive and activated endothelial cell phenotypes. BioEssays 16, 901–906 (1994). 
178. Caputo, K. E., Lee, D., King, M. R. & Hammer, D. A. Adhesive Dynamics Simulations of 
the Shear Threshold Effect for Leukocytes. Biophys. J. 92, 787–797 (2007). 
179. Decuzzi, P. & Ferrari, M. The adhesive strength of non-spherical particles mediated by 
specific interactions. Biomaterials 27, 5307–5314 (2006). 
180. Doshi, N. et al. Flow and adhesion of drug carriers in blood vessels depend on their shape: 
A study using model synthetic microvascular networks. J. Control. Release 146, 196–200 
(2010). 
181. Pawar, P., Jadhav, S., Eggleton, C. D. & Konstantopoulos, K. Roles of cell and 
microvillus deformation and receptor-ligand binding kinetics in cell rolling. Am. J. 
Physiol. - Hear. Circ. Physiol. 295, 1439–1450 (2008). 
182. Chang, K. C. & Hammer, D. a. Adhesive dynamics simulations of sialyl-Lewis(x)/E-
selectin-mediated rolling in a cell-free system. Biophys. J. 79, 1891–1902 (2000). 
183. Brunk, D. K. & Hammer, D. A. Quantifying Rolling Adhesion with Carbohydrate Ligands 
Cell-Free Assay: E-Selectin and Its Carbohydrate Ligands. Biophys. J. 72, 2820–2833 
(1997). 
184. Eniola, A. O., Rodgers, S. D. & Hammer, D. A. Characterization of biodegradable drug 
delivery vehicles with the adhesive properties of leukocytes. Biomaterials 23, 2167–2177 
(2001). 
185. Fakhari, A., Baoum, A., Siahaan, T. J., Le, K. B. & Berkland, C. Controlling ligand 
surface density optimizes nanoparticle binding to ICAM-1. J. Pharm. Sci. 100, 1045–1056 
(2011). 
 208 
186. Gu, F. et al. Precise engineering of targeted nanoparticles by using self-assembled 
biointegrated block copolymers. Proc. Natl. Acad. Sci. 105, 2586–2591 (2008). 
187. Zern, B. et al. Reduction of Nanoparticle Avidity Enhances the Selectivity of Vascular 
Targeteing and PET Detection of Pulmonary Inflammation. ACS Nano 7, 2461–2469 
(2014). 
188. Beauharnois, M. E. et al. Affinity and kinetics of sialyl lewis-X and Core-2 based 
oligosaccharides binding to L- and P-selectin. Biochemistry 44, 9507–9519 (2005). 
189. Haun, J. B. & Hammer, D. A. Quantifying Nanoparticle Adhesion Mediated by Specific 
Molecular Interactions. Langmuir 24, 8821–8832 (2008). 
190. Ley, K., Laudanna, C., Cybulsky, M. I. & Nourshargh, S. Getting to the site of 
inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678–89 
(2007). 
191. Lawrence, M. B. & Springer, T. a. Leukocytes Roll on a Selectin at Physiologic Flow 
Rates: Distinction from and Prerequisite for Adhesion through lntegrins. Cell 65, 859–873 
(1991). 
192. Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R. & Tsourkas, A. Multifunctional 
nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 
338, 903–10 (2012). 
193. Wang, J., Tian, S., Petros, R. a, Napier, M. E. & Desimone, J. M. The complex role of 
multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J. Am. 
Chem. Soc. 132, 11306–13 (2010). 
194. Wang, X. et al. The development of site-specific drug delivery nanocarriers based on 
receptor mediation. J. Control. Release 193, 139–153 (2014). 
195. Mulivor,  a. W. & Lipowsky, H. H. Role of glycocalyx in leukocyte-endothelial cell 
adhesion. Am. J. Physiol. Heart Circ. Physiol. 283, H1282–H1291 (2002). 
196. Wickline, S. a., Neubauer, A. M., Winter, P. M., Caruthers, S. D. & Lanza, G. M. 
Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J. Magn. 
Reson. Imaging 25, 667–680 (2007). 
197. Winter, P. M. et al. Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis 
With αvβ3-Integrin-Targeted Nanoparticles. Circulation 108, 2270–2274 (2003). 
198. Neri, D. & Bicknell, R. Tumour vascular targeting. Nat. Rev. Cancer 5, 436–446 (2005). 
199. Torchilin, V. P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 64, 302–315 (2012). 
200. Muro, S. et al. Control of endothelial targeting and intracellular delivery of therapeutic 
enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol. Ther. 16, 
 209 
1450–1458 (2008). 
201. Garnacho, C., Albelda, S. M., Muzykantov, V. R. & Muro, S. Differential intra-
endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J. 
Control. Release 130, 226–33 (2008). 
202. Hossain, S. S. et al. In silico vascular modeling for personalized nanoparticle delivery. 
Nanomedicine (Lond). 3, 343–357 (2013). 
203. Modery-Pawlowski, C. L. & Sen Gupta, A. Heteromultivalent ligand-decoration for 
actively targeted nanomedicine. Biomaterials 35, 2568–2579 (2014). 
204. Doolittle, E. et al. Spatiotemporal Targeting of a Dual-Ligand Nanoparticle to Cancer 
Metastasis. ACS Nano 9, 8012–8021 (2015). 
205. Robbins, G. P. et al. Tunable leuko-polymersomes that adhere specifically to 
inflammatory markers. Langmuir 26, 14089–14096 (2010). 
206. Hammer, D. A. & Apte, S. M. Simulation of cell rolling and adhesion on surfaces in shear 
flow: general results and analysis of selectin-mediated neutrophil adhesion. Biophys. J. 63, 
35–57 (1992). 
207. Kim, M. J. & Rhee, K. Computational analysis of nanoparticle adhesion to endothelium: 
Effects of kinetic rate constants and wall shear rates. Med. Biol. Eng. Comput. 49, 733–
741 (2011). 
208. Eniola, A. O. & Hammer, D. A. In vitro characterization of leukocyte mimetic for 
targeting therapeutics to the endothelium using two receptors. Biomaterials 26, 7136–
7144 (2005). 
209. Haun, J. B., Robbins, G. P. & Hammer, D. A. Engineering Therapeutic Nanocarriers with 
Optimal Adhesion for Targeting. J. Adhes. 86, 131–159 (2010). 
210. Haun, J. B. & Hammer, D. A. Quantifying nanoparticle adhesion mediated by specific 
molecular interactions. Langmuir 24, 8821–8832 (2008). 
211. Huang, R. B. & Eniola-Adefeso, O. Shear stress modulation of IL-1-induced E-selectin 
expression in human endothelial cells. PLoS One 7, 1–11 (2012). 
212. Liljestro, V., Mikkila, J. & Kostiainen, M. A. Self-assembly and modular 
functionalization of three-dimensional crystals from oppositely charged proteins. Nat. 
Commun. 5, (2014). 
213. Lamberti, G. et al. Adhesive interaction of functionalized particles and endothelium in 
idealized microvascular networks. Microvasc. Res. 89, 107–114 (2013). 
214. Ley, K., Allietta, M., Bullard, D. C. & Morgan, S. Importance of E-selectin for firm 
leukocyte adhesion in vivo. Circ. Res. 83, 287–94 (1998). 
 210 
215. Simone, E., Ding, B. Sen & Muzykantov, V. Targeted delivery of therapeutics to 
endothelium. Cell Tissue Res. 335, 283–300 (2009). 
216. Mayadas, T. N., Johnson, R. C., Rayburn, H., Hynes, R. O. & Wagner, D. D. Leukocyte 
rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 74, 
541–554 (1993). 
217. Robinson, S. D. et al. Multiple, targeted deficiencies in selectins reveal a predominant role 
for P-selectin in leukocyte recruitment. Proc. Natl. Acad. Sci. U. S. A. 96, 11452–11457 
(1999). 
218. Langley, R. R. et al. Quantification of murine endothelial cell adhesion molecules in solid 
tumors. Am J Physiol Hear. Circ Physiol 277, 1156–1166 (1999). 
219. Eniola, A. O. & Hammer, D. A. Characterization of biodegradable drug delivery vehicles 
with the adhesive properties of leukocytes II: effect of degradation on targeting activity. 
Biomaterials 26, 661–70 (2005). 
220. Yu, L. X. et al. Novel Bioequivalence Approach for Narrow Therapeutic Index Drugs. 
Clin. Pharmacol. Ther. 97, 286–291 (2015). 
221. Muller, P. Y. & Milton, M. N. The determination and interpretation of the therapeutic 
index in drug development. Nat. Rev. Drug Discov. 11, 751–761 (2012). 
222. Kai, M. P. et al. Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a 
cisplatin-containing hydrogel nanoparticle. J. Cont 204, 70–77 (2015). 
223. Chu, K. S. et al. Particle Replication in Nonwetting Templates Nanoparticles with Tumor 
Selective Alkyl Silyl Ether Docetaxel Prodrug Reduces Toxicity. Nano Lett. 14, 1472–
1476 (2014). 
224. Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics : an emerging 
treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008). 
225. Ulbrich, K. et al. Targeted Drug Delivery with Polymers and Magnetic Nanoparticles : 
Covalent and Noncovalent Approaches , Release Control , and Clinical Studies. Chem. 
Rev. 116, 5388–5431 (2016). 
226. Koren, E. & Torchilin, V. P. Drug Carriers for Vascular Drug Delivery. IUBMB Life 63, 
586–595 (2011). 
227. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 1–12 
(2016). 
228. Ulbrich, W. & Lamprecht, A. Targeted drug-delivery approaches by nanoparticulate 
carriers in the therapy of inflammatory diseases. J. R. Soc. Interface 1–12 (2009). 
229. Charoenphol, P. et al. Targeting therapeutics to the vascular wall in atherosclerosis–
 211 
Carrier size matters. Atherosclerosis 217, 364–370 (2011). 
230. Grommes, J. & Soehnlein, O. Contribution of Neutrophils to Acute Lung Injury. Mol. 
Med. 17, 293–307 (2011). 
231. Zhang, Y., Huo, M., Zhou, J. & Xie, S. PKSolver: An add-in program for pharmacokinetic 
and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs 
Biomed. 99, 306–314 (2010). 
232. Rosenbaum, S. Basic Pharmacokinetics and Pharmacodynamics, an Integrated Textbook 
and Computer Simulations. (2011). doi:10.1111/j.1365-2125.2011.04077.x 
233. Kameda, H. et al. Re-expression of functional P-selectin molecules on the endothelial cell 
surface by repeated stimulation with thrombin. J. Br. Hematol. 97, 348–355 (1997). 
234. Jo, J. et al. Recylcing and LFA-1-Dependent Trafficking of ICAM-1 to the 
Immunological Synapse. J. Cell. Biochem. 111, 1125–1137 (2010). 
235. Dong, C. & Lei, X. X. Biomechanics of cell rolling: shear flow cell-surface adhesion, and 
cell deformability. J. Biomech. 33, 35–43 (2000). 
236. Yang, Q. et al. Evading Immune Cell Uptake and Clearance Requires PEG Grafting at 
Densities Substantially Exceeding the Minimum for Brush Conformation. Mol. Pharm. 
11, 1250–1258 (2014). 
237. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors Affecting the Clearance 
and Biodistribution of Polymeric Nanoparticles. 5, 505–515 (2008). 
238. Townsley, M. I. Structure and composition of pulmonary arteries, capillaries and veins. 
Compr. Physiol. 675–709 (2013). doi:10.1002/cphy.c100081.Structure 
239. Chou, S. & Woodrow, K. A. Relationships between mechanical properties and drug 
release from electronspun fibers of PCL and PLGA blends. J. Mech. Behav. Biomed. 
Mater. 65, 724–733 (2017). 
240. Menden, H., Tate, E., Hogg, N. & Sampath, V. LPS-mediated endothelial activation in 
pulmonary endothelial cells : role of Nox2-dependent IKK-B phosphorylation. Am J 
Physiol Lung Cell Mol Physiol 304, 445–455 (2013). 
241. Yi, X., Shi, X. & Gao, H. Cellular Uptake of Elastic Nanoparticles. Phys. Rev. Lett. 107, 
1–5 (2011). 
242. Mager, D. Target-mediated drug disposition and dynamics. Biochem. Pharmacol. 72, 1–
10 (2006). 
243. Peters, R. H. The Ecological Implications of Body Size. (Cambridge University Press, 
1983). 
 212 
244. Calderon, A. J. et al. Optimizing endothelial targeting by modulating the antibody density 
and particle concentration of anti-ICAM coated carriers. J. Control. Release 150, 37–44 
(2011). 
245. Kharkar, P. M., Kiick, K. L. & Kloxin, A. M. Designing degradable hydrogels for control 
of cell microenvironments. Chem Soc Rev 42, 7335–7372 (2013). 
246. Kharkar, P. M., Kloxin, A. M. & Kiick, K. L. Dually degradable click hydrogels for 
controlled degradation and protein release. J Mater Chem B Mater Biol Med 2, 5511–5521 
(2014). 
247. de la Rica, R., Aili, D. & Stevens, M. M. Enzyme-responsive nanoparticles for drug 
release and diagnostics. Adv. Drug Deliv. Rev. 64, 967–78 (2012). 
248. Mura, S., Nicolas, J. & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. 
Nat. Mater. 12, 991–1003 (2013). 
249. Patterson, J. & Hubbell, J. A. Enhanced proteolytic degradation of molecularly engineered 
PEG hydrogels in response to MMP-1 and MMP-2. Biomaterials 31, 7836–7845 (2010). 
250. Nel, A. E. et al. Understanding biophysicochemical interactions at the nano-bio interface. 
Nat. Mater. 9, (2009). 
251. Kwon, G. & Teruo, O. Polymeric micelles as new drug carriers. Adv. Drug Deliv. Rev. 21, 
106–117 (1996). 
252. Singh, R. & Jr, J. W. L. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86, 
215–223 (2009). 
253. Simionescu, M., Popov, D. & Sima, A. Endothelial transcytosis in health and disease. Cell 
Tissue Res. 335, 27–40 (2009). 
254. Ye, D. et al. Nanoparticle accumulation and transcytosis in brain endothelial cell layers. 
Nanoscale 5, 11153–11165 (2013). 
255. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. & Hori, K. Tumor vascular permeability and 
the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65, 271–284 
(2000). 
256. Fang, J., Nakamura, H. & Maeda, H. The EPR effect : Unique features of tumor blood 
vessels for drug delivery, factors involved, and limitations and augmentation of the effect. 
Adv. Drug Deliv. Rev. 63, 136–151 (2011). 
257. Peng, Q. et al. Injectable and biodegradable thermosensitive hydrogels loaded with 
PHBHHx nanoparticles for the sustained and controlled release of insulin. Acta Biomater. 
9, 5063–5069 (2013). 
258. Park, K. H., Kim, H., Moon, S. & Na, K. Bone morphogenic protein-2 (BMP-2) loaded 
 213 
nanoparticles mixed with human mesenchymal stem cell in fibrin hydrogel for bone tissue 
engineering. J. Biosci. Bioeng. 108, 530–537 (2009). 
259. Chung, Y. Il et al. Enhanced bone regeneration with BMP-2 loaded functional 
nanoparticle-hydrogel complex. J. Control. Release 121, 91–99 (2007). 
260. Jung, H. J., Abou-Jaoude, M., Carbia, B. E., Plummer, C. & Chauhan, A. Glaucoma 
therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact 
lenses. J. Control. Release 165, 82–89 (2013). 
261. Laroui, H. et al. Drug-Loaded Nanoparticles Targeted to the Colon With Polysaccharide 
Hydrogel Reduce Colitis in a Mouse Model. Gastroenterology 138, 843–853 (2010). 
262. Gou, M. L. et al. A novel injectable local hydrophobic drug delivery system: 
Biodegradable nanoparticles in thermo-sensitive hydrogel. Int. J. Pharm. 359, 228–233 
(2008). 
263. Grazia Cascone, M., Zhu, Z., Borselli, F. & Lazzeri, L. Poly(vinyl alcohol) hydrogels as 
hydrophilic matrices for the release of lipophilic drugs loaded in PLGA nanoparticles. J. 
Mater. Sci. Mater. Med. 13, 29–32 (2002). 
264. Casadei, M. A. et al. Solid lipid nanoparticles incorporated in dextran hydrogels: A new 
drug delivery system for oral formulations. Int. J. Pharm. 325, 140–146 (2006). 
265. Hebeish, A., Hashem, M., El-Hady, M. M. A. & Sharaf, S. Development of CMC 
hydrogels loaded with silver nano-particles for medical applications. Carbohydr. Polym. 
92, 407–413 (2013). 
266. Juby, K. A. et al. Silver nanoparticle-loaded PVA/gum acacia hydrogel: Synthesis, 
characterization and antibacterial study. Carbohydr. Polym. 89, 906–913 (2012). 
267. Lee, Y., Johnson, P. J., Robbins, P. T. & Bridson, R. H. Production of nanoparticles-in-
microparticles by a double emulsion method : A comprehensive study. Eur. J. Pharm. 
Biopharm. 83, 168–173 (2013). 
268. Guzman-villanueva, D., El-sherbiny, I. M., Herrera-Ruiz, D. & Smyth, H. D. C. Design 
and In Vitro Evaluation of a New Nano-Microparticulate System for Enhanced Aqueous-
Phase Solubility of Curcumin. Biomed Res. Int. (2013). 
269. Bohr, A., Water, J., Beck-broichsitter, M. & Yang, M. Nanoembedded Microparticles for 
Stabilization and Delivery of Drug-Loaded Nanoparticles. Curr. Pharamceutical Des. 21, 
5829–5844 (2015). 
270. Bakhtiary, Z. et al. Microparticles containing erlotinib-loaded solid lipid nanoparticles for 
treatment of non-small cell lung cancer. Drug Dev. Ind. Pharm. 43, 1244–1253 (2017). 
271. Roa, W. H. et al. Inhalable nanoparticles , a non-invasive approach to treat lung cancer in 
a mouse model. J. Control. Release 150, 49–55 (2011). 
 214 
272. Imperiale, J. C., Nejamkin, P., Maria, J., Lanusse, C. E. & Sosnik, A. Novel protease 
inhibitor-loaded Nanoparticle-in-Microparticle Delivery System leads to a dramatic 
improvement of the oral pharmacokinetics in dogs. Biomaterials 37, 383–394 (2015). 
273. Tasciotti, E. et al. Mesoporous Silicon Particles as a Multistage Delivery System for 
Imaging and Therapeutic Applications. Nat. Nanotechnol. 3, 151–157 (2008). 
274. Yan, B., Boyer, J., Habault, D., Branda, N. R. & Zhao, Y. Near Infrared Light Triggered 
Release of Biomacromolecules from Hydrogels Loaded with Upconversion Nanoparticles. 
J. Am. Chem. Soc. 134, 16558–16561 (2012). 
275. Pandolfe, W. D. Effect of Dispersed and Continuous Phase Viscosiry on Droplet Size of 
Emulsions Generated by Homogenization. J. Dispers. Sci. Technol. 2, 459–474 (1981). 
276. Chu, K. S. et al. Nanoparticle drug loading as a design parameter to improve docetaxel 
pharmacokinetics and efficacy. Biomaterials 34, 8424–8429 (2013). 
277. Kalepu, S. & Nekkanti, V. Insoluble drug delivery strategies: review of recent advances 
and business prospects. Acta Pharm. Sin. B 5, 442–453 (2015). 
278. Lipinski, C. Poor Aqueous Solubility – an Industry Wide Problem in Drug Discovery. Am. 
Pharm. Rev. 5, 82–85 (2003). 
279. Chevre, R. Mechanical Stabilization of Mouse Carotid Artery for In Vivo Intravital 
Microscopy Imaging of Atherogenesis. Methods Mouse Atheroscler. 349–355 (2015). 
280. Megens, R. & Soehnlein, O. Intravital Microscopy for Atherosclerosis Research. Methods 
Mouse Atheroscler. 41–60 (2015). 
281. Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. a & McNeil, S. E. 
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, 
biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61, 428–37 (2009). 
282. Zwicke, G. L., Mansoori, G. A. & Jeffery, C. J. Utilizing the folate receptor for active 
targeting of cancer nanotherapeutics. Nano Rev. 3, (2012). 
283. Ravikumar, M. et al. Mimicking Adhesive Functionalities of Blood Platelets using 
Ligand- Decorated Liposomes. Bioconjug. Chem. 23, 1266–1275 (2012). 
284. Bot, I., Jukema, J. W., Lankhuizen, I. M., Berkel, T. J. C. Van & Biessen, E. A. L. 
Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE 
deficient mice independent of plasma cholesterol levels. Atherosclerosis 214, 295–300 
(2011). 
285. Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. 1–76 (2014). 
doi:10.1002/14651858.CD004816.pub4.Statins 
286. Ito, T. & Ikeda, U. Inflammatory Cytokines in Cardiovascular Disease. Curr. Drug 
 215 
Targets- Inflamm. Allergy (2003). 
287. Rogerio, A. D. P., Sorgi, C. A., Sadikot, R. & Carlo, T. The Role of Lipids Mediators in 
Inflammation and Resolution. Biomed Res. Int. 2–4 (2015). 
288. Amber E. Rydholm, Kristi S. Anseth,  and C. N. B. Effects of neighboring sulfides and pH 
on ester hydrolysis in thiol-acrylate photopolymers. Acta Biomater. 3, 449–455 (2007). 
289. Yun Suk Jo, Jay Gantz, Jeffrey A. Hubbell,  and M. P. L. Tailoring hydrogel degradation 
and drug release via neighboring amino acid controlled ester hydrolysis. Soft Matter 5, 
440–446 (2009). 
290. Kessenbrock, K., Plaks, V. & Werb, Z. Matrix Metalloproteinases: Regulators of the 
Tumor Microenvironment. Cell 141, 52–67 (2010). 
291. Garcia-Touchard, A. et al. Extracellular proteases in atherosclerosis and restenosis. 
Arteriosclerosis, Thrombosis, and Vascular Biology 25, 1119–1127 (2005). 
292. Galis, Z. S., Sukhova, G. K., Lark, M. W. & Libby, P. Increased expression of matrix 
metalloproteinases and matrix degrading activity in vulnerable regions of human 
atherosclerotic plaques. J. Clin. Invest. 94, 2493–2503 (1994). 
293. Sluijter, J. P. G. et al. Matrix metalloproteinase 2 is associated with stable and matrix 
metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in 
human endarterectomy specimen pointing to a role for different extracellular matrix 
metalloproteinase in. Stroke. 37, 235–9 (2006). 
294. Lehrke, M. et al. MMP-1 serum levels predict coronary atherosclerosis in humans. 
Cardiovasc. Diabetol. 8, 50 (2009). 
295. Inokubo, Y. et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of 
metalloproteinase-1 are increased in the coronary circulation in patients with acute 
coronary syndrome. Am. Heart J. 141, 211–217 (2001). 
296. Padovan, G. J., Leme, I. A., Fassini, P. G., Junior, N. I. & Marchini, J. S. A New O-
phthaldialdeyde (OPA) Solution for Fluorescence HPLC Amine Group Detection without 
Boric Acid Preparation. Chromotography Sep. Tech. 5, (2014). 
297. Hennig, A. et al. Simple Colorimetric Method for Quantification of Surface Carboxy 
Groups on Polymer Particles. Anal. Chem. 83, 4970–4974 (2011). 
298. Kim, J. et al. Characterization of the crosslinking kinetics of multi-arm poly(ethylene 
glycol) hydrogels formed via Michael-type addition. Soft Matter 12, 2076–2085 (2016). 
299. Gough, P. J., Gomez, I. G., Wille, P. T. & Raines, E. W. Macrophage expression of active 
MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest. 116, 59–
69 (2006). 
 216 
300. Wagsater, D., Zhu, C., Bjorkegren, J., Skogsberg, J. & Eriksson, P. MMP-2 and MMP-9 
are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr-/- 
Apob100/100 mouse. Int. J. Mol. Med. 28, 247–253 (2011). 
301. Nandi, S. & Brown, A. C. Platelet-mimetic strategies for modulating the wound 
environment and inflammatory responses. Exp. Biol. Med. 1–11 (2016). 
doi:10.1177/1535370216647126 
302. Kumar, A. & Graham, M. D. Margination and segregation in confined flows of blood and 
other multicomponent suspensions. Soft Matter 8, 10536 (2012). 
303. Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming 
biological barriers to drug delivery. Nat. Biotechnol. 33, 941–951 (2016). 
304. Weifeng Lin, Guanglong Ma, Nir Kampf, Zhefan Yuan,  and S. C. Development of Long-
Circulating Zwitterionic Cross-Linked Micelles for Active-Targeted Drug Delivery. 
Biomacromolecules2 17, (2016). 
305. Jaklenec, A. et al. Sequential release of bioactive IGF-I and TGF-β1 from PLGA 
microsphere-based scaffolds. Biomaterials 10, (2008). 
 
